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NEUROM USCULAR BLOCKING AGENTS
Neuromuscular blocking agents (NMBAs) or muscle relaxants are used in general anaes­
thesia to provide optimal conditions for endotracheal intubation and to optimize surgi­
cal access without hindrance from voluntary or reflex muscle movement. Furthermore, 
NMBAs facilitate artificial pulmonary ventilation in patients resisting such ventilation.1 
The NMBAs have been developed gradually over many years from crude curare extracted 
from South American plants, into modern, completely synthesized and pure drugs. A l­
though NMBAs were initially used in a number of medical disciplines, their application 
today is limited to anaesthesia and intensive care medicine.
The principal pharmacological effect of NMBAs is to inhibit the transmission of nerve im­
pulses at the neuromuscular junction (NMJ).2 The clinically used NMBAs can be divided in 
depolarizing and non-depolarizing relaxants. The depolarizing NMBAs (succinylcholine) 
act as agonists on the postsynaptic nicotinic acetylcholine receptor in the NMJ. They 
mimic the effect of acetylcholine by activating the receptor, causing ion channels to 
open, so ions can move across the muscle membrane and depolarize it. Succinylcholine 
remains on the receptor and repolarization will not take place. The muscle membrane 
cannot be depolarized again, which causes blockade of neuromuscular transmission. The 
non-depolarizing NMBAs act as competitive antagonists of the nicotinic acetylcholine 
receptor; they prevent acetylcholine from reacting and so prevent the ion channel from 
opening and no current will flow through it.2 Recovery from neuromuscular block (NMB) 
occurs as the NM BA diffuses away from the NMJ and is eliminated.
The effect of all NMBAs is widely variable in intensity and duration. This results in the 
occurrence of postoperative residual paralysis. Residual paralysis remains a problem in 
anaesthesia, and is a major risk factor in the development of postoperative pulmonary 
complications, such as aspiration and hypoxia.3, 4
Many factors are responsible for the variability in NM BA effect. Amongst them are age, 
gender, concurrent diseases, concurrent medication, type and depth of anaesthesia, tem­
perature and acid-base balance.5-12 One of the most important factors, however, is renal 
function.113-15
The non-depolarizing NMBAs used today belong either to the chemical structure group of 
the benzylisoquinolines (atracurium, cisatracurium, mivacurium) or to the structure group 
of the aminosteroidal compounds (pancuronium, vecuronium, rocuronium).
The aminosteroidal NMBAs are excreted unchanged in the bile and the urine or me­
tabolised by the liver and then excreted. Where the major excretion takes place differs 
from substance to substance: pancuronium is excreted mainly in the urine. Rocuronium 
is mainly excreted in the bile as the unchanged product.1 The possible metabolites of 
rocuronium are pharmacologically inactive. Of the three metabolites of vecuronium, 
3-desacetyl-vecuronium is the only metabolite with significant neuromuscular blocking
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effect. This can cause a prolongation of the duration of the NMB, especially in critically ill 
patients with renal failure.13,16 Therefore, aminosteroidal relaxants are organ dependent, 
which is a main disadvantage.
REVERSAL OF NEUROM USCULAR BLOCK
To prevent residual paralysis at the end of surgery, the action of the NMBAs is frequently 
reversed by acetylcholinesterase inhibitors (anticholinesterases), such as edrophonium, 
neostigmine and pyridostigmine.1 These drugs inhibit the enzyme acetylcholinesterase, 
resulting in a greater availability of acetylcholine in the NMJ, increasing neuromuscular 
transmission.17 At present, neostigmine is the gold standard for the reversal agents. 
Unfortunately, anticholinesterases are unable to reverse a deep NM B (i.e. a block existing 
immediately after administration of a NMBA, or a block with only two responses to post- 
tetanic stimulation).18-20 In addition, they have many unwanted muscarinic side-effects, 
such as difficulty focusing (blurred vision), salivation, bronchoconstriction, bradycardia 
and abdominal cramps.17, 21 Furthermore, blockades resulting from drug interaction with 
NMBAs, for example aminoglycoside antibiotics, are not always reversible with anticho­
linesterases.21
Sugammadex, a modified y-cyclodextrin, is a recently introduced selective relaxant bind­
ing agent, designed to reverse the neuromuscular blocking effects of rocuronium.22 Cyclo- 
dextrins are cyclic oligosaccharides which can encapsulate a lipophilic guest molecule, 
such as an aminosteroidal NMBA, to form a host-guest inclusion complex. Sugammadex 
forms a complex with rocuronium in the plasma, resulting in a rapid decrease in effector 
site concentration of the unbound muscle relaxant.22 Due to the concentration gradient 
of rocuronium molecules between the NMJ and the plasma, the N M BA  can diffuse away 
from the acetylcholine receptor, resulting in rapid recovery of NM B.23 Sugammadex is free 
from muscarinic side-effects and also able to reverse deep NM B.23-25 
Sugammadex is a water-soluble molecule, cleared by the kidneys.23 Also, the sugamma- 
dex-rocuronium complex is cleared by the kidneys. Therefore, administration of sugam­
madex leads to an altered elimination of rocuronium, which is no longer excreted mainly 
in the bile but mainly in the urine. This could have implications in patients with renal 
insufficiency.
AIM OF THE THESIS
The objective of this thesis is to investigate the efficacy, pharmacokinetics and safety of 
sugammadex in renal failure.
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Chapter 2 is an introductory chapter, with an historic overview on the use of curare, 
synthetic NMBAs, and reversal agents. A number of important issues associated with the 
administration of NMBAs and reversal agents in patients with renal failure are discussed, 
based on the existing literature.
To investigate the influence of renal failure on reversal of aminosteroidal NMBA-induced 
NM B by the reversal agent sugammadex, several studies were conducted.
First, the efficacy of sugammadex was investigated in reversing rocuronium-induced NMB 
in cats with ligated renal pedicles, as a model for acute renal failure. (chapter 3)
Then a comparative clinical study was conducted on the efficacy, safety and pharmacoki­
netics of rocuronium and sugammadex in patients with severe to end-stage renal failure 
and patients with normal renal function. (chapters 4 &  5)
During these clinical investigations, the primary efficacy variable was time from admin­
istration of the reversal agent, sugammadex, to recovery of the acceleromyographic Train 
of Four (TOF) ratio to 0.9. This TOF ratio is routinely used as the primary parameter of 
neuromuscular monitoring for the recovery of NMB. A TOF ratio (T4/T1) must exceed 0.9 
(or 90%) to exclude clinically important residual NM B.26 Performing the clinical investiga­
tions in our institution, it was observed that in some patients the TOF ratio recovered to 0.9 
and even higher, before the first twitch (T1) of the TOF had recovered to 75% of baseline. 
Because this was unusual, a retrospective study was performed, to describe the relation­
ship of recovery of T1 and the TOF ratio after placebo and different doses of sugammadex. 
This is described in chapter 6.
Because prolonged NM B after long-term administration of vecuronium in critically ill 
patients with renal failure has been attributed to 3-desacetyl-vecuronium, the ability of 
sugammadex to reverse NM B induced by 3-desacetyl-vecuronium, the active metabolite 
of vecuronium, was investigated in rhesus monkeys. (chapter 7)
Chapter 8 presents the general discussion and conclusion. Finally, chapter 9 contains a 
summary, including a Dutch translation.
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A SHORT HISTORY OF CURARE AND ITS DERIVATES
The use of arrow poison by South American Indians was first described by Martyr 
D'Anghera in 1516 in his book 'De Orbe Novo'.1 In 1525 Pigafetta mentioned in his book 
'Relazione del primo viaggio intorno al mondo' the death of a soldier after being struck 
by a poisoned arrow on the coast of Patagonia.2 Curare was then described by Raleigh in 
1596 in his book 'Discovery of the Large, Rich, and Beautiful Empire of Guiana'.3 
Although the muscle relaxant effect of curare was known for a long time, its use in medical 
care was first suggested by Brodie in 1811, who after conducting experiments with curare, 
suggested its use in the treatment of tetanus. He also showed that death after administra­
tion of curare could be prevented by the use of artificial ventilation.4;5 Schomburgk (1804­
1865) identified the plants from which curare was produced as the Strychnos species.6 
In 1850 Bernard reported on basic studies on the mechanism of action of curare on frogs. 
He was able to conclude that the effect of curare affected neuromuscular transmission.7 In 
1859 he presented a communication to the Academy of Sciences in Paris from a surgeon, 
M.L. Vella, on the use of curare for the treatment of a soldier with tetanus.8 Thereafter 
only a few physicians used curare for the treatment of tetanus and other spastic muscle 
conditions.
The first use in anaesthesia was reported in 1912 by the German physician Läwen in 
Leipzig.9 However, it was not until Griffith and Johnson had administered curare to their 
patients in 1942, that it became a popular and routine anaesthetic drug.10 
The reason for the delayed routine use in anaesthesia was the limited availability and the 
large variability in effect of the curare which was then still obtained from South American 
plants. Climate and environment affected the potency of the curare. It wasn't until 1935 
when King isolated the active component d-tubocurarine and determined its chemical 
structure that it was possible to produce a more pure and stable compound.11 
Until the introduction of d-tubocurarine, muscle relaxation for intra-abdominal and 
thoracic surgery was provided by the induction of a dangerously deep level of anaes­
thesia. At that time, patients were not intubated or artificially ventilated. Shortly after its 
introduction in anaesthesia in 1942 curare was considered a superb anaesthetic adjuvant, 
as muscle relaxation now could be provided without inducing a potentially harmful deep 
level of anaesthesia.
NEUROM USCULAR BLOCK  
The neuromuscular junction
The neuromuscular junction (NMJ) is responsible for the chemical transmission of electri­
cal impulses from nerve to muscle in order to generate an appropriate muscle contrac­
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tion. The NMJ consists of a prejunctional motor nerve ending separated from a highly 
folded postjunctional membrane of the skeletal muscle fibre by a synaptic cleft (Figure 
1). The nerve ending contains synaptic vesicles necessary to synthesize and transport the 
neurotransmitter acetylcholine. The NMJ contains postsynaptic nicotinic acetylcholine 
receptors (nAChRs) on the skeletal muscle surface and presynaptic nAChRs on the motor 
nerve ending.12
Figure 1: Schematic depiction of the neuromuscular junction. (© E. Crins)
On the arrival of a nerve impulse, a burst of acetylcholine molecules is released from 
the presynaptic nerve ending. Acetylcholine then stimulates the postsynaptic nAChRs, 
causing ion channels to open. This allows ions to move across the muscle membrane, 
which depolarizes the motor end plate, followed by contraction of the muscle fibre. 
Acetylcholine is then rapidly broken down by the enzyme acetylcholinesterase, which is 
present in the synaptic cleft.12;13
Presynaptic nAChRs are responsible for the increased release of acetylcholine into the 
synaptic cleft during high frequency stimulation of the presynaptic nerve terminal.14 
Neuromuscular block (NMB) occurs when nAChRs at the NMJ are occupied by a muscle 
relaxant, and acetylcholine can no longer bind to the receptor.
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Pharmacodynamics of NMBAs and measurement of muscle contraction
Clinically, a common method for determining the onset and duration of NM B is to observe 
the skeletal muscle response evoked by a supramaximal electrical stimulus delivered to 
the nerve by a peripheral nerve stimulator. Most often, the contraction of the adductor 
pollicis muscle after stimulation of the ulnar nerve is used to assess the effect of neuro­
muscular blocking agents (NMBAs).
Mechanomyography (M M G) measures the contraction force, and has for many years 
been considered the gold standard for quantification of NMB. However, the method is 
somewhat cumbersome and is therefore rarely used in everyday practice. 
Acceleromyography (AMG) is replacing this method. The acceleromyographic method of 
monitoring NM B is based on Newton's second law of motion: force = mass x acceleration. 
When the mass (the thumb for example) is constant, the acceleration is directly propor­
tional to the force. The acceleration is measured using a small piezo-electric ceramic 
wafer (Figure 2).15
Figure 2: The setup of acceleromyography.
Two electrodes are placed over the ulnar nerve. The response to nerve stimulation is measured using a 
small piezo-electric wafer, placed on the volar site of the distal phalanx of the thumb. The peripheral 
skin temperature is measured at the palm of the hand.
Before the 1970s, NM B was measured as either the response to single motor nerve stimuli 
(single twitch responses) or the response to brief tetanic stimulation.16 However, it was 
recognised that even with the complete return of a single twitch response, patients were 
still not fully recovered from N M B.16 This was expressed by a phenomenon called fade, a
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gradual diminution of the evoked response, after applying tetanic stimulation. Although 
tetanic fade is a more sensitive method of detecting residual paralysis, tetanic stimulation 
is painful in conscious patients and patients recovering from anaesthesia.
In the 1970s it was suggested that a brief train of 4 single twitches (the so-called Train 
of Four (TOF)) at a low frequency (0.2 Hz and 0.1 msec duration) was a more sensitive 
indicator than the single twitch response. The ratio of the height of the last twitch to the 
height of the first twitch (T4/T1) in this TOF was proposed as an index for recovery (the 
TOF ratio).17 Nowadays, a TOF ratio of at least 0.9 (or 90%) or more is considered full 
recovery from N M B.15
Receptor occlusion during neuromuscular block
A non-depolarizing NM B displays a typical tetanic and TOF fade and a reduction in twitch 
amplitude, which directly reflects the action of the NM BA at different nAChR subtypes. 
Inhibition of the presynaptic subtype by non-depolarizing NMBAs creates the TOF fade, 
whereas reduction in single twitch amplitude is the result of inhibition of the muscle 
nAChR at the postsynaptic muscle membrane.14
Waud and Waud (1975) demonstrated in vitro, using guinea pig lumbrical muscles, that 
roughly 75-80% of the nAChR pool has to be blocked before the single twitch height 
begins to fall, and 90-95% of the receptors have to be blocked before the single twitch 
response is completely abolished.18 According to the same authors, the TOF requires 25­
30 percent free receptors for a normal response.17 This margin of safety can be affected 
by disease states causing up- and down-regulation of nAChRs.19 Therefore, in the clinical 
use of non-depolarizing NMBAs one should realize that due to the margin of safety of 
neuromuscular transmission (abundant amount of acetylcholine released, and only some 
of the available postsynaptic nAChRs are indeed needed for transmission) a large part of 
the nAChRs are still occupied with muscle relaxants, when the NM B is recovered to a 
TOF ratio of > 0.9.17;20 Also, the diaphragm needs fewer free receptors for normal response 
than other muscles, which means that the diaphragm has a greater margin of safety than 
peripheral muscles.21
It is clear that in order to ensure the safety of the patient after NMB, as low a receptor 
occupancy as possible is desirable.
NEUROM USCULAR BLOCKING AGENTS
In chapter 1, we already described the difference between depolarizing and non-depolar­
izing NMBAs. The non-depolarizing NMBAs belong either to the chemical structure group 
of the benzylisoquinolines or to the structure group of the aminosteroidal compounds.
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The benzylisoquinolines
D-tubocurarine, the first non-depolarizing N M BA  of the benzylisoquinoline group, was 
introduced in anaesthesia in 1942, as described earlier. Nowadays, the benzylisoquino­
lines mivacurium, atracurium and cisatracurium are NMBAs widely used in anaesthesia.13 
Atracurium and cisatracurium are degraded spontaneously in the plasma at body tem­
perature and pH (Hofmann elimination). Atracurium is also metabolised by hydrolysis 
by nonspecific plasma esterases. Mivacurium is hydrolyzed by plasma cholinesterases. 
The clearance of the benzylisoquinolines is therefore independent of renal or hepatic 
function.13 However, the benzylisoquinoline compounds may evoke histamine release, 
especially d-tubocurarine, but also the newer NMBAs mivacurium and atracurium.
The aminosteroidal muscle relaxants
Guachamaca, a toxin used for hunting, is associated with several members of the plant 
genus Malouetia (Family Apocynaceae), which is found in both South America and Africa. 
Guachamaca was first mentioned by Codazzi in 1 841.22 He indicated that it was the name 
given in the Apure region of Venezuela to the highly toxic plant also known as guaricamo. 
If its branches happened to be used as a spit, they would cause death to those who eat 
the meat. Early work on guachamaca led to the isolation of an alkaloidal substance which 
was given the name guachamacine. Soon after its isolation, guachamacine was shown to 
have a curare-like action.
Malouetine is pharmacologically certainly the most interesting of the Malouetia alkaloids. 
Quevauviller and Lainé in 1960 described the structure of malouetine after they had 
isolated it from the plant extract.23 Malouetine or related drugs could offer alternatives to 
d-tubocurarine and some compounds were synthesized which appeared indeed to have 
a neuromuscular blocking effect.24Further research led to four aminosteroidal muscle 
relaxants: pancuronium, vecuronium, rocuronium and rapacuronium. Rapacuronium, 
however, was withdrawn from the market shortly after its release because of a high inci­
dence of bronchospasm.
The development of pancuronium, vecuronium and rocuronium
Pancuronium consists of a steroidal nucleus with two acetylcholine moieties. The name 
pancuronium was derived from p(iperidino)an(drostane)cur(arising)-onium. In 1966, 
pancuronium was first given to two patients by Baird.25 In these two patients a dose of 2 
mg produced full NM B without cardiovascular side-effects. Pancuronium appeared to be 
a potent N M BA  with a duration of action comparable to that of d-tubocurarine. In contrast 
to d-tubocurarine, its ganglion-blocking potency and histamine releasing properties were 
weak, and hence the side effects of hypotension and bronchospasm associated with d- 
tubocurarine were absent with pancuronium.
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A series of 3 and 17 substituted pancuronium analogs were synthesized. This group of 16 
compounds was studied. Vecuronium (Org NC45) was the compound selected for further 
development. It is a mono-quaternary compound which is only 1.6 times less potent than 
pancuronium (in cats), shorter acting and without cardiovascular side-effects (in dogs).26 It 
was first administered in humans by Crul and Booij in 1980.27
Many other aminosteroidal compounds were synthesized and tested in animals and some 
of them were also tested in humans. Among them a vecuronium analog, Org 9426 (ro­
curonium), was studied. The results showed that rocuronium had little or no cardiovascu­
lar effects and its duration of action seemed similar to that of vecuronium.28 Rocuronium 
was further developed and proved to have a fast onset of action in humans.
The pharmacology and pharmacokinetics of vecuronium and rocuronium
Vecuronium
Vecuronium is a monoquaternary aminosteroidal NMBA, with an intermediate duration 
of effect and without cardiovascular side-effects.26 In humans its onset of action is about 
3 minutes, and its duration of effect is 20-35 minutes when a dose of 0.1 mg kg-1 (2 x 
ED95) is administered. Like all other relaxants, vecuronium is potentiated by inhalational 
anaesthetics.29
Vecuronium is metabolised by de-acetylation in the liver, producing three metabolites: 
3-desacetyl-vecuronium, 17-desacetyl-vecuronium, and 3,1 7-desacetyl-vecuronium.30 
The metabolite 3-desacetyl-vecuronium exerts a strong pharmacological effect equal to 
80% that of vecuronium.31 This 3-desacetyl-vecuronium may contribute to the cumulative 
effect of repeated doses of vecuronium.32
Biliary excretion of vecuronium in animals and humans accounts for 30-50% of the 
injected dose.33 Only 10-25% is excreted in the urine.34 In patients with renal failure, 
clearance is reduced and terminal elimination half-life is increased.35
Rocuronium
Rocuronium is, like vecuronium, a NM BA with a monoquaternary aminosteroidal struc­
ture. Rocuronium is however, less potent. It is characterized by a short onset time and an 
intermediate duration of effect. After a bolus dose of 0.6 mg kg-1 (2 x ED95) patients can 
be intubated within 1-2 minutes, and NM B lasts for about 35 minutes. W ith a high dose 
of rocuronium (4 x ED95 = 1.2 mg kg-1), the onset time of NM B (mean 55 sec) resembles 
the onset time of succinylcholine (mean 50 sec).36 Therefore rocuronium may serve as 
an alternative for succinylcholine when a rapid sequence induction of anaesthesia is 
needed. However at this high dose the duration of action resembles the long-acting NM BA 
pancuronium, in contrast to the duration of action of succinylcholine (3-5 minutes). Ro-
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curonium has minimal effect on the heart rate and blood pressure and does not cause 
histamine release.37
The pharmacokinetics of rocuronium resembles those of vecuronium. However, compared 
to vecuronium, rocuronium lacks an ester group at position 3 of the steroid skeleton. 
Consequently, de-acetylation, which in the case of vecuronium results in the pharmaco­
logically active 3-desacetyl-vecuronium, cannot occur with rocuronium. So far, active 
metabolites of rocuronium have not been shown in humans. Rocuronium is mainly taken 
up by the liver and excreted via the bile, and only 26%  of an administered single dose 
was recovered from urine within 48 hours.38 Because of this the duration of action may be 
prolonged in patients with renal or hepatic failure.35 In patients with severe renal failure, 
the clearance of rocuronium is reduced by 33-39%, with a 66-84% increase of mean 
residence time of rocuronium.39;40
ANAESTHETIC M ORBIDITY W ITH NON-DEPOLARIZING MUSCLE 
RELAXANTS
Nowadays, it is recognized that the use of NMBAs in anaesthesia contributes considerably 
to its morbidity and mortality. The most important reason for such problems is variability 
in effect, residual paralysis, histamine release and allergic reactions.
The variability in the effect of NMBAs
Many enthusiastic reports on the clinical use of the early curare preparations appeared in 
the literature, heralding curare as the drug for muscle relaxation. The clinical anaesthesiol- 
ogist, however, was entirely dependent on the subjective observations of the surgeon as to 
whether the patient was sufficiently relaxed. This led to a high incidence of unrecognised 
residual paralysis at the end of surgery.
The development of clinical quantitative evaluation methods resulted in a more objective 
measurement of muscle relaxation and the recognition of residual paralysis. Many meth­
ods have been developed for objective neuromuscular transmission monitoring, including 
the methods mentioned earlier, M M G  and AM G, which have made it easier to detect the 
presence of residual paralysis and recognize the variability in the duration of action of the 
NMBAs.
It was realized that variability in effect might be a factor in the morbidity and mortality of 
anaesthesia. Many NMBAs have been synthesized and clinically investigated. However, 
although they provided excellent muscle relaxation, the variability in effect remained. 
Even the newer NMBAs, belonging to either the benzylisoquinolines or aminosteroidal 
compounds, display a wide variability in the degree of effect and duration of action.
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Numerous factors contribute to such variability. For example inter-individual differences 
exists in liver and kidney function, body composition41, age42, gender43, concurrent medi­
cation44, concurrent diseases35;40, haemodynamics, acid-base status, and temperature. 
There are also differences in the type, the depth, and the duration of the anaesthetic 
administered.45 Moreover, different NMBAs have a different pharmacological profile. 
All these factors have an effect on the pharmacodynamics of the NMBAs. This causes a 
large variation in their duration of action, leading to the possibility of unwanted residual 
postoperative paralysis.
Residual paralysis
The second major problem related to the use of NMBAs is the occurrence of residual 
paralysis, or postoperative residual curarization (PORC). Variability in effect is one of the 
most important factors causing PORC and postoperative pulmonary complications. 
Residual paralysis is still a frequent phenomenon in the post anaesthesia care unit 
(PACU).46-49 The incidence of PORC and postoperative pulmonary complications was 
proven to be higher with NMBAs with a long duration of effect in comparison to those 
with an intermediate duration of effect.50 Despite the application of techniques proven to 
limit the degree of residual paralysis, such as the use of intermediate-acting NMBAs and 
pharmacological reversal at the end of surgery, up to 33%-64%  of patients have evidence 
of residual paralysis on arrival to the PACU.51;52 Debaene et al. demonstrated that even 
after a single intubating dose of a NM BA with an intermediate duration of action, 16% of 
the patients had a TOF ratio <0.7 and 4 5 %  a TOF ratio <0.9.46
Residual NM B has been identified as a common aetiological factor in anaesthesia-related 
mortality and morbidity.53 In a number of papers it was indicated that PORC resulted in 
postoperative pulmonary complications, such as upper airway obstruction and hypox­
ia.53-58 PORC is also associated with inadequate recovery of pulmonary function, reduced 
pharyngeal muscle coordination increasing the risk of aspiration and an impaired hypoxic 
ventilatory response.59-62
Residual paralysis was defined in the past as a TOF ratio < 0.7. This was based on the 
research by Ali et al., who found that at a TOF ratio of 0.7, post tetanic fading was no 
longer present.63 Later, it was demonstrated by Eriksson et al. that at a TOF ratio of 0.7, the 
sensitivity of the peripheral chemoreceptors for hypoxia was still depressed.59;60;64 There­
fore, with residual paralysis severe hypoxemia may occur. Also at a TOF ratio of 0.7 visual 
disturbances, pharyngeal dysfunction (disturbances in swallowing) and muscle weakness 
still exist.61;62 These studies led one to the reconsideration of the value indicating return 
of complete recovery from NMB. Today, a TOF ratio of > 0.9 is considered full recovery 
from N M B.15
It must be concluded that PORC contributes to the morbidity and mortality of anaesthesia. 
Therefore neuromuscular transmission must be monitored whenever a NM BA is adminis­
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tered and a reversal agent should be administered whenever residual paralysis (TOF ratio 
< 0.9) is present at the end of surgery.
Histamine release
Part of the morbidity related to NMBAs is due to histamine release, a characteristic es­
pecially associated with the benzylisoquinoline derivatives and also succinylcholine.13 
Histamine release not only leads to facial erythema, hypotension and tachycardia, but 
also to bronchospasm and hypoxia, and is therefore potentially harmful.
Histamine release associated with the administration of d-tubocurarine was described as 
early as 1 939.65 The histamine release associated with benzylisoquinolines, including the 
newer benzylisoquinolines atracurium and mivacurium, has been confirmed by many 
authors.66 The mechanism is due to the non-immunologic degranulation of mast-cells. 
Such effects have not been described for the aminosteroidal NMBAs.
Allergic reactions
Immediate hypersensitivity reactions, such as allergic or anaphylactic reactions, occur in 
one of every 5000 to 10.000 anaesthetics. NMBAs represent the most frequently incrimi­
nated substances and are responsible for 50-70% of the cases.67 Hypersensitivity reactions 
to NMBAs are mainly acute immunoglobulin E (IgE)-dependent allergic reactions. In 
sensitized individuals these IgE antibodies bind to receptors in mast cells and blood baso­
phils, and stimulate cells to release inflammatory mediators, such as histamine, tryptase 
and several cytokines. The involved target organs include the skin, mucous membranes, 
cardiovascular and respiratory systems and the gastrointestinal tract, causing erythema, 
urticaria, hypotension, tachycardia or bronchospasm. Clinical manifestations show 
variations, ranging from mild hypersensitivity reactions to severe anaphylactic shock and 
death.67;68
In most reports succinylcholine seems to be more frequently involved. Pancuronium and 
cisatracurium are the NMBAs associated with the lowest incidence of anaphylaxis during 
anaesthesia. Some controversy has arisen concerning a potential increased prevalence of 
allergic reactions to rocuronium.67 The quaternary ammonium ions are suggested to be the 
allergenic determinants in NMBAs.68
In 15-50% of cases, the reactions are reported at the first known contact with a NMBA. 
This suggests a possible cross-reaction with IgE-antibodies generated by previous contact 
with apparently unrelated chemicals. An example is the report that an exposure to a cough 
mixture containing pholcodine may be responsible for the significant increase in specific 
IgEs to NMBAs, leading to an increased risk of allergic reactions to NMBAs.67;69
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THE USE OF NEUROM USCULAR BLOCKING DRUGS IN RENAL FAILURE
Prolonged NMB has been reported in patients with renal failure after administration of 
older non-depolarizing NMBAs (such as gallamine, d-tubocurarine and pancuronium), all 
of which are excreted, in part, by the kidney.13 This has also been described for the newer 
NM BA rocuronium: the mean time to spontaneous recovery to a TOF ratio of 0.7 from 
rocuronium-induced NM B was significantly prolonged in patients with end-stage renal fail­
ure compared with patients with normal renal function.40 This has been confirmed in several 
other clinical studies, although not consistently so.39;70 Also, inter-individual variability is 
increased in renal failure patients, resulting in a less predictable duration of action.35 
The prolonged duration of action of NM B in renal patients may be due to the reduced 
clearance of rocuronium, but also due to the disease state itself (causing a different volume 
of distribution, for example) and the possible interactions with additional medication often 
taken by these patients. Therefore, patients with renal insufficiency have an increased risk 
of PORC and postoperative respiratory complications.
Vecuronium has no prolonged duration of action in patients with renal failure. However, 
residual paralysis has been described after long-term administration of vecuronium in 
critically ill patients with renal failure.71 Vecuronium undergoes hydrolysis to three phar­
macologically active metabolites, of which 3-desacetyl-vecuronium is the most potent.30,31 
This 3-desacetyl-vecuronium, which has 80%  of the potency of the parent compound 
vecuronium, is probably responsible for the reported episodes of prolonged NM B in criti­
cally ill patients with renal insufficiency.71;72
THE REVERSAL OF NEUROM USCULAR BLOCK
Reversal of NM B is important not only for the prevention and treatment of residual pa­
ralysis at the end of an operation, but also as an escape route in situations where, after 
administration of a NMBA, it is impossible to intubate the trachea and to ventilate the 
patient by mask (cannot intubate cannot ventilate). Reversal of NM B can be achieved by 
administration of acetylcholinesterase inhibitors.
Short history of the use of acetylcholinesterase inhibitors in anaesthesia
The curare reversal effect of neostigmine was described in 1931 by Aeschlimann and 
Reinert.73 The muscarinic side effects, such as bradycardia, bronchoconstriction, hyper­
salivation, abdominal cramps, and nausea and vomiting,74 made anaesthetists reluctant to 
use reversal agents in anaesthesia. Hunter in 1953 demonstrated that neostigmine could 
cause considerable cardio-depression.75 He advocated the simultaneous administration of 
1.3 mg atropine with 2.5 mg of neostigmine. However, atropine also has side effects, such
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as blurred vision, dry mouth and tachycardia. Nevertheless neostigmine is still used today 
and is considered the gold standard for reversal of NMB.
After Gray had introduced the 'Liverpool anaesthetic technique' with administration of 
high dose curare, the administration of neostigmine at the end of surgery became more 
or less routine in the United Kingdom.76 In continental Europe, however, administration 
of neostigmine was not considered 'a must', and was even believed indicative of the poor 
capabilities of the anaesthetist, not being able to appropriately dose the various drugs ac­
cording to the need of the individual patient. Only when monitoring of the neuromuscular 
transmission became more frequently applied, the need to reverse NM B became clear. 
Variability of effect and PORC nowadays underline the need for adequate reversal of 
NMB.
Reversal of neuromuscular block with acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors (anticholinesterases) inactivate the enzyme acetylcholines­
terase at the NMJ, inhibiting the breakdown of the neurotransmitter acetylcholine, leading 
to an increase of the concentration of acetylcholine available for the nAChR.77 However, 
once the enzyme is completely inactivated, additional administration of anticholinesterase 
produces no further increase in the availability of acetylcholine. Therefore, a dose exceed­
ing 0.07 mg kg-1 neostigmine is unlikely to achieve additional effect.78 Administration 
of an anticholinesterase has no effect on the NM BA itself and therefore no effect on the 
concentration of the N M BA  at the NMJ.
Until recently the administration of anticholinesterases was the common method of re­
versing a NMB. As with NMBAs, there is a large inter-individual variability in the effect of 
these compounds. Furthermore, specific antibiotics may augment the NM B and some of 
these combined blocks may be not reversed by neostigmine.79
The most important factor in the ease of reversal is the degree of N M B.80 More time and 
larger doses are required for the reversal of a profound NM B compared to more shal­
low depths of block.81;82 The administration of anticholinesterases results in an increased 
concentration of acetylcholine which then competes with the NM BA to cause reversal of 
NMB. All the anticholinesterases have a ceiling effect when all the acetylcholinesterase is 
blocked and further administration of the inhibitor no longer increases the concentration 
of acetylcholine. Anticholinesterases fail to fully reverse a NM B when relaxant concentra­
tions are high, making the rapid reversal from a deep NM B impossible.78 
The anticholinesterases also have muscarinic side effects, described above, which con­
tribute to morbidity and mortality. In patients with asthma the administration of anti­
cholinesterases may provoke an asthma exacerbation, as neostigmine causes significant 
bronchoconstriction.83 Anticholinesterases increase the motility of the gastro-intestinal 
tract. Postoperatively, increased intestinal motility can lead to disruption of intestinal 
anastomoses.84
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Further developments in reversal of neuromuscular block
It was necessary to search for an alternative reversal agent with a better pharmacological 
profile. Other existing anticholinesterases were tested for their NM B reversing ability. New 
anticholinesterases were developed, with the aim of specifically inhibiting the acetylcho­
linesterase at the NMJ, thus avoiding the unwanted muscarinic side effects. However, this 
proved to be impossible.
Gaddum in 1957 mentioned antagonism by neutralisation: two drugs combining with 
one another to form an inactive compound.85 Removal of NM BA from the receptor was 
mentioned as a possibility to reverse paralysis in 1961 by Linssen in his PhD thesis at 
the Radboud University in Nijmegen.86 He described in vitro and in vivo studies with 
germanine, antagonizing gallamine, d-tubocurarine and succinylcholine. He wrote:
'By  chemical antagonism or antagonism by neutralisation is an antagonism meant in 
which a pharmacological active substance is removed from the (receptor) environment 
via another, possible pharmacological inactive, substance. The effective concentration of 
the pharmacological active substance in the biophase is thereby decreased. '
And further: 'In case of chemical antagonism is the activity of the antagonist not determined 
by its affinity for certain specific receptors, but by the affinity between the pharmacologi­
cal active substance, the agonist, and the antagonist
Following to this principle of drug binding, studies started on the potential reversal of 
NMBAs by chemical chelation with anionic cyclophanes (Organon Laboratories in New- 
house, Scotland).87 This was based on the knowledge that both quaternary ammonium and 
steroidal groups form complexes with the hosting cyclophanes. The compounds proved 
in vitro to be less potent in their reversal activity than the traditionally used neostigmine. 
However, one of the compounds when used in a high concentration almost caused com­
plete reversal of the NMB. Unfortunately, the cavity of such small host-molecules varied 
considerably and their water solubility was relatively low. It was anticipated that this 
might cause problems for reliability and safety of reversal.
In 1996 Bom at the Organon Laboratories searched for a new solvent for rocuronium. He 
observed that rocuronium was less potent when dissolved in cyclodextrin than when dis­
solved in the original buffer solution.88 He made the mental connection of the retention of 
rocuronium by the cyclodextrin. He also realised that cyclodextrins have a better defined 
lipophilic cavity and were more soluble in water than the cyclophanes which were tested 
previously. W ith this serendipity, the idea of encapsulation as a method for reversal of 
NM B was born.
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SUGAMMADEX
The idea of Bom started the search for more specific binding of rocuronium to cyclodex- 
trins to produce host-guest complexes. Only the ß- and y-cyclodextrin cavities were large 
enough to hold the steroid nucleus of rocuronium. Initially, a series of y-cyclodextrins with 
an increased binding ability for rocuronium was synthesized. Unfortunately the whole 
steroid nucleus of rocuronium was still unable to fit into the cavity. Extending the cavity 
height by adding side chains was indicated. Theoretically, by giving these side chains on 
the y-cyclodextrin molecule a negative charge electrostatic binding with the positively 
charged ammonium group of the rocuronium molecule would occur. Anionic carboxylic 
functions were added to the y-cyclodextrin at the glucose monomers 6 position. This 
served to increase the electrostatic affinity for rocuronium, as well as increasing the height 
and the width of the cavity.89
Nine members of this modulated series of y-cyclodextrin derivatives were studied in 
animals. Compound Org 25969 (per-6-(2-carboxyethylthio)-per-6-deoxy-y cyclodextrin 
sodium salt) was selected because of its high affinity for rocuronium compared with 
the other compounds.90 Finally, this led to the compound sugammadex, a modified 
y-cyclodextrin which encapsulates aminosteroidal NMBAs.91
The mechanism of action of sugammadex
Sugammadex is the first selective relaxant binding agent designed to reverse the NMB 
induced by aminosteroidal NMBAs. Sugammadex does not interfere with acetylcholin­
esterase or the nAChR, but binds the NM BA molecule itself (Figure 3). Each molecule of 
sugammadex encapsulates one molecule of rocuronium or vecuronium, which leads to a 
rapid decrease of the concentration of free NM BA molecules in the plasma. As a result of 
the concentration gradient of free molecules between plasma and NMJ, steroidal NM BA 
molecules diffuse away from the NMJ (and the nAChR) into the plasma. This leads to a 
rapid dissociation of the NM BA from the nAChR and a rapid recovery from NMB. Acetyl­
choline receptor occupation can then recur and muscle contraction becomes possible.91;92 
The binding of the steroidal molecules by sugammadex is very strong. This is due to the 
intermolecular (van der Waals) forces, hydrogen bonds and hydrophobic interactions. 
The complex of the steroidal NM BA with sugammadex exists in equilibrium, with a high 
association rate and a low dissociation rate, which favours the complex formation. The 
association constants of sugammadex for vecuronium and rocuronium are 10 x 106 mol-1 
and 25 x 106 mol-1 , respectively.94
Due to its mechanism of action sugammadex has no effect on the acetylcholine con­
centration in the nicotinic or muscarinic synapses. Therefore, sugammadex is free from 
muscarinic effects such as bradycardia, vomiting, and bronchoconstriction. Also, sugam-
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Figure 3: X-ray crystal structures of a rocuronium molecule (A) and a sugammadex molecule (B). 
Encapsulation of rocuronium by sugammadex at 1:1 ratio.
Gijsenbergh et al. Anesthesiology 2005; 1 03: 695-703,93 with permission from MSD.
madex does not interfere with any receptor, which also makes the occurrence of unwanted 
effects very unlikely.
In vitro and in vivo animal studies with sugammadex
Studies in mouse nerve-hemidiaphragm indicated that rocuronium-induced NM B is more 
effectively reversed by sugammadex than vecuronium-induced NM B.94 Studies were also 
performed using atracurium and mivacurium, neither of which were reversed by sugam­
madex.95 Sugammadex proved to be specific for aminosteroidal NMBAs.
NMBAs, reversal of neuromuscular block and renal function 31
In a study in guinea pigs it was demonstrated that after administration of sugammadex 
the total plasma concentration of rocuronium increased.92 Later, this was confirmed in 
studies in humans.93;96;97 This increase of rocuronium is explained by rapid formation of 
the rocuronium-sugammadex complex in the plasma. After sugammadex administration, 
free rocuronium molecules in the plasma are rapidly bound to sugammadex. This creates 
a concentration gradient of free rocuronium molecules between the NMJ and the central 
compartment (the plasma). As they enter the plasma, more free rocuronium molecules 
are encapsulated by abundant sugammadex. As the assay method cannot differentiate 
between free and encapsulated rocuronium, the encapsulation of rocuronium appears as 
an increase in total plasma rocuronium concentration.
This confirmed the concept that sugammadex binds rocuronium, resulting its removal 
from the effect compartment (the NMJ) and the diffusion of rocuronium to the plasma, thus 
resulting in recovery from NMB.
In some relatively rare situations, is it necessary to re-establish NM B after reversal by su­
gammadex of a previous NMB. In these circumstances some free sugammadex may still be 
present and will encapsulate newly administered NMBAs, decreasing the neuromuscular 
blocking effect. The duration of action of sugammadex was therefore studied in anaes­
thetized rhesus monkeys.98 The effect of the second dose of rocuronium, after reversal by 
sugammadex, increased with the time delay after the sugammadex administration and 
almost reached the original effect after a delay of 60 min. This experiment indicates that 
after reversal of NM B with sugammadex, it is possible to reinstate NM B with rocuronium, 
although, depending on the elapsed time, a higher dose of rocuronium will be required.99 
Since non-steroidal NMBAs (succinylcholine and benzylisoquinolines) are not reversed by 
sugammadex, it is also possible to re-establish NM B with these NMBAs.
The conclusion from these animal studies is that sugammadex proved to be a safe, rapid, 
and effective reversal agent for shallow and profound NM B induced by steroidal NMBAs, 
and in particular rocuronium.
Clinical studies with sugammadex
In the first study in volunteers it was demonstrated that dosages of 4-8 mg kg-1 of sugam­
madex resulted in an adequate and rapid reversal (within 2-3 minutes) of a rocuronium- 
induced NMB, even when sugammadex was administered within 3 minutes after the 
rocuronium administration.93 Sugammadex not only is effective in reversing rocuronium- 
induced NMB, but also in reversing vecuronium-induced NM B and with a higher dose, 
pancuronium-induced N M B.100-102
The longer the time interval between the administration of rocuronium and that of su­
gammadex, the faster complete recovery of NM B after sugammadex administration is 
achieved.96 However, sugammadex in a high dose was also effective in reversing a pro­
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found NM B induced by a high dose of rocuronium (1.2 mg kg-1), even when sugammadex 
was administered only 3 minutes after induction of NMB. 103
Inhalational agents potentiate the effect of NMBAs.45 The effect of sugammadex, however, 
does not differ between inhalational and intravenous anaesthesia.104 The time of reversal 
of NM B by sugammadex is similar in all the age groups at a dose of 2 mg kg-1 for reversal 
of shallow NM B (after reappearance of the second twitch of the TOF).105 
Sugammadex was administered in patients with pulmonary and cardiovascular dis­
eases.10^ 107 Unwanted effects were not observed, and the effect of sugammadex was not 
affected by the diseases. A study in volunteers demonstrated that sugammadex has no 
effect on QT-time.108
Sugammadex is biologically inactive, and appeared to be safe and well-tolerated in the 
clinical studies described. In some clinical trials dysgeusia (a metallic or bitter taste) was 
reported, which was mainly seen after sugammadex dosages > 32 mg kg-1.109 A few cases 
of allergy-like reactions (flushing, erythematous rash) were reported.110
Comparison with neostigmine
The reversal of rocuronium-induced NM B is faster with sugammadex than either with 
neostigmine or edrophonium.111;112 In another study it has been proven that rocuronium 
reversed with sugammadex has a faster recovery than cisatracurium reversed with neostig­
mine.113 Furthermore, neostigmine is unable to reverse deep NM B whereas sugammadex 
16 mg kg-1 is able to reverse the effects of high-dose rocuronium even 3 minutes after 
induction of the N M B.103;114
Pharmacokinetics of sugammadex
After intravenous administration, sugammadex demonstrates linear pharmacokinetic 
properties over the dose range of 1-16 mg kg-1. Sugammadex and the sugammadex- 
rocuronium complex do not bind to plasma proteins or erythrocytes. Sugammadex does 
not appear to undergo metabolism and is primarily excreted in the urine as the unchanged 
drug; the elimination half-life is approximately 1.7 hours. The plasma clearance is esti­
mated to be 85-120 ml min-1, which is similar to the glomerular filtration rate. In healthy 
volunteers, a mean percentage of 59-80% was excreted in the urine up to 24 hours after 
sugammadex administration.93
When sugammadex is administered after a dose of rocuronium, urinary excretion of 
rocuronium increases, with increasing doses of sugammadex. In patients receiving ro­
curonium alone, 19% of the rocuronium dose is recovered in the urine until 16 hours after 
administration. After administration of sugammadex, the proportion of the rocuronium 
dose excreted in the urine is increased to 53%  until 16 hours after administration.97 The 
percentage urinary excretion of a dose of rocuronium increases up to a maximum of 68% 
over 24 hours. After encapsulation by sugammadex, rocuronium is confined in the space
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in which sugammadex resides and the plasma clearance of rocuronium assimilates into 
the plasma clearance of sugammadex.93
The molecule has a very limited trans-placental transfer and passage of the blood-brain 
barrier. Unlike rocuronium, the sugammadex-rocuronium complex is not eliminated via 
the biliary route.
Interaction of sugammadex with other drugs
Theoretically, sugammadex is able to bind other drugs. Such interactions were studied 
in vitro for two reasons. First, because these drugs may displace rocuronium, which can 
result in recurrence of NMB. Second, the effect of the other drugs may be decreased 
when they are encapsulated by sugammadex. Many relevant compounds (>300) have 
been studied and it was found that sugammadex also binds toremifene (a substituent of 
the anticancer drug taxol), flucloxacillin (an antibiotic), and fusidic acid (a bacteriostatic 
agent).115
The ability of sugammadex to form complexes with other steroidal and non-steroidal com­
pounds such as cortisone, atropine, hormonal contraceptives, remifentanil, verapamil, 
fusidic acid, and flucloxacillin is insignificant and approximately 120-700 times less than 
the affinity for rocuronium.115 However, it is recommended that flucloxacillin should be 
avoided until 6 h after sugammadex and a missed dose advice should be followed in 
patients taking oral contraceptives when given sugammadex.110
In none of the clinical studies performed so far any sign of drug interactions was noticed. 
Conclusion
Sugammadex is an effective selective relaxant binding agent that rapidly reverses shallow, 
moderate and profound levels of NM B induced by aminosteroidal NMBAs. Its effect is not 
influenced by either inhalational or intravenous anaesthesia. It is free from muscarinic side 
effects and can modify the time course of action of the steroidal NMBAs to the individual 
need of the case. W ith sugammadex available sufficient NM B can be maintained until the 
end of surgery without concern about residual paralysis, easing the work of the surgeon. 
The duration of action of rocuronium can be changed from intermediate to short because 
its effects can be rapidly reversed by sugammadex even just 3-5 min after a large dose 
of rocuronium. Rapid reversal of rocuronium can be achieved if there is difficulty with 
airway management and tracheal intubation (cannot intubate cannot ventilate), and may 
enable rapid return of spontaneous respiration, so called 'rescue' reversal.
Most importantly, sugammadex may improve patient safety, as it prevents PORC after the 
use of aminosteroidal NMBAs. Reduction of the incidence of PORC may also decrease 
the incidence of postoperative pulmonary complications, which may have an effect on 
anaesthesia-related morbidity.
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THE USE OF SUGAMMADEX IN RENAL FAILURE
As described before, patients with renal failure are especially vulnerable to the effects of 
NMBAs. They may have a longer duration of action of rocuronium and are therefore at risk 
of developing residual paralysis. This patient group would benefit from a selective relaxant 
binding agent, such as sugammadex, with few side effects.
However, sugammadex and the sugammadex-rocuronium complex are eliminated by the 
kidneys.93 Also, administration of sugammadex leads to altered elimination of rocuronium, 
as it promotes the renal excretion of rocuronium, and the extrarenal route of elimination is 
expected to be unavailable for encapsulated rocuronium.96
Patients with renal failure will retain the sugammadex-rocuronium complex for a longer 
period of time. This raises concerns regarding the safety of the drug in this patient group: 
when the elimination pathway of rocuronium is diverted from hepatic clearance to renal 
clearance after administration of sugammadex, what will happen to the complex when 
renal clearance is decreased? W ill the reversal of rocuronium-induced NM B by sugamma­
dex be effective? And if the complex is not cleared renally, will patients with severe renal 
failure have more side effects from the drug? Is there a possible risk, when rocuronium is 
not cleared from the body, that paralysis will recur?
The aim of the studies described in this thesis is to investigate the efficacy of sugammadex 
in reversing NM B in renal failure, both in animals (the cat) and in humans; to describe the 
pharmacokinetics and the safety profile of sugammadex and rocuronium in renal failure 
patients compared to healthy controls; and to investigate the efficacy of sugammadex in 
reversing NM B induced by 3-desacetyl-vecuronium, a metabolite of vecuronium, possibly 
leading to residual paralysis in critically ill patients with renal failure.
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Sugammadex is a selective relaxant binding agent designed to encapsulate the 
aminosteroidal neuromuscular blocking agent rocuronium, thereby reversing its effect. 
Both sugammadex and the sugammadex-rocuronium complex are elim inated by the 
kidneys. This study investigated the effect of sugammadex on recovery of rocuronium- 
induced neuromuscular block in cats w ith clamped renal pedicles, as a model for acute 
renal failure.
Methods
Twelve male cats were divided into two groups and anesthetized w ith medetomidine, 
ketamine and alpha-chloralose. The cats were intubated and ventilated w ith a mixture 
of oxygen and air. Neuromuscular monitoring was performed by single twitch monitor­
ing. Rocuronium 0.5 mg kg-1 i.v. was administered. After spontaneous recovery from 
neuromuscular block, both renal pedicles were ligated. A  second dose of rocuronium
0.5 mg kg-1 i.v. was given. One minute after disappearance of the twitches, in Group 1 
placebo (0.9% saline) and in Group 2 sugammadex 5.0 mg kg-1 i.v. was administered. 
Onset time, duration of neuromuscular block and time to recovery to 25, 50, 75 and 90% 
were determined.
Results
After renal pedicle ligation, sugammadex reversed rocuronium-induced neuromuscular 
block significantly faster than spontaneous recovery. Mean time (SEM) to 90% recovery of 
the twitch response was 4.7 (0.25) minutes (Group 2) versus 31.1 (5.0) minutes (Group 1) 
(p<0.0001). No signs of recurrence of neuromuscular block were observed for 90 minutes 
after complete twitch restoration. Sugammadex caused no significant cardiovascular ef­
fects.
Conclusion
Sugammadex rapidly and effectively reversed rocuronium-induced neuromuscular block 
in anesthetized cats, even when both renal pedicles were ligated and renal elim ination of 
the drugs was no longer possible.
Sugammadex in cats with renal failure 45
Rocuronium is a non-depolarizing aminosteroidal neuromuscular blocking agent, 
w ide ly used in anesthesia.1 Recovery from neuromuscular block occurs spontaneously 
as the muscle relaxant diffuses away from the neuromuscular junction and is eliminated. 
However, postoperative residual curarization is a potential problem after administra­
tion of neuromuscular blocking agents, as it is a risk factor for postoperative pulmonary 
complications, for example aspiration and hypoxia.2 Reversal of neuromuscular blocking 
agents has traditionally been achieved by administration of acetylcholinesterase inhibitors 
(anticholinesterases). However, anticholinesterases are only effective in reversing neuro­
muscular block if recovery has already started.3 Also, anticholinesterases have muscarinic 
side-effects (nausea, vomiting, bradycardia, bronchoconstriction), which require the con­
comitant administration of atropine.3
Sugammadex, a modified y-cyclodextrin, is the first selective relaxant binding agent de­
signed to encapsulate and inactivate rocuronium, thereby rapidly reversing its effect.4 The 
high affinity of sugammadex for rocuronium (association constant Ka of the sugammadex- 
rocuronium complex is 25 x 106 M -1) results in complex formation (1:1).4,5 Sugammadex 
encapsulates a large fraction of the rocuronium molecules in plasma, which results in a 
rapid decrease in the concentration of free (unbound) rocuronium in plasma. This creates 
a concentration gradient of free rocuronium molecules between the effect compartment, 
the neuromuscular junction, and the plasma. Rocuronium molecules return to the plasma, 
where they are encapsulated by more sugammadex molecules.4,6 Second, because of the 
high concentration of uncomplexed sugammadex in plasma, sugammadex molecules w ill 
rapidly distribute from plasma towards the extracellular compartment, because of the 
concentration gradient.5 As a result of these concentration gradients, complexation w ill 
occur rapidly and the neuromuscular block w ill decrease.
Because sugammadex does not interfere w ith acetylcholinesterase, it lacks muscarinic 
side-effects. Also, it has been proved to reverse profound neuromuscular block directly 
after a high dose of rocuronium had been administered.7 Sugammadex is a water-soluble 
molecule, which is excreted in the urine in its unchanged form.8
In patients receiving rocuronium, the drug is mainly taken up by the liver and excreted 
into the bile.1 The mean percentage of rocuronium recovered from the urine w ith in 48 
hours after administration is 26% of the administered dose.9 After complex formation by 
rocuronium and sugammadex, the pathway of hepatic uptake and b ilia ry excretion of 
encapsulated rocuronium is no longer possible and the complex can on ly be excreted by 
the kidneys. Therefore, administration of sugammadex promotes the renal elim ination of 
rocuronium, dose-dependently, up to 74% after administration of high doses of sugam­
madex (8 mg kg-1). 8,10
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Because of the changed distribution and elim ination of rocuronium (from hepatic to renal 
elim ination) after its encapsulation by sugammadex, the efficacy and persistence of re­
versal of neuromuscular block could be related to the renal excretion of the rocuronium- 
sugammadex complex. Because excretion of the complex by the kidneys is no longer 
possible in renal failure, there are concerns regarding the safety of the drug, and the pos­
sib ility of recurrence of neuromuscular block. The objective of this study was to determine 
whether the sugammadex-induced reversal of rocuronium-induced neuromuscular block 
was modified by occlusion of both renal arteries in anesthetized cats.
METHODS
In-vivo experiments were performed in the Animal Laboratories for Experimental Anes­
thesia, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. The 
experiments were approved by the regional ethics committee on animal experiments. 
Twelve experiments were performed on 12 different male cats, weighing between 3.3 
and 5.5 kg (mean weight 4.65 kg). The cats were deeply anesthetized w ith medetomidine 
(Dormitor®, Norden Labs) 80 |ig kg-1 and ketamine (Ketaset®, W illow s Francis) 5 mg kg-1, 
intramuscularly. A lpha chloralose (BHD) 90 mg kg-1 was administered intraperitoneally, 
followed by intravenous administration of 10 mg kg-1 as required, for maintenance of 
anesthesia. Two intravenous lines were placed; one for anesthetic administration, includ­
ing rocuronium, the other for test drug administration.
After anesthesia induction, the cats were intubated endotracheally and the lungs were 
ventilated w ith a m ixture of oxygen and air in a volume ratio of 1:3. Heart rate, oxygen 
saturation, blood pressure and temperature were monitored and recorded every 10 s. Heart 
rate and peripheral oxygen saturation were determined at the ear w ith a pulse-oximeter 
(Biox; Ohmeda, Madison, W I, USA); also a blood gas analyzer (Rapidlab 248, Bayer) was 
used for arterial oxygen saturation measurement. Blood pressure was determined using an 
arterial line placed into the right femoral artery. Temperature was recorded w ith a rectal 
probe and was kept at 37-38 0 C.
A  laparotomy was performed to place a ligature at both renal pedicles, so both renal 
arteries and veins could be occluded later during the experiment.
For monitoring purposes the sciatic nerve of the right leg was stimulated supramaximally 
using clamp electrodes and a force displacement transducer for mechanomyography was 
connected to the tibialis muscle. Stimulation was performed w ith 2 ms square wave pulses 
in a single twitch sequence of 0.1 Hz by a Grass S88 Stimulator (Grass Medical Instru­
ments, Quincy, MA, USA).
W hen the animal was in a hemodynamic stable situation and neuromuscular monitoring 
was stable, rocuronium bromide was administered as an intravenous bolus injection in a
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dose of 2 x ED90 (0.5 mg kg-1). The ED90 was defined as the dose of rocuronium which pro­
duced a mean maximum neuromuscular block of 90% in the cat population. The animals 
were left to recover from neuromuscular block (100% recovery of the twitch response) 
spontaneously. N inety minutes after recovery of the twitch responses both renal pedicles 
were ligated. Thirty minutes after the renal pedicle ligation, a second dose of rocuronium 
bromide 0.5 mg kg-1 was administered.
Twelve cats were studied and were divided into two groups. In Group 1 (control, n=5), 
placebo (0.9% saline) was administered 1 minute after complete neuromuscular block 
was induced by the second dose of rocuronium. In Group 2 (n=7), 5.0 mg kg-1 sugam­
madex was administered, 1 minute after induction of neuromuscular block by the second 
dose of rocuronium.
Onset time of neuromuscular block, duration of neuromuscular block, time to recovery of 
the twitch response to 25, 50 and 90% and the recovery index (time from 25% recovery 
to 75% recovery) were determined for each rocuronium administration. Onset of neuro­
muscular block was defined as the time (min) from administration of rocuronium until 
disappearance of single twitch response. Duration of neuromuscular block was defined as 
the time (min) from disappearance of twitch response until the first visible twitch response. 
Time to 25, 50, 75 and 90% recovery was defined as the time (min) from administration of 
rocuronium until recovery of the twitch response to 25, 50, 75 and 90% of twitch height 
relative to baseline values. Residual block and recurrence of neuromuscular block were 
assessed by continuing neuromuscular monitoring for another 90 minutes after complete 
twitch restoration.
Blood pressure and heart rate were recorded for analysis at four time points: before injec­
tion of rocuronium (both groups), 1 minute after rocuronium (both groups), before sugam­
madex (Group 2) and 1 minute after sugammadex (Group 2). The changes were expressed 
as percentages of the values before either rocuronium or sugammadex injection.
A t the end of the experiment, intravenous administration of methylene blue confirmed 
successful renal pedicle clamping in all cats. After completion of the experiment, the 
animals were killed.
Statistics
During the experiments all variables were automatically collected, in real time intervals 
of 10 s, and assembled in a data file, which was imported into EXCEL to perform all 
calculations. The data were statistically analyzed w ith the SAS (v 8.02) procedures (SAS, 
Cary, NJ, USA). Data are presented as mean values w ith SEM in parentheses. A ll measure­
ments obtained from first and second administration of rocuronium were treated as paired 
observation (difference). To reduce inter-individual variability, onset and duration times 
of neuromuscular block were treated as relative paired observation (difference between 
two observations normalized to the first). Changes in blood pressure and heart rate as a
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result of rocuronium or sugammadex were also analyzed as relative paired observations 
(difference/value before) w ith in the groups. Student's t test was performed. The level of 
significance used was p < 0.05.
RESULTS 
Neuromuscular Block
The experimental time course w ith spontaneous recovery is illustrated in the tracing of an 
experiment of Group 1 (control) and presented in Figure 1. Figure 2 is an experiment of 
Group 2, showing recovery after sugammadex administration. Various periods can be rec­
ognized: equilibration (A), constant neuromuscular block 100% (B), spontaneous recovery 
(C), period of renal pedicle clamping at 100% twitch height (D), recovery in presence of 
sugammadex (E), and period for evaluation of any recurrence of neuromuscular block (F). 
The effect of sugammadex on recovery times from rocuronium-induced neuromuscular 
block before and after bilateral renal pedicle ligation is shown in Table 1.
Onset time and duration of rocuronium-induced neuromuscular block after the first 
administration of rocuronium 0.5 mg kg-1 was not significantly different between the two 
groups. Neither was the onset time after the second administration. Spontaneous recovery 
times of neuromuscular block after administration of rocuronium 0.5 mg kg-1, before or
Figure 1: Experimental time course in Group 1 (controls).
Rocuronium, twitch, control
Twitch response after administration of rocuronium 0.5 mg kg-1. After spontaneous recovery, renal 
arteries were clamped. Thirty minutes after renal clamping, a second dose of rocuronium 0.5 mg 
kg-1 was administered. One minute after disappearance of the twitches, placebo (0.9% saline) was 
administered. A: equilibration; B: constant neuromuscular block 100%; C: spontaneous recovery; D: 
period of renal clamping at 100% twitch height; F; period of evaluation of recurrence of neuromuscular 
block.
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Figure 2: Experimental time course in Group 2 (sugammadex).
Rocuronium, twitch, sugammadex
Twitch response after administration of rocuronium 0.5 mg kg-1. After spontaneous recovery, renal 
arteries were clamped. Thirty minutes after renal clamping, a second dose of rocuronium 0.5 mg kg-1 
was administered. One minute after disappearance of the twitches, sugammadex 5.0 mg kg-1 was 
administered. A: equilibration; B: constant neuromuscular block 100%; C: spontaneous recovery; D: 
period of renal clamping at 100% twitch height; E: recovery after administration of sugammadex; F: 
period of evaluation of recurrence of neuromuscular block.
Table 1: Effect of sugammadex on recovery times from rocuronium-induced neuromuscular block 
before and after bilateral renal pedicle ligation.
In Group 1, after the second administration of rocuronium, placebo (0.9% saline) was administered 1 
minute after complete neuromuscular block. In Group 2 sugammadex 5.0 mg kg-1 was administered 1 
minute after complete neuromuscular block after the second administration of rocuronium.
Data are presented as the mean time (SEM) in minutes after administration of an i.v. bolus dose of 
rocuronium 0.5 mg kg-1. Statistics: In Group 2, onset time, duration times and recovery times are 
treated as relative paired observation (difference between two observations relative to the first).
Level of significance: p<0.05. ns= not significant.
Group 1 (N=5) 
(controls)




in Group 2 in the two 
administrations
Rocuronium First Admin. Second Admin. First Admin. Second Admin. Significance 
(Paired relative)
Renal blood flow Intact Interrupted Intact Interrupted
Onset time (min) 1.0 (0.17) 0.9 (0.17) 0.7 (0.03) 0.8 (0.05) ns
Duration (min) 13.8 (2.7) 16.8 (3.2) 17.6 (2.0) 2.5 (0.07) <0.0001
Recovery of the singl e twitch response to
25% (min) 18.5 (2.7) 21.8 (3.4) 23.3 (2.9) 3.0 (0.12) <0.0001
50% (min) 21.2 (3.0) 25.1 (3.9) 26.2 (3.3) 3.5 (0.15) <0.0001
90% (min) 26.4 (3.3) 31.1 (5.0) 30.6 (3.8) 4.7 (0.25) <0.0001
Index 25-75 (min) 5.2 (0.8) 6.7 (1.8) 5.9 (1.0) 1.0 (0.09) <0.0001
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after renal clamping, were also not significantly different (limited to the control group). 
(Table 1)
In Group 2, 30 minutes after renal clamping, sugammadex 5.0 mg kg-1 was administered 
1 min after disappearance of the twitches after the second dose of rocuronium 0.5 mg 
kg-1. After renal pedicle ligation, time to complete recovery of rocuronium-induced neu­
romuscular block was significantly shorter after the administration of sugammadex 5.0 
mg kg-1. Mean time (SEM) to recovery to 90% of the twitch height was 4.7 (0.25) min in 
de sugammadex-induced recovery group (Group 2), compared w ith 31.1 (5.0) min in 
the control group (Group 1), both after interruption of renal blood flow. In Group 2, the 
second recovery to 90%, after renal pedicle ligation and sugammadex-induced recovery 
(4.7 min), was also significantly shorter (p <0.0001) than spontaneous recovery to 90% 
after the first administration of rocuronium (30.6 (3.8) min) and normal renal function. 
After administration of sugammadex 5.0 mg kg-1 all recovery times were significantly faster 
than spontaneous recovery times of rocuronium 0.5 mg kg-1, although renal blood flow 
was interrupted and renal excretion of sugammadex and rocuronium was no longer pos­
sible.
During neuromuscular monitoring for 90 minutes after complete twitch restoration after 
sugammadex no signs of residual paralysis or recurrence of neuromuscular block were 
observed in any of the cats. Also, during recovery from neuromuscular block, the stable 
T1 response was w ith in 80 - 120% of the control (baseline) value, as should be the 
case according to the guidelines on good clinical research practice in pharmacodynamic 
studies of neuromuscular blocking agents. 11
Hemodynamics
Because of technical problems, two cats in Group 2 did not provide usable recordings of 
blood pressure. A  small (3%) but significant increase in heart rate (p=0.035 and 0.037 in 
Group 1 (n=5) and Group 2 (n=5) respectively and p=0.0012 for the two groups together) 
was observed in both groups after all administrations of rocuronium. After sugammadex 
injection in Group 2, there were no significant changes, although there was a tendency 
towards a decrease of heart rate (2.6 %, SEM = 1.1) (p=0.075). Inspecting the heart rate 
tracings suggests that sugammadex immediately reverses the small increase in heart rate 
observed after rocuronium administration.
There were no significant changes in mean arterial pressure after either drug. 
DISCUSSION
This study investigated the efficacy of sugammadex in reversing rocuronium-induced neu­
romuscular block in an animal model of acute renal failure. After complete interruption
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of renal perfusion, sugammadex rapidly and effectively reversed the effect of rocuronium, 
even when renal e lim ination of both drugs was no longer possible. Sugammadex still 
reversed rocuronium-induced neuromuscular block completely in a time significantly 
faster than spontaneous recovery. Recurrence of neuromuscular block was not observed 
for 90 minutes after twitch restoration.
This demonstrates that reversal of neuromuscular block and the speed of reversal are not 
dependent on the renal elim ination of the sugammadex-rocuronium complex. It is the 
formation of the complex between rocuronium and sugammadex and the redistribution of 
rocuronium molecules that prevents their action at the neuromuscular junction. Because 
of the strong complex formation (KA=25,000,000 M -1), a large fraction of the rocuronium 
molecules is always encapsulated by sugammadex, although the compounds cannot be 
excreted in renal failure.
In one study in humans w ith end-stage renal failure, sugammadex effectively and rapidly 
reversed rocuronium-induced neuromuscular block. Recovery times after sugammadex
2.0 mg kg-1 to reverse the neuromuscular blocking effect of rocuronium 0.6 mg kg-1 were 
not statistically different in renal patients compared w ith healthy controls.12 Sugammadex 
was safe and well-tolerated in end-stage renal fa ilure patients and no patients showed 
signs of recurrence of neuromuscular block.12 However, the number of patients studied 
was small.
This does raise questions regarding the long-term safety of sugammadex in renal failure. 
W ha t happens w ith the sugammadex-rocuronium complex which normally is excreted via 
the kidneys and which cannot be metabolized by humans?
Therefore, more animal and human studies are needed to determine the long-term safety 
aspects and the disposition of sugammadex in renal failure, because the clearance of both 
rocuronium and sugammadex is much reduced.13 However, it is to be expected that, as 
long as the b iliary route is open for the free rocuronium molecules, it is most like ly that 
rocuronium plasma concentration w ill decrease faster than that of sugammadex. 
Sugammadex is a y-cyclodextrin, an oligosaccharide forming a cylindrical capsule with 
a lipophilic internal cavity and a hydrophilic exterior.4 Cyclodextrins are highly water- 
soluble and do not have intrinsic biological activity; it is therefore un like ly that side effects 
w ill occur.4 This has also been demonstrated in other animal studies and in various clinical 
trials in humans.6,781014 In our study there was a tendency towards a decrease in heart rate 
after administration of sugammadex, which could be interpreted as a restoration of the 
increase in heart rate caused by the preceding injection of rocuronium.
The results of this study also show that occlusion of both renal pedicles in anesthetized 
cats does not significantly prolong the neuromuscular blocking effect of rocuronium and 
the subsequent spontaneous recovery of neuromuscular function, as recovery times before 
and after renal clamping in Group 1 are not significantly altered.
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In patients w ith normal renal function receiving rocuronium intravenously, 26 % of the 
administered dose of rocuronium was recovered from the urine in 48 h.9 In cats a mean 
percentage of 8.7% of an injected dose of rocuronium is excreted into the urine in 6
h.15 Rocuronium is not dependent on renal blood flow for its major route of excretion, 
but is taken up by the liver and excreted into the bile in high concentrations.9 Although 
hepatic uptake and b iliary elim ination are thought to be the main routes of elim ination for 
rocuronium, it seems that renal fa ilure can have a marked effect on rocuronium pharma­
cokinetics and pharmacodynamics, although not consistently so.161718 In patients w ith no 
or m inimum renal function, the clinical duration and recovery time of rocuronium 0.6 mg 
kg-1 increased significantly.161718 The only explanation that can be given is a change in the 
volume of distribution of rocuronium in renal fa ilure patients. It is probably redistribution 
rather than excretion that is responsible for the duration of action of rocuronium. In our 
study, we clamped the renal pedicles of the cats 30 min before administering the second 
dose of rocuronium, which is a different situation from chronic end-stage renal failure. 
This probably explains why we did not find any differences in onset and duration of 
action, after renal pedicle ligation. Acute renal failure very like ly has no effect on the 
duration of action of rocuronium. W e therefore conclude that in this experiment recovery 
times before and after renal clamping are comparable.
In conclusion, this study shows that after complete interruption of renal perfusion, sugam­
madex still causes rapid and complete reversal of rocuronium-induced neuromuscular 
block, w ithout signs of recurrence of neuromuscular block and w ithout significant car­
diovascular effects. Reversal of neuromuscular block and the speed of reversal are not 
dependent on the renal excretion of the sugammadex-rocuronium complex.
Further studies in humans are required, because this animal model of acute renal fa ilure is 
not fu lly  comparable w ith humans w ith chronic end-stage renal fa ilure and more informa­
tion is needed regarding the long-term safety aspects of sugammadex in renal failure.
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Sugammadex, a modified y-cyclodextrin, is the first selective relaxant binding agent 
that specifically encapsulates the steroidal neuromuscular blocking agent, rocuronium. 
The action of rocuronium is prolonged in patients w ith renal failure. As sugammadex is 
p rim arily cleared renally, this phase III trial investigated the efficacy and safety of sugam­
madex for reversal of rocuronium-induced neuromuscular block (NMB) in patients with 
end-stage renal failure.
Methods
Thirty adult patients were studied: 15 renally-impaired (creatinine clearance (CLcr) <30 
ml min-1) and 15 controls (CLcr >80 ml m in-1). Anaesthesia was induced and maintained 
using i.v. opiates and propofol. Neuromuscular monitoring was performed by accelero­
myography and train-of-four (TOF) nerve stimulation. Rocuronium 0.6 mg kg-1 was given, 
followed by a single i.v. dose of sugammadex 2.0 mg kg-1 at reappearance of the second 
twitch of the TOF. The primary efficacy variable was time from administration of sugam­
madex to recovery of the TOF ratio to 0.9. Safety variables included clinical evidence of 
reoccurrence of NMB.
Results
After sugammadex administration, the mean (SD) time to recovery of the TOF ratio to 0.9 
was 2.0 (0.72) min in renal patients and 1.65 (0.63) min in controls (NS). Recurrence of 
NMB was not observed in any patient. No sugammadex-related serious adverse events 
were reported.
Conclusions
Sugammadex administered at reappearance of T2 rapidly and effectively reverses NMB 
induced by rocuronium in renal fa ilure and healthy patients. Sugammadex was well toler­
ated by all patients. Further safety studies on sugammadex in patients w ith severe renal 
impairment are warranted.
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Rocuronium is a non-depolarizing aminosteroidal neuromuscular blocking agent (NMBA), 
w ith a rapid to intermediate onset of action and an intermediate duration of effect.1 Re­
covery from neuromuscular block (NMB) occurs as the NM BA diffuses away from the 
neuromuscular junction (NMJ) and is eliminated. Use of an acetylcholinesterase inhibitor, 
such as neostigmine or edrophonium, enhances recovery and reduces the risk of residual 
block after operation.2 However, residual NMB remains a potential problem in anaesthe­
sia, as it is a risk factor for postoperative pulmonary complications and antagonists are 
not always administered.3 In addition, acetylcholinesterase inhibitors do not effectively 
reverse profound NMB, particularly in the presence of vo latile anaesthetics, and are inef­
fective when reversal is attempted before spontaneous recovery.456
Sugammadex is a modified y-cyclodextrin, designed to selectively reverse the effects of 
rocuronium. It is also the first selective relaxant binding agent (SRBA). Cyclodextrins are 
cyclic oligosaccharides which can encapsulate a lipophilic guest molecule, such as an 
aminosteroidal NMBA, to form a stable host-guest inclusion complex.7 Sugammadex 
forms a stable complex w ith rocuronium in the plasma, resulting in a rapid decrease in 
effector site concentration of the unbound relaxant.7 Ow ing to the concentration gradient 
of rocuronium molecules between the NMJ and the plasma, the drug can diffuse away 
from the nicotinic receptor, giving rapid recovery from NM B.8,9
Prolonged NMB has been reported in patients w ith renal fa ilure after administration of 
older non-depolarizing NMBAs (gallamine, tubocurarine, pancuronium), all of which are 
excreted, in part, by the kidney.1 In addition, the mean time to spontaneous recovery 
(train-of-four (TOF) ratio of 0.7) from rocuronium- induced NMB has been shown to be 
significantly prolonged in patients w ith end-stage renal fa ilure in comparison w ith patients 
w ith normal renal function.10 As sugammadex and the sugammadex-rocuronium complex 
are cleared by the kidneys,11 this Phase III investigation compared the efficacy and safety 
of sugammadex for the reversal of rocuronium-induced NMB in patients w ith normal or 
severely impaired renal function.
METHODS
The study was approved by the Independent Ethics Committee of each trial centre and 
was conducted in compliance w ith the current revision of the Declaration of Helsinki, the 
International Conference on Harmonisation guidelines, Good C lin ical Practice and cur­
rent regulatory guidelines. A ll patients provided written informed consent. Thirty patients 
aged >18 years were included in the trial: 15 ASA class II-III patients w ith end-stage 
renal failure (creatinine clearance (CLcr) <30 ml min-1) and 15 ASA class I-II control
INTRODUCTION
58 Chapter 4
patients (CLcr >80 ml m in-1). CLcr was calculated using the serum creatinine value and 
the Cockroft & Gault formula.12
Patients were undergoing elective surgical procedures in the supine position under gen­
eral anaesthesia where it was anticipated that only one dose of rocuronium given before 
tracheal intubation would be required. Pregnant and breast-feeding women, patients with 
known or suspected neuromuscular disorders, a history of malignant hyperthermia, or 
allergy to narcotics, NMBAs or other medication used during general anaesthesia were 
excluded, as were patients receiving medication known to interfere w ith the action of 
rocuronium, for example, aminoglycoside antibiotics, anticonvulsants or Mg2+. 
Anaesthesia was induced and maintained using i.v. infusions of propofol and opiates. 
Blood pressure, heart rate, ECG, oxygen saturation, central core temperature (measured by 
nasopharyngeal or rectal probe), and end-tidal CO 2 were recorded throughout.
After induction of anaesthesia, neuromuscular function was monitored continuously by 
acceleromyography (AMG) at the adductor pollicis muscle using the TOF-Watch® SX 
(Organon Ireland Ltd, a part of Schering-Plough Corporation, Dublin, Ireland). Surface 
paediatric ECG-electrodes (Neotrode®, Conmed, Utica, NY, USA) were placed over the 
ulnar nerve, near the wrist. A  temperature sensor was attached to the ball of the thumb: 
peripheral temperature was maintained above 32°C.13 Central core temperature was main­
tained above 35 °C. The AM G  transducer was attached to the distal phalanx of the thumb, 
perpendicular to its movement. The arm and other fingers were immobilized on an arm 
board. After induction of anaesthesia, a 5 s of 50 Hz tetanic stimulation was performed to 
reduce the time required to stabilize the response to subsequent TOF stimulation. This was 
followed by 2-5 min of TOF pulses at 2 Hz, repeated every 15 seconds, until the twitch 
response stabilized. The TOF-Watch® SX device was then calibrated. After stabilization of 
the TOF signal and calibration, repetitive TOF stimulation was performed every 15 s using 
supramaximal stimuli of 0.2 ms.
A  single i.v. dose of rocuronium (0.6 mg kg-1) was administered. After maximal NMB was 
obtained, tracheal intubation was performed followed by mechanical ventilation w ith a 
mixture of oxygen and air. End-tidal CO 2 was maintained w ith in a range of 4.0 - 5.3 kPa. 
A t reappearance of the second twitch response (T2), a single i.v. dose of sugammadex (2.0 
mg kg -1) was given. Anaesthesia and neuromuscular monitoring were continued until 
recovery of the TOF ratio to 0.9, and for a m inimum of 30 min after the administration of 
sugammadex.
The primary efficacy variable was the time from administration of sugammadex to recov­
ery of the TOF ratio to 0.9.14 Secondary efficacy variables were the time from the start of 
administration of sugammadex to recovery of the TOF ratio to 0.7 (which was previously 
considered satisfactory clinical recovery)15 and 0.8. Recurrence of NMB was defined as a 
decrease in the TOF ratio to < 0.9 after fu ll recovery had been detected, or as a deteriora­
tion in the clinical signs of recovery from block.
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After operation, oxygen saturation and respiratory rate were monitored for 7 h after ad­
ministration of sugammadex in patients w ith normal renal function and for at least 24 
h in patients w ith impaired renal function. A ll patients were assessed for clinical signs 
of recovery (5 s head lift test, diplopia, general muscle weakness and tongue depressor 
test)15 after admission to the recovery room and 1, 2, 4, 6, 8, 12, 18 and 24 hours after 
administration of sugammadex. Renal patients were also assessed for clinical signs of 
recovery 36 and 48 h after administration of sugammadex. A ll subjects were assessed for 
adverse events (AEs) and serious adverse events (SAEs).16
For safety analysis, a urine sample for chemistry and sediment analysis was collected the 
day before surgery. Blood samples for blood biochemistry (sodium, potassium, chloride, 
ionized calcium, ionized magnesium, creatinine, blood urea nitrogen, alanine trans­
aminase, aspartate transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, 
creatine kinase, lactate dehydrogenase, total b ilirub in, total protein, albumin, fasting 
glucose, total cholesterol, fasting triglycerides and haptoglobin) and haematology (hae- 
matocrit, haemoglobin, erythrocyte count, leucocyte count, differential count and platelet 
count), were collected at induction of anaesthesia, and at 20 min and 4-6 hours after 
administration of sugammadex. Assessment of vital signs, blood chemistry and haematol­
ogy analysis and urinalysis were repeated on the day after surgery and during a follow-up 
visit 2-4 weeks after surgery. A ll c lin ically relevant abnormal laboratory or vital signs were 
reported as AEs.
Statistical analysis
In previous trials (Organon database) in which a dose of 2.0 mg kg -1 sugammadex was 
administered at reappearance of T2, the standard deviation (SD) of the times to recovery 
of the TOF ratio to 0.9 was 45 s. Thirteen patients per group would be required to show 
equivalence at a power of 81% (significance level a=0.05). Assuming a 10-15% dropout 
rate, 15 patients per group were required.
The confidence interval (CI) approach was used to demonstrate equivalence between 
patients w ith normal renal function and those w ith impaired renal function for the time 
to recovery of the TOF ratio to 0.7, 0.8 and 0.9 after reversal w ith sugammadex. W ith  
respect to induced recovery, a difference of 60 s or less between the two patient groups 
in the time to recovery of the TOF ratio to 0.7, 0.8 and 0.9 was considered not to be 
c lin ica lly relevant. Equivalence was established if the two-sided 95% CI for the difference 
between the two groups lay entirely w ith in  the range of -60 to +60 s. The 95% CI for the 
difference between the two groups was calculated from a two-way full analysis of vari­
ance (ANOVA), w ith patient group and trial site as factors. If the patient group by centre 
interaction was not statistically significant (significance level of 5%), a post hoc two-sided 
additive A N O VA  model was also used to calculate the 95% CI.
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Comparison of the physical characteristics of the two patient groups was performed by 
post hoc analysis using the Student's t test, %2 test and the Fisher's exact test. A  statistically 
significant difference was defined as P<0.05.
RESULTS
Fifteen renally impaired patients and 15 controls were enrolled and completed the trial 
between June 2005 and April 2006. The number of renally impaired and control patients 
was evenly distributed w ith in each study site. There were no significant differences in age, 
weight, height, sex or ethnicity between the two groups (Table 1).
Table 1. Physical and baseline characteristics by patient group.
ASA, American Society of Anesthesiologists; CLcr, total plasma creatinine clearance; SD, standard 
deviation.
CLcr < 30 ml min-1
Patient group 
(n=15) CLcr > 80 ml min-1 (n=15)
Age (yr), mean (range) 61 (29-81) 54 (32-70)
Weight (kg), mean (SD) 76 (13) 84 (15)
Height (cm), mean (SD) 170 (9) 170 (11)
Sex (n (%)) Female 7 (47) 9 (60)
Male 8 (53) 6 (40)
Ethnicity (n (%)) Asian 2 (13) 0 (0)
Caucasian 13 (87) 15 (100)
ASA Class (n (%)) Class I 0 (0) 5 (33)
Class II 1 (7) 10 (67)
Class III 14 (93) 0 (0)
CLcr (ml min-1) Mean (SD) 12 (5) 103 (24)
Min - max 4 - 24 81 - 181
The majority of the renal patients were ASA class III (93%), whereas in the control group
all patients were ASA I or II. The CLcr in the renal fa ilure group ranged from 4.3 ml m in-1 to 
24.1 ml m in-1. Ten of the 15 patients w ith end-stage renal fa ilure were undergoing dialysis; 
one patient was having peritoneal dialysis and nine were undergoing haemodialysis at the 
time of the investigation. The mean CLcr in the renally impaired group was 12 ml min-1 
while  in the control group it was 103 ml min-1.
The time from administration of rocuronium to reappearance of T2 was 53.8 min 
(SD=22.4 min) in the renally impaired group and 40.6 min (SD=13.9 min) in the control 
group (P=0.06). The coefficient of variation in the renally impaired group was 41%.
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In one subject (control), the TOF traces and recovery variables were unreliable due to 
poor recording. Data from this subject were excluded. Administration of sugammadex at 
reappearance of T2 after a bolus dose of rocuronium resulted in a mean time to recovery 
of the TOF ratio to 0.9 of 2.0 min for renal patients, and 1.65 min for control patients 
(Table 2). The estimated mean absolute difference in time from the start of administration 
of sugammadex to recovery of the TOF ratio to 0.9 between the renal patients and controls 
was +2 7.3 s. The corresponding 95% CI for this difference ranged from -10.9 to +65.5 
s. The CI was not completely w ith in the predefined equivalence interval of -60 to +60 s 
and equivalence could therefore not be claimed. However, since the interaction between 
trial site and subject group was not statistically significant (p=0.73), the post hoc additive 
A N O V A  model excluding the group-by-centre interaction was applied. Using this ap­
proach the estimated mean absolute between-group difference was 20.1 s and the 95% CI 
(-12.1 to +52.3 s) was w ith in the predefined equivalence interval.
Table 2. Time (min) from the start of administration of sugammadex to recovery of the TOF ratio to 
0.7, 0.8 and 0.9 by patient group.
* One patient was excluded from the control group due to poor recording resulting in unreliable TOF 
traces and recovery variables. ANOVA, analysis of variance; CLcr, total plasma creatinine clearance; 
NS, not significant; SD, standard deviation; TOF, train-of-four.
CLcr < 30 ml min-1 (n=15)
Patient Group
CLcr > 80 ml min-1 (n=14)* ANOVA
Recovery to TOF ratio 0.7 1.45 (0.47) 1.17 (0.38) NS
Mean (SD) 0.8 1.60 (0.57) 1.32 (0.45) NS
0.9 2.00 (0.72) 1.65 (0.63) NS
The mean times from start of administration of sugammadex to recovery of the TOF ratios 
to 0.7 and 0.8 were 1.45 min vs 1.17 min and 1.60 min vs 1.32 min for renal patients and 
controls, respectively (Table 2). The estimated mean absolute difference between renal pa­
tients and controls for the time from the start of administration of sugammadex to recovery 
of the TOF ratio to 0.7 and 0.8 was +20.6 s and +22.5 s, respectively. The corresponding 
95% CI for these differences ranged from -2.4 to +43.6 s and -4.9 to +49.9 s, respectively. 
Both CIs were w ith in the predefined equivalence interval of -60 to +60 s.
Recurrence of NMB was not observed in any of the patients during the neuromuscular 
monitoring or post-operative clinical monitoring period. In one control patient, a decrease 
in oxygen saturation was reported after operation. This was not considered a clinical sign 
of recurrence of NMB, but was attributed to the i.v. administration of meperidine on the 
recovery ward. This mild opioid-induced respiratory depression was successfully treated 
w ith oxygen (2 litre m in-1).
Blood biochemistry analysis showed hypocalcaemia in four patients (three renal patients, 
and one control). The lowest serum calcium measured, in a renal patient, was 1.17 mmol
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litre-1 at 20 minutes after administration of sugammadex. In one control patient, elevated 
alanine transaminase (144 U litre-1), aspartate transaminase (177 U litre-1), b ilirub in (44.5 
|imol litre-1) and gamma-glutamyl transpeptidase levels were recorded a day after surgery. 
A t the follow-up assessment (postoperative day 19), the levels were w ith in the safety 
ranges. One control patient had thrombocytopenia (68 x 109 litre-1) 4-6 h after administra­
tion of sugammadex. The platelet counts at baseline, post-anaesthetic and follow-up visit 
were w ith in normal ranges. None of these abnormal values was considered to be related 
to sugammadex. Haematology and blood biochemistry results were comparable between 
the two groups, except for serum creatinine and blood urea nitrogen levels, for which the 
differences existed at baseline.
The urinary variables were comparable between the two groups, except for N-acetyl 
glucosaminidase, beta-2 m icroglobulin and microalbumin, which are indicators of renal 
damage. For these variables, values above the safety ranges were seen pre-dominantly in 
the renally impaired group and were already present at the screening assessment.
Twenty patients had at least one AE perioperatively: eight patients in the renally impaired 
group and 12 patients in the control group. The most frequently reported AEs were nau­
sea (n=6), procedural pain (n=6), pain (n=3), anaesthetic complications (coughing and 
movement during anaesthesia shortly after administration of sugammadex) (n=3), and 
hypocalcaemia (n=4). Five patients, two in the renally impaired group and three in the 
control group, experienced a total of eight AEs possibly related to sugammadex. These 
were diarrhoea (n=2), nausea (n=1), anaesthetic complications (n=3), headache (n=1) and 
decreased oxygen saturation (n=1). None of the patients were discontinued from the trial 
because of an AE.
SAEs were reported in two patients. One patient (renally impaired) experienced hypo­
calcaemia after parathyroidectomy and was re-admitted to hospital before recovering 
satisfactorily. The other (control) was involved in a road traffic accident on day 6 and 
suffered a high impact trauma, contusion of the knee and a forearm fracture. Neither SAE 
was considered to be related to the administration of sugammadex.
Five patients had abnormal changes in blood pressure from baseline (>20% decrease or 
increase) after administration of sugammadex. In the renally impaired group, two patients 
had a low systolic and one patient had a low diastolic blood pressure, whereas in the 
control group, one patient had a low and another patient had an elevated diastolic blood 
pressure. In all subjects, the blood pressure changes were considered to be clin ically 
unimportant and returned to baseline after anaesthesia. No markedly abnormal heart rate 
values were observed.
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DISCUSSION
NMB induced by rocuronium (0.6 mg kg-1) was rapidly and effectively reversed by admin­
istration of sugammadex (2.0 mg kg-1), both in renally impaired and in control patients. 
Although reversal of NMB by sugammadex tended to be slower in renal patients (not 
statistically significant), a mean value of 2.0 min for recovery of the TOF ratio to 0.9 in 
patients w ith impaired renal function is still good, especially as clinical signs of recurrence 
of NMB were not observed in any of the 30 patients. Furthermore, equivalence between 
groups was demonstrated w ith the post hoc statistical analysis.
This finding confirms that reversal of rocuronium-induced NMB by sugammadex can be 
attributed to rapid binding of rocuronium, which prevents it from acting at receptors, and 
is not dependent on its elim ination by renal excretion.
This is consistent w ith an animal study which demonstrated that after complete interrup­
tion of renal perfusion in anaesthetized cats, sugammadex still caused a rapid reversal of 
rocuronium-induced NM B.17 Although this animal model of acute renal fa ilure is not a 
model for chronic renal insufficiency in humans, it did demonstrate that reversal of NMB 
by sugammadex is not dependent on renal excretion of the sugammadex-rocuronium 
complex.
Although available evidence suggests that the sugammadex-rocuronium complex w ill re­
main stable over time 718, there may be concerns for patients w ith renal insufficiency, who 
w ill retain the complex for a longer period than patients w ith normal renal function. For 
this reason, we monitored the renal patients during 48 hours for signs of recurarization, 
but none experienced recurrence of NMB.
It is of note that a recovery time of 2.0 min is quicker than the time to reversal of 
rocuronium-induced NMB by acetylcholinesterase inhibitors in healthy patients.1920 
Sugammadex has already been shown to reverse rocuronium-induced NMB more rapidly 
than neostigmine. Sugammadex at a dose of 4 mg kg-1 for reversal of rocuronium-induced 
NMB achieved a TOF ratio of 0.9 in < 5 min, compared w ith only 5%  of patients given 
neostigmine 70 |ig kg-1.20
Mechanomyography (MMG) has for many years been considered the 'gold standard' for 
quantification of NMB. An M M G  TOF of 0.9 is considered necessary to exclude residual 
paralysis.1314 However, this method is now infrequently used and electromyography and 
A M G  have largely replaced it in clinical research and practice.13 The AM G  and M M G  
methods cannot be used interchangeably, as a TOF ratio measured by AM G  may overes­
timate recovery when compared w ith M M G .21 Therefore, it must be accepted that slight 
levels of residual paralysis may not always be detected by the AM G .21,22 The recently 
updated version of the Good C linical Research Practice guidelines recommend that " In ­
vestigators using AM G  should always report the time to an uncorrected (not normalized) 
TOF ratio of 0.9, but are encouraged to report the times to TOF ratio of 1.0". They also
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state that more comparative data are needed to determine the impact of the practice of 
normalization, whereby the final TOF ratio becomes the control value, to improve the 
accuracy of AMG-derived recovery data.13 The final TOF ratio in our study was almost 
identical to the baseline. In seven patients (three renal patients and four control patients) 
reversed fade (TOF ratio > 1.1) was recorded before administration of rocuronium. A ll 
patients returned to their baseline TOF level after administration of sugammadex.
As expected, the duration of clinical relaxation after rocuronium but before administration 
of sugammadex (time to reappearance of T2) tended to be longer in patients w ith impaired 
renal function, although this finding was not significantly significant. This observation and 
large between-patient differences in clinical response to rocuronium in renal fa ilure have 
been reported in other studies.10 23 24 The efficacy of sugammadex in patients w ith renal 
failure reported in this trial indicates that it may be useful in this patient group, where a 
prolonged duration of action of rocuronium and increased risk of post-operative residual 
paralysis and respiratory complications are more likely.110
As cyclodextrins are water soluble and do not possess direct intrinsic biological activity, 
they are un like ly to cause side-effects, although drug interactions could occur. O f the 
severe AEs reported in this trial, none were considered to be related to sugammadex. 
AEs possibly related to sugammadex were diarrhoea, nausea, headache and coughing 
or movement under anaesthesia. Coughing or movement after sugammadex has been 
reported in other studies.8,25 This may be due to the rapid onset of effect of sugammadex 
in reversing NMB at a time of relatively light anaesthesia.
In conclusion, sugammadex at a dose of 2.0 mg kg-1 effectively and safely reverses NMB 
induced by rocuronium 0.6 mg kg-1, in patients w ith normal or impaired renal function 
(CLcr <30 ml m in-1). Recovery to the necessary TOF ratio of 0.9 before extubation oc­
curred very rapidly and no signs of recurrence of NMB were reported. In patients with 
renal failure, sugammadex may be useful for lim iting the risks of residual post-operative 
paralysis. Further safety studies on sugammadex in patients w ith severe renal impairment 
are warranted.
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Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromus­
cular blocking agent, rocuronium. The sugammadex-rocuronium complex is eliminated 
by the kidneys. This trial investigated the pharmacokinetics (PKs) of sugammadex and 
rocuronium in patients w ith renal failure and healthy controls.
Methods
Fifteen ASA class II-III renal patients (creatinine clearance (CLcr) <30 ml m in-1) and 15 
ASA I-II controls (CLcr > 80 ml m in-1) were included. After induction of anaesthesia, 
a single i.v. dose of rocuronium 0.6 mg kg-1 was given, followed by a single i.v. dose 
of sugammadex 2.0 mg kg-1 at reappearance of the second twitch of the train-of-four 
response. Plasma concentrations of rocuronium and sugammadex were estimated and 
PK variables determined using non-compartmental analyses. Percentages of sugammadex 
and rocuronium excreted in the urine were measured.
Results
PK data were obtained from 26 patients. Mean total plasma clearance (CL) of sugammadex 
was 5.5 ml m in-1 in renal patients and 95.2 ml m in-1 in controls (P<0.05). Rocuronium 
CL was 41.8 ml m in-1 in renal patients and 167 ml m in-1 in controls (P<0.05). The median 
amount of sugammadex and rocuronium excreted in the urine over 72 h in renal patients 
was 29% and 4%, respectively, and 73% and 42%  over 24 h in controls.
Conclusions
Large differences in the PKs of sugammadex and rocuronium between patients w ith renal 
failure and healthy controls were observed. The effect of renal impairment on the PK 
variables of rocuronium was less than w ith sugammadex. U rinary excretion of both drugs 
was reduced in renal patients.
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Sugammadex is a modified y-cyclodextrin and the first selective relaxant binding agent 
designed to encapsulate the aminosteroidal neuromuscular blocking agent (NMBA) 
rocuronium.1-3 Cyclodextrins are cyclic oligosaccharides, capable of encapsulating lipo­
philic  guest molecules such as steroids.1 Sugammadex forms a 1:1 host-guest inclusion 
complex w ith rocuronium in the plasma. Free rocuronium molecules in the plasma are 
captured by sugammadex, resulting in a rapid decrease in the free rocuronium plasma 
concentration. This creates a concentration gradient between free rocuronium in the 
effect compartment (the neuromuscular junction (NMJ)) and the central compartment 
(the plasma and extracellular fluid). As a result, free rocuronium molecules return to the 
plasma, where they are captured by sugammadex, leading to a rapid reversal of neuro­
muscular block (NMB).4
Rocuronium is an NM BA w ith an intermediate duration of effect,5 which is w ide ly used 
in anaesthesia. Recovery from NMB occurs spontaneously as rocuronium diffuses away 
from the NMJ and is redistributed before being metabolized by the liver and/or eliminated 
in the bile and urine.
Administration of sugammadex leads to altered elim ination of rocuronium. Sugammadex 
is a water-soluble molecule which is cleared mainly by the kidneys.6 After encapsulation by 
sugammadex, rocuronium is confined to the space in which sugammadex resides and the 
plasma clearance of rocuronium assimilates into the plasma clearance of sugammadex.6 
Human studies have shown that the percentage urinary excretion of a dose of rocuronium 
increases up to a maximum of 68% over 24 h w ith increasing doses of sugammadex.6 
This phase III trial was conducted to determine the efficacy, safety and pharmacokinetics 
(PKs) of sugammadex in patients w ith chronic renal failure, including patients on dialysis. 
The pharmacodynamic and safety findings of this study have already been reported.7 This 
article describes the effect of severe to end-stage renal failure on the PKs of sugammadex 
and rocuronium and on the elim ination of rocuronium encapsulated by sugammadex.
METHODS 
Patient selection
The study protocol was approved by the Independent Ethics Committee of each trial centre 
(one in the UK, two in the Netherlands) and was conducted in compliance w ith the current 
revision of the Declaration of Helsinki, the International Conference on Harmonisation 




The study was performed between June 2005 and April 2006. Thirty patients aged >18 
years were included in the trial: 15 ASA class II-III patients (American Society of Anesthe­
siologists physical status classification) w ith severe to end-stage renal fa ilure (creatinine 
clearance (CLcr) <30 ml min-1) and 15 ASA class I-II control patients (CLcr >80 ml m in-1). 
CLcr was calculated using the serum creatinine value and the Cockcroft and Gault formula.8 
The pharmacodynamic and safety findings of this study have been reported previously.7 
Patients were undergoing elective surgical procedures in the supine position under gen­
eral anaesthesia, where it was anticipated that only one dose of rocuronium 0.6 mg kg-1 
would suffice. Pregnant and breast-feeding women, patients w ith known or suspected 
neuromuscular disorders, those w ith a history of malignant hyperthermia, or allergy to 
narcotics, NMBAs, or other medication used during general anaesthesia were excluded, 
and also patients receiving medication known to interfere w ith the action of rocuronium, 
for example, aminoglycoside antibiotics, anticonvulsants or magnesium (Mg2+).
Study procedures
An i.v. cannula was inserted solely for the administration of all anaesthetic drugs, includ­
ing rocuronium and sugammadex. Anaesthesia was induced and maintained using i.v. 
infusions of propofol and opiates. Another i.v. cannula was inserted for blood sampling. 
After induction of anaesthesia, a single i.v. dose of rocuronium 0.6 mg kg-1 was given. 
W hen maximal block had been achieved, tracheal intubation was performed and the 
lungs were ventilated w ith a m ixture of oxygen and air. End-tidal C O 2 was maintained 
w ith in 4.0-5.3 kPa. No potent inhalational agents were used.
Neuromuscular monitoring was performed continuously using acceleromyography of 
the adductor pollicis muscle and the TOF-Watch® SX (Schering-Plough, Dublin, Ireland). 
Surface paediatric ECG electrodes (Neotrode®, Conmed, Utica, NY, USA) were placed 
over the ulnar nerve near the wrist. A  temperature sensor was attached to the ball of the 
thumb: peripheral temperature was maintained above 32°C.9 Core body temperature was 
measured using a nasopharyngeal or rectal probe and maintained between 35°C and 
37°C.10
At reappearance of the second twitch (T2) of the train-of-four (TOF) response a single
i.v. dose of sugammadex 2.0 mg kg -1 was administered. Anaesthesia and neuromuscular 
monitoring were continued until the end of surgery and at least until recovery of the T4/T1 
ratio of the TOF to 0.9, and for a m inimum of 30 min after administration of sugammadex. 
Patients received dialysis during the study if indicated, according to usual practice.
Pharmacokinetic assessments
Plasma and urine sampling were conducted to determine the plasma concentration and 
the percentage of the administered dose of sugammadex and rocuronium excreted in 
the urine. Venous blood samples for determination of rocuronium concentration were
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obtained pre-dose and at 2, 3, 5, 10, 15 and 20 min after administration of rocuronium. If 
reappearance of T2 occurred before all the post-rocuronium samples had been obtained, 
the remaining post-rocuronium samples were ignored. Venous blood samples to assess 
total rocuronium and sugammadex plasma concentrations were obtained directly before 
administration of sugammadex and at 2, 3, 5, 10, 15, 20, 30 and 60 min and 2, 4, 6, 8, 
12, 18 and 24 h after administration of sugammadex. In patients w ith renal failure, further 
plasma concentrations of rocuronium and sugammadex were also determined at 36 and 
48 h after sugammadex administration. The actual time of blood sampling was recorded 
in each instance. Additional pre- and post-dialysis samples were obtained if the patient 
underwent haemodialysis w ith in 72 h of administration of sugammadex.
Plasma samples were stored in 4 ml heparin collection tubes. W ith in  15 minutes of col­
lection, the plasma samples were centrifuged. If centrifugation could not be performed 
w ith in 15 min, the tubes were stored in ice (0-4 °C). The heparin tubes were centrifuged 
for 15 min (2000 g-3000 g). Centrifuged plasma was stored in two hard plastic tubes (one 
for rocuronium and one for sugammadex) at -20 °C.
U rinary rocuronium and sugammadex concentrations and total amounts excreted were 
assessed from all healthy patients and those renal patients who still produced urine. Urine 
was collected at 6 h intervals, starting from administration of rocuronium to 6 h after 
administration of sugammadex and for 6-12 h, 12-18 h and 18-24 h after administra­
tion of sugammadex. In patients w ith renal failure, urine was also collected 24-36 h, 
36-48 h and 48-72 h after administration of sugammadex. The actual collection times 
and volumes were recorded.
The collected urine was stored at 4 °C. Two samples of 1.0 ml of the collected urine for 
each interval were stored in a hard plastic tube: one for rocuronium and one for sugam­
madex. These tubes were stored at -20 °C. No preservatives were used.
Rocuronium and sugammadex concentrations in plasma and urine were determined using 
validated liquid chromatographic assay methods w ith mass spectrometric detection by 
the Department of C linical Pharmacology and Kinetics, Schering-Plough, Oss, The Neth­
erlands. The assays were carried out in fu ll compliance w ith Good Laboratory Practice 
regulations. The lower limits of quantification (LLOQ) for the assays were: sugammadex 
0.1 |ig ml-1 (plasma) and 5 |ig ml-1 (urine); and rocuronium 2.0 ng ml-1 (plasma) and 50 ng 
m l-1 (urine). The upper limits of quantification (ULOQ) for the assays were: sugammadex 
40 |ig m l-1 (plasma) and 200 |ig m l-1 (urine); and rocuronium 1000 ng m l-1 (plasma) and
10.000 ng m l-1 (urine). A ll samples w ith a concentration >ULO Q  were processed and 
analysed after an appropriate dilution to bring the concentration w ith in the calibration 
range.
The assay methods do not differentiate between sugammadex and rocuronium in their free 
or complexed forms, as the sugammadex-rocuronium complex dissociates on the liquid 
chromatography column. Thus, plasma concentrations, urine concentrations and PK pa­
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rameters pertain to total plasma and urine concentrations of sugammadex and rocuronium 
only and do not indicate the degree of encapsulation.
Pharmacokinetic parameter calculation
PK parameters were calculated using conventional non-compartmental analysis methods. 
For determination of term inal half-life, the slope (-Xz) of the term inal log-linear phase of 
the concentration vs time curve was determined by linear regression. The log-transformed 
concentrations were fitted to a model w ith intercept and slope, starting w ith the last three 
points w ith measurable concentration (concentrations lower than LLOQ in the e lim ina­
tion phase were ignored). The procedure continued, adding preceding data points one at 
a time and fitting the regression equation sequentially. The term inal log-linear portion was 
defined by the data yield ing the smallest mean square error term in the regression analysis. 
The elim ination half-life (t, J  was then calculated as log 2A, .' 1/2, ß7 oe z
The area under the concentration vs time curve (AUC) from time zero to ta (AUC0 tlast) was 
calculated by means of the linear trapezoidal rule, where ta represents the last time point 
w ith a measurable concentration above the LLOQ w ith in a subject. W hen a renal patient 
received dialysis during the study, t!ast was the last pre-dialysis time point. This time point 
differed for each of the renally impaired patients. The AUC from time zero to infin ity was 
calculated as A U C  = AUC... . + C., ,A  , where C, , was the fitted concentration at time0-~ 0-tlast tlast z' tlast
t!ast using the regression line from which Xz was calculated. W ith  respect to the dialysed 
patients in the renally impaired group, AUC0-m was calculated by extrapolating from the 
pre-dialysis sample, ignoring plasma concentrations during and after dialysis.
The total plasma clearance (CL) was calculated as dose/AUC0-m. The mean residence time 
(MRT) was calculated as (AUMC/AUC0-J-(duration administration dose/2), where AUM C 
is the area-under-the-moment-curve which is calculated from the product of concentra­
tion and time by means of the linear trapezoidal rule until t!ast plus C tast x tlas/ K )  + C tJ  
Xz2). The effective half-life (tf/2 effective) was calculated as loge2 x MRT. The apparent volume 
of distribution at steady state was calculated as Vs = CL x MRT.
In patients w ith renal fa ilure who were treated w ith haemodialysis w ith in  72 h after 
administration of sugammadex, the rocuronium and sugammadex plasma concentrations 
were assessed pre-dialysis (C , , . ) and post-dialysis (C . ). A  post hoc analysis wasI > pre-dialysis' I > ' post-dialysis ' i >
performed on the reduction ratio (RR) during dialysis, which was calculated as RR=Cpost 
/Cdialysis pre-dialysis
From the sugammadex and rocuronium concentrations in urine and the urine volumes 
recorded for each collection interval, the amount excreted in urine (Ae) was calculated 
for each interval, assuming a urine density of 1.0 g m l-1. The cumulative amount excreted 
in urine up to any time t (Aecum t), where time t is the endpoint of a collection interval, was 
obtained by adding the total amounts excreted in each collection interval up to that time.
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Statistical analysis
A  power calculation was performed to calculate the number of patients needed to show 
pharmacodynamic equivalence.7 A  separate power analysis was not performed for the PK 
part of the study.
PK assessments were performed in the population of patients who received study medica­
tion, had no protocol violations interfering w ith the PK analysis, and for whom at least 
one PK parameter could be calculated. Linear regression analyses were performed of 
sugammadex and rocuronium CL vs CLcr as a measure of renal function. Renal patients 
undergoing haemodialysis were excluded from this calculation, as CLcr may be over­
estimated in this patient group, when calculated using the Cockroft and Gault formula. 
Correlation plots were made of CL vs CLcr including regression lines.
The PK variables in the renal fa ilure and control groups were compared using Student's t 
test on loge-transformed values. Point estimates and 95% confidence intervals for the ratio 
of renal fa ilure to control means were calculated using geometric means. If there were 
no significant group effects, then the PKs were considered comparable between the renal 
fa ilure group and the control group.
PK evaluation was performed using SAS version 8.2 (SAS Institute Inc, Cary, NC, USA) 
on a PC running under Windows XP v5.1 (Microsoft Corporation, Redmond, W A, USA). 
Comparison of the physical characteristics and patient details of the two groups were 




Thirty patients were enrolled; 15 patients w ith renal failure (seven in Radboud Univer­
sity Nijmegen Medical Centre (RUNMC), six in Canisius-Wilhelmina Ziekenhuis (CWZ), 
Nijmegen and two in Liverpool) and 15 controls (seven in CWZ, six in RUNM C and 
two in Liverpool). In four patients (two renal patients and two controls), the data on the 
plasma and urine samples (time, date and patient number) did not correspond w ith those 
recorded on the Case Report Forms. These samples may have been reversed. For these 
subjects, no PK variables were calculated. Thus, 13 patients in each group were evaluable 
for PK assessment.
Table 1 shows the baseline characteristics of the 26 patients. There were no significant 
differences in age, weight, height or BMI between the two groups. The CLcr in the renal 
fa ilure group ranged from 4.3 ml m in-1 to 24.1 ml m in-1.
A ll patients received propofol for induction and maintenance of anaesthesia, an intubat­
ing dose of rocuronium (median 0.6 mg kg-1; range 0.59-0.61 mg kg-1), and one dose
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Table 1. Physical characteristics and patient data by patient group.
BMI, body mass index; CLcr, total plasma creatinine clearance; SD, standard deviation. * Mean 
creatinine clearance may be overestimated in haemodialysis patients, when calculated using the 
Cockroft and Gault formula.
Patient group
Renal Failure, CLcr < 30 ml min-1 Control, CLcr > 80 ml min-1 
(n = 13) (n = 13)
Age (yr), mean (range) 61 (29 - 81) 54 (32 - 70) P=0.23
Weight (kg), mean (SD) 76.8 (13.8) 83.4 (16.0) P=0.24
Height (cm), mean (SD) 170 (8.7) 168 (9.1) P=0.68
BMI (kg m-2), mean (SD) 26.6 (4.1) 29.5 (5.5) P=0.06
CLcr (ml min-1), mean (SD)* 12.3 (5.7) 103.8 (26.0) P=0.00
of sugammadex (median 2.0 mg kg-1; range 1.99-2.05 mg kg-1). The most frequently 
administered analgesic drugs were i.v. fentanyl and morphine. A ll patients were receiv­
ing concomitant medication. The drugs most frequently taken were alfacalcidol (10 of 
15 renal patients) and acetaminophen (11 renal patients and 14 controls). None of the 
patients received an NM BA other than rocuronium, a second dose of rocuronium, or a 
reversal agent other than sugammadex.
As previously reported, the mean (standard deviation) time from administration of ro­
curonium to reappearance of T2 was 53.8 min (22.4 min) in the renally impaired group 
and 40.6 min (13.9 min) in the control group.7 Mean time (standard deviation) from the 
start of administration of sugammadex at reappearance of T2 to recovery of the TOF ratio 
to 0.9 was 2.0 min (0.72) for renal patients and 1.65 min (0.63) in healthy controls (not 
significant).7 No clinical signs of recurarization were observed in any of the patients for 
up to 48 h.7
Plasma pharmacokinetics
In one control patient, the rocuronium plasma concentration after 24 h was considered to 
be a PK outlier (laboratory error). The concentration at this time point was 3.94 ng m l-1, 
although the plasma concentration after 12 h was 2.1 ng m l-1 and after 18 h was <2.00 
ng ml-1. This sample was excluded from all calculations. In one renal patient undergoing 
haemodialysis, the pre-dialysis plasma rocuronium concentration (24 h after administra­
tion of sugammadex) was also considered an outlier: the plasma concentration was 28.6 
ng m l-1, which was lower than the post-dialysis concentration (270 ng m l-1). Therefore, 
the pre-dialysis sample was excluded from all calculations. For those patients in the renal 
failure group undergoing haemodialysis (nine patients), the samples obtained at time 
points after haemodialysis was started were excluded from the descriptive statistics. 
Median plasma concentrations for sugammadex (Fig. 1A and B) and rocuronium (Fig. 2A 
and B) are presented by group. For the first 60 min after administration, median plasma
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Figure 1: Sugammadex plasma concentrations vs time plots for patients with renal failure and 
control patients.
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A. Median (range) sugammadex plasma concentration (^ .g ml-1) vs time (min), for time points up to 60 
min after injection of sugammadex.
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Renally impaired group (n=13)
-a - Control group (n=13)
B. Semi-logarithmic plot: median (range) sugammadex plasma concentration (^g ml-1) vs time (h), for 
time points up to 48 h after injection of sugammadex. Plasma concentrations were below the limit of 
quantification after 8 h in the control group. The numbers (n) of samples at each time point are given 
for the renally impaired group.
concentrations of sugammadex were sim ilar in the control and renally impaired groups 
(Fig. 1A). A t later time points, plasma concentrations of sugammadex showed a slower 
decline in the renally impaired group compared w ith the control group (Fig. 1B). A  sim ilar 
effect was seen for rocuronium (Fig. 2A  and B). For both groups and both compounds, the 
concentration vs time curves showed a log-linear terminal decline.
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A. Median (range) rocuronium plasma concentration (ng ml-1) vs time (min) after administration of 
rocuronium and sugammadex, for time points up to 60 min after injection of sugammadex.
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B. Semi-logarithmic plot: median (range) rocuronium plasma concentration vs time, for time points 
up to 48 h after administration of sugammadex. Plasma concentrations were below the lower limit of 
quantification after 18 h in the control group. The numbers (n) of samples at each time point are given 
for the renally impaired group.
The main PK variables for sugammadex and rocuronium are given in Table 2.
Statistically significant differences (P<0.05) were observed between the control and the 
renal fa ilure groups for sugammadex in total plasma CL, and the related parameters, AUC, 
t1/2 p and MRT (Table 2). Exposure (AUC0_J, t 1/2 and MRT were 15 - 20 times higher and
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the CL 17 times lower in the renal failure group compared w ith the control group. The Vss 
did not differ significantly between the renal fa ilure and the control groups.
Statistically significant differences (P<0.05) were also observed in these variables for 
rocuronium (Table 2). The exposure (AUC0-J , t1/2 p, and MRT were 2.5 -5 times higher 
and the CL was four times lower in the renally impaired group compared w ith the control 
group. Again, the V ss of rocuronium did not differ significantly between the two groups. 
The effect of renal impairment on the PK variables was smaller for rocuronium than for su­
gammadex. The CL, AUC, t1/2 and MRT of sugammadex were highly variable in patients 
w ith renal failure, w ith coefficients of variation >100%. The variab ility w ith in renal failure 
patients in the PK parameters for rocuronium was smaller.
Table 2. PK variables for sugammadex 2.0 mg kg-1 and rocuronium 0.6 mg kg-1.
Blood samples obtained before and after sugammadex administration were used to determine the 
rocuronium PKs. Data are presented as geometric mean (geometric coefficient of variation (%) ) and 
overall ranges. AUC, area under the curve; CL, total plasma clearance; V ss, volume of distribution at 
steady state; t1/2 p, terminal elimination half-life; MRT, mean residence time. * Statistically significant 
(Student's t-test), P< 0.05 vs renal failure group.
Renal Failure Control
Sugammadex kinetic variables
AUC 0 m (^g min ml-1) 27,500 (114) 1730 (34.8)*
Range (p.g min ml-1) 6480 - 147,000 1060 - 3330
CL (ml min-1) 5.5 (108) 95.2 (22.1)*
Range (ml min-1) 1.15 - 18.1 58.3 - 138
Vss (litre) 16.0 (35.5) 13.8 (20.5)
Range (litre) 9.3 - 31.8 10.0 - 19.7
t1/2, p (h) 35.7 (121) 2.3 (44.4)*
Range (h) 10.7 - 282 1.6 - 7.5
MRT (h) 48.2 (132) 2.4 (25.5)*
Range (h) 13.2 - 399 1.8 - 4.0
Rocuronium kinetic variables
AUC 0 m (^g min ml-1) 1080 (53.8) 296 (37.4)*
Range (p.g min ml-1) 412 - 2370 143 - 538
CL (ml min-1) 41.8 (46.9) 167 (30.8)*
Range (ml min-1) 23.2 - 88.8 108 - 314
Vss (litre) 22.1 (29.9) 19.1 (28.3)
Range (litre) 14.0 - 41.6 12.2 - 30.7
t1/2, p (h) 7.5 (39.9) 3.0 (67.5)*
Range (h) 3.4 - 13.3 1.2 - 8.2
MRT (h) 8.8 (52.7) 1.9 (29.2)*
Range (h) 3.7 - 19.7 1.2 - 3.3
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Correlation plots were made of CL of sugammadex and rocuronium against creatinine 
clearance in controls and patients w ith renal insufficiency not yet on dialysis (Fig. 3). 
Regression analyses showed that both for sugammadex and for rocuronium, the correla­
tion between CL and CLcr is h ighly significant (P<0.0001).
Figure 3: Regression plots of total plasma clearance (CL) of sugammadex and rocuronium vs CLcr 
(creatinine clearance) in normal controls and patients with renal insufficientcy not yet on dialysis.
Creatinine
A. Regression plot of sugammadex CL vs CLcr (r=0.72)
B. Regression plot of rocuronium CL vs CLcr (r=0.60)
Urinary excretion
In six patients w ith renal failure and four control patients, urine sampling was incomplete. 
Two patients w ith renal failure did not produce urine. N ine of 13 patients w ith renal 
failure underwent haemodialysis during the period of urine collection, which may have 
influenced urinary excretion of the drugs.
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Urinary excretions of sugammadex and rocuronium were much lower in the renal failure 
group than in the control group. In renal failure patients (n=10), the median (range) total 
amount of sugammadex excreted in urine (in 72 h) was 29%  (3.9 - 121%) of the admin­
istered dose. In the control group (n=11), renal excretion of sugammadex was almost 
complete in 24 h: median (range) total amount of sugammadex excreted was 73% (56 
- 101%).
One renal patient was calculated to excrete 121% of the administered sugammadex dose, 
which reflects either an imprecision in the bioassay or in the urinary sampling. In nine 
of the 10 evaluable renal patients, the amount of sugammadex excreted over 72 h was 
<70%.
For rocuronium, a much smaller fraction of the dose was excreted in the urine than for 
sugammadex, both for the renally impaired group and the control group. Median (range) 
total amount of rocuronium excreted in urine was 4.4% (0.8 - 18) of the administered 
dose in 72 h in the renal fa ilure group (n=10) and 42%  (14 - 75) in 24 h in the control 
group (n=12).
Haemodialysis
Nine renal patients underwent haemodialysis between 0 and 72 h after administration of 
sugammadex. The plasma concentrations of sugammadex and rocuronium were measured 
pre- and post-dialysis. Median time for dialysis was 225 min.
In patients undergoing low-flux haemodialysis (n=7), no significant reductions in sugam­
madex plasma concentrations were observed after dialysis. The median (range) reduction 
ratio (RR) of sugammadex was 0.93 (0.87 - 1.20) and that of rocuronium was 0.65 (0.57 
- 0.90). As there were only two patients undergoing high-flux haemodialysis, no conclu­
sions regarding dialysability w ith these membranes can be presented from this study.
DISCUSSION
This multicentre, parallel-group, comparative trial was the first to investigate the PKs of 
sugammadex and rocuronium in patients w ith severe to end-stage renal failure. This phase 
III study showed large differences in the PKs of sugammadex and rocuronium between 
patients w ith renal fa ilure and healthy controls. Plasma concentrations of sugammadex 
showed a slower decline in the renal fa ilure group compared w ith the control group. Total 
plasma CL of sugammadex was 17 times lower and mean t1/2 was 16 times higher in the 
renal fa ilure group.
The effect of renal impairment on PK variables was less for rocuronium. Figure 2A shows 
no significant differences between renal patients and controls in rocuronium plasma 
concentrations before the administration of sugammadex. This is probably because re­
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distribution of rocuronium, rather than CL, determines its plasma concentration during 
the in itial 30-45 min after administration. However, after administration of sugammadex, 
total plasma CL of rocuronium was four times lower in the renal failure group than the 
control group.
U rinary excretion of sugammadex and rocuronium was also much lower in patients with 
renal failure.
In this investigation, venous sampling was performed for 48 hours in the renal failure 
patients and for 24 hours in the control group, which may have influenced the PK cal­
culations. In renal fa ilure patients, the calculated half-lives are longer than the sampling 
period, potentially making them inaccurate. However, the term inal e lim ination half life (t 
1/p) and MRT for sugammadex are both greatly prolonged in renal fa ilure compared w ith 
controls, suggesting a significant effect of renal impairment.
The major routes of elim ination of rocuronium are b iliary and urinary excretion.11 Ro­
curonium is taken up by the liver and metabolized, excreted, or both in bile and faeces in 
high concentrations. The mean urinary recovery of rocuronium w ith in 48 h of administra­
tion in subjects w ithout a history of renal disease is 26% .11 In patients w ith severe renal 
failure, CL of rocuronium is reduced by 33-39%, w ith a 66-84% increase in the MRT. 12 13 
For sugammadex, a water-soluble molecule, renal excretion is the main route of e lim ina­
tion. In pre-clinical and clinical studies, renal excretion of the unchanged product was 
observed.4 6 14The plasma CL of sugammadex in healthy non-anaesthetized volunteers is 
~ 120 ml m in-1, which is sim ilar to the glomerular filtration rate.6
As urinary excretion is the main route of e lim ination of the sugammadex-rocuronium 
complex, the extrarenal route of elim ination is expected to be unavailable for encapsulated 
rocuronium. After administration of sugammadex, the percentage of rocuronium excreted 
in the urine increases w ith increasing doses of sugammadex.6 15 These data indicate that 
encapsulation by sugammadex diverts the elim ination of rocuronium from its normal p ri­
mary pathway of hepatic clearance to less effective renal clearance.14 Such PK behaviour 
should have no consequences in surgical patients w ith normal renal function. However, 
patients w ith renal insufficiency w ill retain the sugammadex-rocuronium complex for a 
longer period of time and it is still unclear whether this prolonged exposure w ill have an 
impact on safety.
The plasma concentrations of rocuronium plateaued after administration of sugammadex. 
During the first hour after rocuronium injection, the plasma concentration of rocuronium 
decreased rapidly, mainly by redistribution and binding in the liver. After administration of 
sugammadex, the concentration of rocuronium showed a plateau or even an increase. This 
may be due to the fact that sugammadex attracts some rocuronium already bound in the 
liver back into the plasma, or that the assay cannot distinguish between free rocuronium 
and encapsulated rocuronium, thus leading to a higher total rocuronium concentration. 
In addition, the increased concentration gradient of non-encapsulated rocuronium mol­
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ecules between the plasma and NMJ w ill result in free rocuronium at the NMJ returning 
to the plasma.
Available evidence suggests that the rocuronium-sugammadex complex remains stable 
over time.1 16 The sugammadex-rocuronium complex exists in equilibrium  w ith a very 
low dissociation rate (dissociation constant, Kd =  0.1 x 10-6 M) because of strong bind- 
ing.1 16 No drug interactions have been described between sugammadex and other agents 
used in general anaesthesia, such as opioids or propofol. In this trial, renal patients were 
monitored for 48 h after administration of sugammadex for clinical signs of recurarization. 
None of them experienced recurrence of NMB. Despite the large differences in the PKs 
of rocuronium and sugammadex between patients w ith renal fa ilure and healthy controls, 
reversal of rocuronium-induced NMB by administration of sugammadex was rapid and 
effective in both patient groups.7 It is appreciated, however, that the number of patients 
studied was small.
Cyclodextrins are water-soluble molecules, which are used as solubilizing agents for 
many drugs and foods. Sugammadex is bio logically inactive and has been shown to be 
well tolerated. Toxicity studies on y-cyclodextrins after oral or parenteral administration 
show that the drugs are well tolerated and safe to use in the dose ranges recommended 
for sugammadex.17 No data based on prolonged follow-up are available on the safety of 
sugammadex in patients w ith renal failure, where elim ination of the drug is compromised. 
In this study, the effect of renal impairment on the kinetic variables was smaller for ro­
curonium than for sugammadex. These data suggest that in patients w ith renal failure, 
extrarenal clearance of rocuronium does take place, in spite of complexation. However, 
we did not measure b ilia ry concentrations of rocuronium, which would be necessary to 
determine if elim ination, metabolism, or both by the liver of encapsulated rocuronium 
was continuing. Even after encapsulation of rocuronium by sugammadex, there may still 
be a low concentration of rocuronium unbound and available for hepatic metabolism and 
elim ination. However, since the assay method cannot differentiate between encapsulated 
and free rocuronium, it is not possible at present to determine the plasma concentration 
of unbound rocuronium. If a higher dose of sugammadex had been administered even 
more rocuronium would have been encapsulated, and rocuronium clearance in renal 
patients would have more closely approximated the clearance of sugammadex in this 
patient group.
W e obtained PK data in only four pre-dialysis patients w ith severe to end-stage renal 
fa ilure and nine dialysis patients. In the latter group, the time of the first postoperative 
haemodialysis was patient specific and occurred before the last sampling time of 48 h 
after administration of sugammadex in eight patients. This might have influenced the PK 
parameters. The haemodialysis, together w ith the incomplete urine sampling, may have 
resulted in an underestimation of the urinary excretion of sugammadex and rocuronium.
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O ur study showed a significant correlation between sugammadex and rocuronium CL and 
creatinine clearance (P <0.0001), although it may not be linear. W e did not investigate 
patients w ith mild renal failure (CLcr 30-80 ml m in-1). Further PK studies in a larger patient 
group, in patients w ith different degrees of renal dysfunction and population PK ap­
proaches are needed to determine a more detailed profile of these drugs in such patients. 
After administration of sugammadex, an increase in rocuronium plasma concentration 
was detected. This has been described in other PK studies.4 6 14 15 This is consistent w ith the 
rapid formation of the rocuronium-sugammadex complex in the plasma.4 After administra­
tion of sugammadex, free rocuronium molecules in the plasma are encapsulated. This 
creates a concentration gradient of free rocuronium molecules between the NMJ and 
the central compartment. As they enter the plasma, more free rocuronium molecules are 
encapsulated by sugammadex. As the assay method cannot yet differentiate between free 
and encapsulated rocuronium, the complexation of rocuronium appears as an increase in 
total plasma rocuronium concentration.14 15
Dialysis membranes are classified into high and low flux, depending on their perme­
ability. High-flux membranes are more porous non-cellulosic membranes w ith increased 
permeability, particularly to larger molecules.18 O f the nine patients w ith renal failure who 
underwent haemodialysis during the investigation, seven were dialysed using low-flux 
membranes, which seemed almost ineffective in removing sugammadex from the circula­
tion. However, the small number of subjects per filter type and the limited sampling means 
that the results must be viewed as preliminary. Further investigation is necessary to obtain 
more detailed information regarding d ialysability of sugammadex and rocuronium.
In conclusion, large differences in the PKs of rocuronium and sugammadex were observed 
between patients w ith severe to end-stage renal fa ilure and healthy controls. Total plasma 
CL of sugammadex and rocuronium was much lower in renal patients compared w ith con­
trols. However, reversal of NMB induced by rocuronium 0.6 mg kg-1 w ith sugammadex
2.0 mg kg-1 was rapid and effective in both patient groups. No patient showed signs of 
recurarization.7 The sugammadex-rocuronium complex is retained in the body for longer 
in patients w ith severe to end-stage renal fa ilure and no clinical data on its long-term 
disposition are yet available. Furthermore, detailed studies should be conducted w ith a 
longer follow-up period, preferably w ith a higher dose of sugammadex, to determine more 
accurately whether prolonged exposure to sugammadex and the rocuronium-sugammadex 
complex has an impact on safety in patients w ith end-stage renal failure.
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Sugammadex reverses rocuronium-induced neuromuscular block (NMB). In all published 
studies investigating sugammadex, the primary outcome parameter was a Train-of-Four 
(TOF) ratio of 0.9. Recovery time of T1 was not described. This retrospective investigation 
describes the recovery of T1 versus TOF ratio after reversal of NMB w ith sugammadex.
Methods
Two studies were analyzed. In study A, a phase II dose-finding study, ASA I-II patients 
received an IV  dose of rocuronium 1.2 mg kg-1 followed by an IV  dose of sugammadex 
(2.0, 4.0, 8.0, 12.0 or 16.0 mg kg-1) or placebo (0.9% saline) after five minutes. In study 
B, a phase III trial comparing patients w ith renal failure and healthy controls, rocuronium 
0.6 mg kg-1 was used to induce NMB; sugammadex 2.0 mg kg-1 was administered at 
reappearance of T2. Neuromuscular monitoring was performed by acceleromyography 
and TOF nerve stimulation. Primary efficacy variable was time from administration of 
sugammadex to recovery of the TOF ratio to 0.9. Retrospectively, time to recovery of T1 
to 90% was calculated.
Results
After reversal of rocuronium-induced NMB w ith an optimal dose of sugammadex (16 
mg kg-1 (A) or 2 mg kg-1 (B)), the TOF ratio recovered to 0.9 significantly faster than T1 
recovered to 90%. C linical signs of residual paralysis were not observed.
Conclusions
After reversal of NMB by sugammadex, full recovery of the TOF ratio is possible when T1 
is still depressed. The TOF ratio as the only measurement for adequate reversal of NMB by 
sugammadex may not always be reliable. Further investigations for clinical implications 
are needed.
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Sugammadex is a modified y-cyclodextrin that encapsulates the neuromuscular block­
ing agent (NMBA) rocuronium bromide, forming a 1:1 complex w ith a high affinity.1 
Chemical encapsulation of rocuronium promotes dissociation of rocuronium from the 
nicotinic acetylcholine receptor (nAChR), thereby rapidly reversing neuromuscular block 
(NMB) w ithout the side effects associated w ith acetylcholinesterase inhibitors.1-3 There are 
now numerous published clinical studies which show that sugammadex rapidly reverses 
rocuronium-induced NMB, at any depth of the block.3-9
Non-depolarizing NMBAs, such as rocuronium, block the transmission in the neuromus­
cular junction (NMJ) by inhibition of the nAChRs, both presynaptically and postsynap- 
tically.10-12 The presynaptic nAChR plays a role in mobilizing acetylcholine (ACh) from 
the intraneuronal reserve to the readily releasable pool of transmitter, in order that ACh 
release is proportional to the demand of the high frequencies of nerve impulses that are 
characteristic of transmission to striated muscle.10 Blockade of these presynaptic nAChRs 
by NMBAs is thought to account for the so-called fade phenomenon that occurs during 
partial non-depolarizing NM B.10 Fade, a gradual dim inution of evoked response during 
repetitive nerve stimulation, is a typical phenomenon observed during recovery from 
NMB caused by non-depolarizing NMBAs, but not by depolarizing agents such as suc­
cinylcholine.10
During the last years the fade phenomenon, as expressed in the Train-of-Four (TOF) ratio, 
or height of the fourth evoked response as a fraction of the first evoked response in the 
same train (T4 /T1), is routinely used as the basic parameter of neuromuscular monitoring 
for recovery from NM B.13 Studies have shown that the acceleromyographic TOF ratio must 
exceed 0.9 to exclude c lin ically important residual NM B.13;14 It is even suggested that the 
uncorrected (not normalized) acceleromyographic TOF ratio should be 1.0, or even higher 
to exclude c lin ically significant residual paralysis.15;16
In the reported clinical trials about sugammadex the primary outcome parameter for 
adequate recovery of NMB was an acceleromyographic TOF ratio of 0.9. In none of the 
studies the recovery of the T1 response was reported.
As the TOF ratio reflects the effects of the N M BA at the presynaptic membrane of the 
neuromuscular junction (NMJ), the single twitch response reflects the events at the post­
junctional membrane and is directly related to the force generated. During spontaneous 
recovery from non-depolarizing NMBAs the single twitch response and the T1 response 
of the TOF normally recover to baseline, while  at this point the TOF ratio may still be no 
more than 0.7, which is nowadays considered insufficient recovery from NM B.13;14;17 The 
same pattern occurs after reversal of non-depolarizing NMBAs w ith neostigmine.18 
The aim of this retrospective analysis is to describe the temporal relationship of recovery of 
T1 and the TOF ratio, after reversal of rocuronium-induced NMB w ith sugammadex. The
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data are derived from two prospective studies investigating the efficacy of sugammadex in 
reversing rocuronium-induced NMB, after placebo and different doses of sugammadex in 
healthy patients and after sugammadex 2 mg kg-1 in patients w ith severe renal dysfunction 
and healthy controls. Results of both clinical investigations have been published prev i - 
ously.5;9
METHODS
The first study (A) was designed as a multi-centre, randomized, assessor-blinded, placebo­
controlled, phase II, parallel and dose-escalating dose-finding study in patients of ASA 
I-II.5 The second study (B) was designed as a multicenter, parallel-group, comparative, 
phase III trial, in both ASA I-II patients w ith normal renal function and ASA II-III patients 
w ith severe to end-stage renal failure.9 Both studies investigated the efficacy of sugam­
madex in reversing rocuronium-induced NMB after a single dose.
The studies were approved by the Central Ethics Committee and the Independent Ethics 
Committee of each trial centre. A ll patients provided written informed consent.
Methods of both investigations were published previously, including inclusion and exclu­
sion criteria of both studies.5;9 A ll patients were aged > 18 years and were undergoing 
elective surgical procedures in the supine position under general anaesthesia where it 
was anticipated that on ly one dose of rocuronium given before tracheal intubation would 
be required. In study B, patients w ith renal failure included in the study had a creatinine 
clearance (CLcr) < 30 ml m in-1, as calculated using the serum creatinine value and the 
Cockroft and Gault formula.19 Healthy control patients had a CLcr > 80 ml m in-1.
Anaesthetic Technique
On arrival of the patient in the operating room an intravenous (IV) line was placed for 
anaesthetic administration, including rocuronium and sugammadex. Non-invasive arte­
rial pressure, oxygen saturation, capnography, electrocardiography and core temperature 
were monitored. Anaesthesia was induced w ith propofol IV, followed by a continuous 
infusion of propofol and an opiate to maintain anaesthesia.
After induction of anaesthesia, neuromuscular function was monitored continuously by 
acceleromyography (AMG) at the adductor pollicis muscle using the TOF Watch® SX 
(Organon Ireland Ltd, now Merck, Dublin, Ireland). Surface paediatric ECG-electrodes 
(Neotrode®, Conmed, Utica, NY, USA) were placed over the ulnar nerve, near the wrist. 
A  temperature sensor was attached to the ball of the thumb: peripheral temperature was 
maintained above 32°C. Core temperature was maintained above 35°C.13 The AM G  trans­
ducer was attached to the distal phalanx of the thumb, perpendicular to its movement. The 
arm and other fingers were immobilized on an arm board. After induction of anaesthesia,
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a 5 s of 50 Hz tetanic stimulation was performed to reduce the time required to stabilize 
the response to subsequent TOF stimulation. This was followed by 2-5 min of TOF pulses 
at 2 Hz, repeated every 15 s, until the twitch response stabilized. The TOF Watch® SX 
device was then calibrated. After stabilization of the TOF signal and calibration, repetitive 
TOF stimulation was performed every 15s using supramaximal stimuli of 0.2 ms.
After calibration of the TOF-watch® SX, the patients received a bolus dose of rocuronium 
bromide 1.2 mg kg-1 (study A) or 0.6 mg kg-1 (study B), administered w ith in 10 seconds into 
a fast running IV  infusion. This was followed by endotracheal intubation and mechanical 
ventilation w ith a m ixture of oxygen and air. In study A, five minutes after the administra­
tion of rocuronium to induce profound NMB, an IV  bolus dose of either sugammadex (2.0, 
4.0, 8.0, 12.0 or 16.0 mg kg-1), or placebo (0.9% saline) was administered. In study B, at 
reappearance of the second twitch response (T2) of the TOF, a single IV dose of sugam­
madex 2.0 mg kg-1 was given. In both studies, anaesthesia and neuromuscular monitoring 
were continued until recovery of the TOF ratio to 0.9.
A t the end of the surgical procedure, the patients were allowed to recover from anaesthe­
sia and were transferred to the post anaesthesia care unit (PACU), where the possibility 
of postoperative recurrence of NMB was assessed by monitoring the patients' oxygen 
saturation, breathing pattern, breathing frequency and clinical signs of recovery.
In study A, the patients were monitored for at least 120 minutes after administration of 
sugammadex or placebo.5 In study B, patients w ith normal renal function were observed 
on the PACU for 7 h after administration of sugammadex and patients w ith renal failure 
for at least 24 h. After sugammadex administration clinical signs of recovery were assessed 
for patients w ith normal renal function for 24 h, and for renal failure patients for 48 h.5;9
Efficacy Variables
The primary efficacy variable in both studies was the time from the start of the administra­
tion of either sugammadex or placebo, to recovery of the TOF ratio to 0.9.5;9 Post hoc we 
retrieved the time from start of administration of sugammadex or placebo until recovery 
of T1 to 90% from the original recorded neuromuscular database of the patients included 
in these investigations.
A ll T1 recovery parameters were adjusted to the final, stable T1 value (normalization), 
as described in the guidelines for Good C linical Research Practice in pharmcodynamic 
studies of NMBAs.13 If, for example, the final T1 was 80%, a recorded T1 value of 72% 
implicated a 90% recovery of T1 (0.72 / 0.80). Also, the height of T1 at the time of recovery 
of the TOF ratio to 0.9 was recovered from all recordings. The post hoc analysis of these 
data was performed by 2 investigators.
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Statistical analysis
Results were imported into an Excel database and analysed w ith SAS (SAS Inc, v 8.02, 
Cary, NJ, USA) statistical routines. Data are presented as mean values w ith SEM in paren­
theses. The difference in recovery times of the TOF ratio versus T1 were analyzed using 
Student's t-test for paired observations. To reduce inter-individual variability, differences 
between T1 and TOF ratio recovery times were analyzed as relative paired observations 
(difference/recovery time T1) w ith in the groups.
The difference in recovery times of the TOF ratio and T1 between renal fa ilure group and 
control group (in study B) were analyzed using Student's t-test for unpaired observations. 
The level of significance used was p < 0.05.
RESULTS 
Study A
In study A, 43 patients were treated w ith either sugammadex or placebo.5 O f these 
patients, 40 were elig ib le for analysis of recovery of NMB (one patient was excluded 
because of a sugammadex dosing error, in one patient the time to recovery of the TOF 
ratio to 0.9 was not available and one patient received neostigmine). O f these 40 patients, 
times to recovery of the TOF ratio to 0.9 have already been published.5 In six out of 40 
registrations, it was impossible to determine the time to recovery of T1 to 90%, due to 
poor recording or due to movement of the operating table. Data from these subjects were 
excluded from the retrospective analysis.
In all registrations the final TOF ratio was almost identical to the baseline TOF ratio, before 
administration of rocuronium. A ll patients returned to at least their baseline TOF level after 
the administration of sugammadex.
During recovery, a stable T1 response should be 80-120% of the baseline value.13 In three 
patients, stable T1 response after recovery from NMB was lower than 80% of baseline T1 
value (78%, 72% and 72%).
Results of the recovery times of the TOF ratio to 0.9 and our post hoc analyses of recovery 
times of the first twitch of the TOF are presented in Table 1.
W hen placebo is administered, a normal recovery pattern of NMB after a dose of 
rocuronium 1.2 mg kg-1 is seen. First T1 recovers to 90%, after a mean (SEM) time of 
107.5 (2.2) minutes after administration of placebo. Recovery of the TOF ratio to 0.9 is 
significantly slower: 130.5 (4.7) min after administration of placebo. The mean difference 
between the recovery times is 23.0 min (P=0.018).
W ith  sugammadex given 5 min after administration of rocuronium 1.2 mg kg-1, the relative 
effect on TOF vs. T1 recovery depends on the dose of sugammadex administered. When a 
dose of sugammadex 2.0 mg kg-1 is given, the mean difference in time to recovery of the
Table 1: Recovery times of the TOF to 0.9 and T1 to 90% , in study A.
Summary of the recovery times (min) from start of the administration of sugammadex or placebo to recovery of the TOF ratio to 0.9 and the height of T1 to 90% 
of stable twitch height after a single dose of rocuronium 1.2 mg kg"1, in study A.















TOF ratio to 0.9 Mean (SEM) (min) 130.5 (4.7) 56.5 (2.4) 18.1 (14.3) 2.7 (0.2) 1.5 (0.1) 1.1(0.1)
Min - Max 123.5-139.5 50.5 - 65.1 3.3-46.6 2.2 -3.6 1.1 -1.9 0.7-1.5
T1 to 90% Mean (SEM) (min) 107.5 (2.2) 39.3 (4.9) 13.7 (9.6) 4.9 (0.9) 2.9 (0.7) 2.2(0.4)
Min - Max 104.4-111.8 24.3 - 52.0 4.0-32.9 2.4-10.9 1.9-6.3 1.2 -4.3
Difference (min) Mean (SEM) -23.0 (3.2) -17.3 (4.2) -4.4 (4.7) 2.2 (0.8) 1.5 (0.7) 1.1(0.4)
Min - Max -27.8 - (-17.0) (-26.3)-(-2.8) (-13.8)-0.8 (-0.5)-7.5 0.25 -4.8 0.5 -3.0
Significance P=0.018 P=0.014 P= 0.445 P= 0.021 P=0.084 P=0.040
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TOF to 0.9 and recovery of T1 to 90% is 17.3 minutes (Table 1). Recovery of T1 to 90% oc­
curs statistically significantly earlier than recovery of the TOF ratio to 0.9 (p=0.014). After 
a dose of sugammadex 4.0 mg kg-1, this mean difference in recovery times is 4.4 minutes 
(T1 first, than TOF ratio), however, this difference is not statistically significant (p=0.445). 
After a dose of 8, 12 and 16 mg kg-1 the recovery of the TOF ratio to 0.9 occurs earlier 
than the recovery of T1 to 90%. There is a statistically significant difference in recovery 
times of T1 to 90% and TOF ratio to 0.9 in the dose groups of 8.0 mg kg-1 (p=0.021) and
16.0 mg kg1 (p=0.040).
After an optimal dose of sugammadex (16 mg kg-1) was administered, at the time of recov­
ery of the TOF ratio to 0.9, T1 had recovered to a mean of 53%.
Figure 1 is a graphic depiction of the recovery times from administration of sugammadex 
or placebo to recovery of the TOF ratio to 0.9 and T1 to 90% and the different doses of 
sugammadex.
Signs of residual NMB or recurrence of NMB were not observed in any of the patients. 
Study B
In study B two patient groups were examined: patients w ith severe to end-stage renal 
failure and healthy ASA I-II controls.9 Fifteen renal patients and 14 healthy controls were 
eligible for fu ll analysis of recovery of NMB. In one control patient, the recovery variables 
were unreliable due to poor recording. Data from this subject were excluded. In this study, 
sugammadex 2.0 mg kg-1 was administered at reappearance of T2.
In all patients in study B the stable T1 response during recovery of NMB was w ith in the 
predefined limits (80-120% of baseline T1 value).13 In all registrations the final TOF ratio 
was almost identical to the baseline TOF ratio, before administration of rocuronium. 
Results of the recovery times of the TOF ratio to 0.9 and our post hoc analyses of recovery 
times of T1 are presented in Table 2.
In both patient groups, recovery of T1 to 90% was significantly slower than recovery of 
the TOF ratio to 0.9. In patients w ith normal renal function the mean (SEM) difference 
between recovery of the TOF ratio to 0.9 and recovery of T1 to 90% was 79.4 (19.5) 
seconds (p=0.0013). In patients w ith renal impairment, this difference was even larger: 
mean (SEM) difference was 157.6 (23.4) seconds (p<0.0001).
In the renal patient group, at the time the TOF ratio had recovered to 0.9, T1 had recovered 
to a mean of 72%. In the control group, T1 had recovered to a mean of 71% when the TOF 
ratio had recovered to 0.9.
Recovery times to a TOF ratio of 0.9 were not statistically different between the renal 
failure patients and the controls, as published previously.9 However, the time to recovery 
of T1 to 90% was statistically significantly faster for the patients w ith normal renal func­
tion, compared to the patients w ith renal insufficiency (p=0.001). Also, the difference in 
recovery times between recovery of the TOF ratio to 0.9 and T1 to 90% was significantly
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smaller for the patients w ith normal renal function, compared to renal fa ilure patients 
(p=0.017).
Recurrence of NMB was not observed in any of the patients.
Figure 1: Recovery times of the TOF ratio to 0.9 and T1 to 90% after different doses of sugammadex, 
in study A.
X-axis: administered dose of sugammadex to reverse profound rocuronium-induced neuromuscular 
block (NMB), in mg kg-1.
Y-axis: mean time from administration of sugammadex to recovery of the train-of-four (TOF) ratio to
0.9 or recovery of the first twitch of the TOF (T1) to 90%, in minutes.
After a low dose of sugammadex (2 or 4 mg kg-1) or placebo is administered to reverse a profound 
rocuronium-induced NMB, T1 recovers to 90% before the TOF ratio recovers to 0.9.
At a sugammadex dose of around 6 mg kg-1, the recovery of the TOF ratio to 0.9 and recovery of T1 
occur at about the same time.
At high doses of sugammadex (8 mg kg-1 and higher), recovery of the TOF ratio to 0.9 occurs earlier 
than the recovery of T1 to 90%.
Sugammadex (mg kg'1)
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Table 2: Recovery times of the TOF to 0.9 and T1 to 90%, in study B.
Summary of the recovery times (sec) from start of the administration of sugammadex to recovery of the 
TOF ratio to 0.9 and the height of T1 to 90% of stable twitch height after a single dose of rocuronium 
0.6 mg kg-1, in study B.
The difference is the mean (SEM) absolute difference in recovery times of TOF ratio to 0.9 and T1 to 90%. 
P<0.05 = statistically significant
N




TOF ratio to 0.9 Mean (SEM) (sec) 123.7 (12.3) 99.4 (10.2)
Min - Max 69 - 221 58 - 185
T1 to 90% Mean (SEM) (sec) 281.3 (22.0) 178.8 (18.3)
Min - Max 145 - 476 102 - 281
Difference (sec) Mean (SEM) 157.6 (23.4) 79.4 (19.5)
Min - Max (-30) - 315 (-75) - 180
Significance <0.0001 0.0013
DISCUSSION
Nowadays neuromuscular monitoring is an evidence-based practice and should routinely 
be used whenever a non-depolarizing N M BA is administered. Such monitoring can im ­
prove patient outcome.20 Measurement of the TOF ratio is considered the standard, with 
a normalized acceleromyographic TOF ratio of 0.9 now accepted as safe w ith regard to 
postoperative risk of respiratory complications, such as aspiration and hypoxia. Several 
studies clearly show that airway protection and respiratory control have not fu lly  recov­
ered until an adductor pollicis TOF ratio of 0.9 has been reached.21;22 
However, TOF fade (expressed by the TOF ratio) represents presynaptic receptor block­
ade, whereas postsynaptic receptor block is expressed by depression of the single twitch 
response or T1.10 The two phenomena represent two different physiological sites of action, 
and may not be used interchangeably in all conditions.
It has been demonstrated by A li et al., using mechanomyography, that when the single 
twitch height had recovered to baseline after recovery from NMB, the TOF ratio varied 
between mean 64 and 74%, depending on the NM BA.23 Mc Coy et al reported that at a 
TOF ratio of 0.6 or greater, single twitch had returned to 90%.24 Hence, as considerable 
residual paralysis may still be present at full recovery of the single twitch height, it is 
considered misleading to use the single twitch monitoring as the single criterion for return 
of neuromuscular function.
Although there is difference between currently used NMBAs in their ab ility to produce 
fade, during spontaneous recovery from NMB the fade effect persists longer than twi tch 
depression.25 26-28 Fade disappears and TOF ratio recovers to >0.9 only after normalisa-
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tion of T1 tension.24 When antagonizing w ith classical reversal agents (anticholinesterase 
drugs) the time course of recovery from NMB is identical: first fu ll return of T1 and then 
recovery of the TOF ratio to 70 and 90%.23
The present study shows that after reversal of rocuronium-induced NMB by sugammadex 
the return of a normal TOF ratio can, dose-dependently, precede the return of a normal 
twitch height. W hen the dose of sugammadex is high enough for fast reversal of deep 
rocuronium-induced NMB (8 mg kg-1 and higher), the recovery of the TOF to 0.9 pre­
cedes the recovery of T1 to 90%, sometimes by minutes. This is also the case when the 
recommended dose of sugammadex (2.0 mg kg-1) is administered at reappearance of T2 
(moderate NMB). In healthy patients the mean difference in reversal time (TOF vs. T1) was 
79 seconds, but could take as long as 3 minutes, and in renal patients the mean difference 
in reversal time was 157 seconds, but could take as long as 5 minutes.
This study shows that after reversal w ith an adequate dose of sugammadex, the traditional 
relationship between TOF ratio and T1 recovery is no longer valid. Recovery of the TOF 
ratio to 0.9 precedes the recovery of T1, and the TOF ratio may be fu lly  recovered when 
this is not yet the case for T1. Therefore, the TOF ratio as the only measurement for ad­
equate reversal of NMB, is no longer reliable in all cases after reversal w ith sugammadex, 
and twitch height has to be taken into account as well.
Bom and Thomson showed in the mouse hemi-diaphragm during TOF stimulation that su­
gammadex in a lower concentration produced a faster recovery from rocuronium-induced 
NMB of T1 than T4, wh ile  after a higher concentration the recovery of T1 and T4 were 
rather sim ilar and the TOF ratio even reached 0.9 when T1 was still depressed.29 They sug­
gested that the TOF ratio might be an unreliable indicator of recovery in those situations. 
The present study is the first to show in humans that after reversal of rocuronium-induced 
NMB by sugammadex a full recovery of the TOF ratio is possible when T1 is still depressed. 
The transmitter ACh, in addition to acting on the postjunctional nicotinic ACh receptor 
(nAChR), also acts on the prejunctional nAChR to mobilize ACh from the reserve to the 
readily releasable store, so that the availab ility for release can keep up w ith the demands 
of high frequencies of nerve impulses that are characteristic of transmission to striated 
muscle.10 Blockade of these presynaptic receptors w ill thus impair mobilization and ac­
counts for the so-called "fade" that occurs during partial non-depolarizing NMB. Normal 
single twitches may be produced in the presence of 75 - 80% receptor occlusion by a 
NMBA, but it is necessary for about 50%  of the receptors to be unoccupied by NMBAs 
before tetanic fade at 100Hz is no longer evident.30 How then can it be explained that 
after the administration of sugammadex, a recovery to a TOF ratio of 0.9 precedes the 
recovery of T1 to 90%?
Non-depolarizing NMBAs, such as rocuronium, block nAChRs located in the NMJ in a 
competitive manner. Muscle nAChRs are assembled from four different subunits arranged 
as the pentamer (a1)2ßl8g.31;32 A t NMJ the receptors are composed of two a1-subunits in
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combination w ith one each of ß1-, 8-, and e-subunits. Non-depolarizing NMBAs compete 
w ith ACh to bind to an a  subunit of the receptors. Under these conditions, the ion channel 
w ill not open and no current w ill flow through it. Also, the presynaptic axon terminals 
are equipped w ith nAChRs. These neuronal nAChRs include homomeric and heteromeric 
receptors, where the heteromeric receptors are formed by a combination of a2-6 and ß2- 
4.32 It has been shown that inhibition of the presynaptic a3ß2 nAChR subtype at the motor 
nerve end induces tetanic fade.33 Therefore it is like ly that the fade phenomenon seen 
during non-depolarizing NMB is due to an inhibition of this a3ß2 nAChR subtype. Jonsson 
et al. showed that non-depolarizing NMBAs inh ib it neuronal nAChRs and that the inh ib i­
tory mechanism differs between individual receptor subtypes and NMBAs.34 The NMBAs 
had individual action profiles on different receptors. The c lin ically used NMBAs inhibited 
the a3ß2 nAChR subtype, which provides a molecular explanation for the tetanic and TOF 
fade seen during NMB by non-depolarizing NMBAs.34 Also, succinylcholine, which does 
not produce TOF fade, does not block the a3ß2 nAChR subtype.35
Different non-depolarizing NMBAs produce different degrees of fade response.25 26;27 
This is probably due to a difference in potency of the NMBAs in blocking the neuronal 
presynaptic nAChR. In vitro studies showed that non-depolarizing NMBAs have a much 
higher affinity for the postsynaptic a1 ß1 e8 nAChR subtype compared w ith the presynaptic 
a3ß2 subtype.34 In the presence of high concentrations of sugammadex, only a low con­
centration of free rocuronium molecules remains in the NMJ and w ill preferentially block 
the postsynaptic nAChR. This could explain why after an optimal dose of sugammadex, 
the fade phenomenon disappears very fast, while  the postsynaptic single twitch is still 
depressed, even when the TOF ratio has recovered to 0.9.
After an effective dose of sugammadex, fu ll recovery of T1 followed recovery to a TOF 
ratio of 0.9 w ith in a few minutes, and it is not known yet if this w ill have clinical implica­
tions. In the present study, none of the subjects showed clinical signs of residual paralysis 
after reversal of a rocuronium-induced NMB by sugammadex, even when reversal of T1 
was significantly slower than reversal of the TOF ratio. After a lower dose of sugammadex, 
which does not produce fast recovery of deep NMB (4 mg kg-1 or less), the recovery of 
TOF to 0.9 did not precede the recovery of T1 and thus behaved like after spontaneous 
recovery from rocuronium-induced NMB. This means there is no reason to expect that the 
absence of the TOF fade response may be misleading in such circumstances. Therefore it 
is not likely, when a low dose of sugammadex is given, that a recovery to a TOF ratio of 
0.9 would carry the risk of incomplete recovery of the muscle strength.
However, patients taking medication known to interfere w ith the postsynaptic response 
of NMBAs (for example aminoglycoside antibiotics 36;37 or magnesium 38), were excluded 
from the studies here described. Ratients w ith known or suspected neuromuscular disor­
ders were also excluded, such as patients w ith diseases involving the AChR, for example 
myasthenia gravis.39 It is possible that in patients receiving such medication or suffering
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from such a disease, recovery of the single twitch response after administration of sugam­
madex, will be remarkably slower, and there could be a risk of residual paralysis, even 
though the TOF ratio has recovered to 0.9. Further investigation is necessary.
Also, for the renal patients in study B, recovery of T1 to 90%  was significantly slower 
compared to the patients with normal renal function. Renal patients may therefore be 
more vulnerable for developing residual paralysis, even when a TOF ratio of 0.9 has been 
reached.
In conclusion, after reversal of rocuronium-induced NM B with an optimal dose of sugam­
madex, the TOF ratio recovered to 0.9 significantly faster than T1 recovered to 90%. A 
full recovery of the TOF ratio was possible when T1 was still depressed. Therefore, after 
reversal with sugammadex the TOF ratio as the only measurement for adequate reversal of 
NM B may not always be reliable and twitch height has to be taken into account as well.
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3-Desacetyl-vecuronium is an active metabolite of the neuromuscular blocking agent 
(NMBA) vecuronium, which might lead to residual paralysis after prolonged administra­
tion of vecuronium in critically ill patients with renal failure. This study investigated the 
ability of sugammadex to reverse 3-desacetyl-vecuronium-induced neuromuscular block 
(NMB) in the anaesthetised rhesus monkey.
Methods
Experiments were performed in anaesthetised female rhesus monkeys. After bolus 
intravenous injection of vecuronium (n=8) or 3-desacetyl-vecuronium (n=8) 10 |ig kg-1 
(ED90), a continuous infusion of the same N M BA  was started to maintain the first twitch 
of the Train-of-Four (TOF) at 10% of baseline value. The infusion was stopped and NMB 
recovered spontaneously. The procedure was repeated, but immediately after stopping the 
infusion an intravenous bolus dose of sugammadex 0.5 or 1.0 mg kg-1 was given. For each 
NMBA, four placebo experiments were performed, in which the second recovery from 
NM B was also spontaneous. For all experiments time to recovery of the TOF ratio to 90% 
was retrieved.
Results
After administration of sugammadex for reversal of 3-desacetyl-vecuronium-induced 
NMB, recovery was significantly faster than spontaneous recovery. Mean time to recovery 
of TOF to 90%  was 3.2 min (sugammadex 0.5 mg kg-1) and 2.6 min (1.0 mg kg-1), com­
pared to spontaneous recovery (17.6 min). For vecuronium-induced NM B mean time to 
recovery of TOF to 90% was 17.1 min (0.5 mg kg-1) and 4.6 min (1.0 mg kg-1), compared 
to spontaneous recovery (23.4 min).
Conclusions
Sugammadex rapidly and effectively reversed 3-desacetyl-vecuronium-induced NM B in 
the rhesus monkey, at a lower dose than needed to reverse vecuronium-induced NMB.
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Vecuronium is an aminosteroidal neuromuscular blocking agent (NMBA), with a high 
safety profile, which is used in many surgical cases and for facilitation of mechanical 
ventilation. Like all other NMBAs, it may cause residual paralysis, resulting in hypoventila­
tion, airway obstruction, pulmonary complications and hypoxia.1, 2 Therefore, reversal of 
neuromuscular block (NMB) is important for the acceleration of patient recovery and 
prevention of residual paralysis and prolonged mechanical ventilation. Sugammadex, a 
selective relaxant binding agent, was specifically designed to encapsulate and inactivate 
the aminosteroidal NM BA rocuronium, thereby rapidly reversing N M B.3-7 It has also been 
shown to be effective in reversing vecuronium-induced NM B.8-10
Vecuronium is associated with residual paralysis, with an increased risk after cumulative 
doses and long-term administration.1112 Segredo et al.'2 described two critically ill patients 
with renal failure and prolonged NM B lasting many hours after discontinuation of long­
term administration of vecuronium. High plasma concentrations of 3-desacetyl-vecuroni- 
um (also known as 3-hydroxy-vecuronium), the principal metabolite of vecuronium, were 
found in these patients. 3-Desacetyl-vecuronium has significant neuromuscular blocking 
potency, up to 80%  of its parent compound vecuronium.13,14 It was likely that accumula­
tion of the metabolite 3-desacetyl-vecuronium was the main cause of the residual paralysis 
in the patients described.12
It is important to know if such a residual paralysis can be terminated with sugammadex. 
Although sugammadex is effective in binding rocuronium and vecuronium, it is not 
known whether sugammadex is also capable of encapsulating 3-desacetyl-vecuronium. 
Theoretically, after reversal of vecuronium-induced NM B by sugammadex, 3-desacetyl- 
vecuronium might, thus, cause residual paralysis, should sugammadex not be capable 
of inactivating this active metabolite. To demonstrate the ability of sugammadex to also 
reverse 3-desacetyl-vecuronium-induced NMB, the present study was designed in the 
anaesthetised rhesus monkey. To assess a possible difference in reversing power of su­
gammadex for 3-desacetyl-vecuronium versus vecuronium, identical experiments were 
performed with a NM B induced by vecuronium.
METHODS
These in-vivo experiments were performed in the research laboratories of the Department 
of Anaesthesiology, Rain and Ralliative Medicine at the Radboud University Nijmegen 
Medical Centre in Nijmegen, The Netherlands.
Female rhesus monkeys (CSIMS, Beijing, China) were sedated with ketamine 10 mg kg-1 
(Nimatek; Eurovet, Bladel, the Netherlands) administered by intramuscular injection. Two
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intravenous (i.v.) lines were inserted; one for the administration of anaesthetics, includ­
ing vecuronium or 3-desacetyl-vecuronium, the other for sugammadex administration. 
Anaesthesia was induced by i.v. bolus injection of pentobarbital sodium 25 mg kg-1 (Ceva 
Sante Animale) and a subsequent continuous infusion of 5-10 mg kg-1 h -1. The trachea was 
intubated and the lungs were mechanically ventilated with a mixture of oxygen and nitrous 
oxide at a ratio of 2:3, to maintain normoventilation, as determined by capnography. Heart 
rate and oxygen saturation were determined at the ear using a pulse oximeter (Ohmeda 
Biox; Ohmeda, Madison, USA). Blood pressure was determined non-invasively with a 
cuff placed around the tail (Ohmeda, Finapres). Body temperature was kept constant at 
37-38°C.15
For monitoring neuromuscular transmission, the median nerve of the right arm was stimu­
lated supramaximally near the wrist using needle electrodes.15 Stimulation was performed 
with 2 ms square wave pulses in a Train-of-Four (TOF) sequence of 2 Hz with a train 
interval of 15 s, delivered by a Grass S88 Stimulator (Grass Medical Instruments, Quincy, 
Massachusetts, USA). The resulting contractions of the thumb muscles were quantified 
with a force displacement transducer, and recorded on a polygraph. The level of 10% 
recovery of the first twitch response (T1) of the TOF was chosen as the point for reversal. 
This point was chosen in analogy of previous experiments with sugammadex.15 Each time 
a TOF stimulus was triggered (every 15 s), all variables were requested by the measuring 
computer from both the pulse oximeter and the blood pressure device.
The study drugs vecuronium and 3-desacetyl-vecuronium were provided by Organon, 
now a part of Merck Sharp & Dohme BV, Oss, the Netherlands. Vecuronium was supplied 
as commercially available Norcuron® and 3-desacetyl-vecuronium was supplied as a 
powder which was dissolved in NaCl 0.9%. The 3-desacetyl-vecuronium as supplied was 
at least 99%  pure.
In this study in female rhesus monkeys, 12 experiments were planned using vecuronium 
and 12 using its metabolite 3-desacetyl-vecuronium as the NMBA. A flowchart of the 
study protocol is shown in Figure 1. After i.v. bolus injection of about the ED90 dose (in the 
rhesus monkey) of either vecuronium (10 |ig kg-1)16 or 3-desacetyl-vecuronium (10 |jg kg-1, 
known from pilot experiments to be the ED90), a continuous infusion of vecuronium or 
3-desacetyl-vecuronium was started in order to maintain T1 at approximately 10 %  (± 
5% ) of its baseline value. After a constant NM B had been maintained for about 10 min, 
the infusion was stopped and the NM B was allowed to recover spontaneously. After full 
recovery of the TOF ratio (height of T4 versus height of T1 or T4/T1) one extra hour of 
recovery was allowed, before a second bolus of NM BA was given and the process was 
repeated. At the time the second infusion of NM BA was stopped, sugammadex either 0.5 
or 1.0 mg kg-1 was administered as a rapid bolus i.v. (n=4 for each dose of sugammadex; 
eight experiments with 3-desacetyl-vecuronium and eight with vecuronium).
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To verify that these data could be compared in a paired fashion, these experiments were 
preceded by eight placebo experiments (four for vecuronium and four for 3-desacetyl- 
vecuronium), in which the second recovery from NM B was spontaneous (instead of 
administration of sugammadex; Fig. 1).
From all experiments the time intervals from stopping the infusion to recovery of the TOF 
ratio to 90% were measured. After the response had recovered to baseline values, TOF 
monitoring was continued for an extra hour, to evaluate possible recurrent paralysis, as the 
effect of sugammadex may disappear 60 minutes after administration.17 
At the end of the experiments, the animals recovered from anaesthesia, in a guarded 
recovery area. They were monitored in the presence of a warming lamp until normal 
behaviour had fully restored.
Figure 1: Flowchart of the study protocol.
Ethics
Ethical approval for this study (protocol number 1999-64B and 2000-62) was provided by 
the Radboud University Nijmegen Animal Experiment Committee, Nijmegen, the Nether­
lands (Rrofessor Dr R. Zwart, October 2 7, 2000) which is governed by the Dutch law on 
Animal Experiments (revision 5/2/1997) and is based on the guidelines of the EU Directive 
86/609. The two authors holding the animal lab authorization to perform this investigation 
were Dr J van Egmond (licensed in 1999 for article 9 of the cited Dutch law) and Ms F van 
de Rol (licensed in 1988 for article 12 of the same law).
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Statistical analysis
The placebo experiments were used to show that two consecutive spontaneous recoveries 
for a single rhesus monkey, with sufficient recovery time in between, in a single experi­
ment were reproducible.
Recovery times with (R2) and without (R1) the reversal agent were compared for the same 
NM BA and the same dose of sugammadex or placebo, in a Student's t test for paired 
observations. To eliminate more interindividual variance than simple paired observations, 
the recovery times were scaled to the first value (i.e. comparison of the difference/first 
value, (R2-R1)/R1, with 0). All values of the recovery times are presented as mean (SEM). 
To compare recovery times of two different doses of sugammadex with the same NMBA, 
the ratio (R2-R1)/R1 was compared in a Student's t-test for unpaired data. Similarly, recov­
ery times at the same sugammadex dose were compared between the two NMBAs. 
P-values < 0.01 were considered statistically significant.
RESULTS
The experiments were performed in 24 different female rhesus monkeys (body weight 5.2 
- 7.0 kg). Twelve experiments were conducted using vecuronium (four placebo experi­
ments, four with sugammadex 0.5 mg kg-1 and four with sugammadex 1.0 mg kg-1) and 
12 using 3-desacetyl-vecuronium (four placebo experiments, four with sugammadex 0.5 
mg kg-1 and four with sugammadex 1.0 mg kg-1). (Fig. 1) To maintain T1 at 10%, infusion 
rates varied between 7.4 and 39.0 |ig kg-1 h-1 for vecuronium and between 12.9 and 54.4 
|ig kg-1 h-1 for 3-desacetyl-vecuronium.
Recovery times for either 3-desacetyl-vecuronium or vecuronium are presented in Table 1. 
In the placebo group, after the second administration of the NM BA the spontaneous 
recovery times did not change statistically significantly, compared to recovery times 
after the first administration of the NMBA. Figure 2 shows a representative recording of 
a TOF registration of a placebo experiment (spontaneous recovery) with vecuronium in 
one animal. The overlap figure in Fig. 2 shows that there is no difference in spontaneous 
recovery pattern after the first and second administration of vecuronium in a representa­
tive experiment in the placebo group. From these data it is clear that the two consecutive 
spontaneous recoveries for a single monkey in a single experiment are reproducible, 
allowing evaluation of the effect of a reversal agent in a paired fashion as described. 
Table 1 also presents the results of the experiments in which sugammadex was adminis­
tered after the second administration of the NMBA. Recovery to a TOF ratio of 90% from 
both 3-desacetyl-vecuronium-induced and vecuronium-induced NM B was significantly 
faster after injection of sugammadex 1.0 mg kg-1, compared to spontaneous recovery.
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Table 1: Recovery times of neuromuscular block, spontaneous and after administration of 
sugammadex.
Mean (SEM) time intervals (min) from stop of the continuous administration of 3-desacetyl-vecuronium 
or vecuronium to recovery of the train-of-four (TOF) ratio to 90%  after spontaneous recovery or 
reversal with sugammadex 0.5 mg kg-1 or sugammadex 1.0 mg kg-1. Spontaneous recovery: after the 
first administration of the neuromuscular blocking agent (NMBA) and after the second administration 
of the N M BA  in the placebo experiments. Reversal with sugammadex: after the second administration 
of the NMBA.
a Unpaired comparison of these groups showed no significant difference in 90%  recovery time 
(p=0.84). b Unpaired comparison of these groups showed a significant reduction of 9 0%  recovery time 
for the highest sugammadex dose (p=0.0069). Statistically significant P<0.01.






Placebo (n=4) 19.8 (1.61) 19.3 (0.77) 0.81
Sugammadex 0.5 mg kg-1 (n=4) 20.5 (3.58) 3.2 (1.17)a 0.0004
Sugammadex 1.0 mg kg-1(n=4) 17.6 (1.51) 2.6 (0.94)a 0.0003
Vecuronium (n=12)
Placebo (n=4) 23.9 (2.00) 25.3 (2.83) 0.36
Sugammadex 0.5 mg kg-1(n=4) 25.4 (2.95) 17.1 (3.99)b 0.0487
Sugammadex 1.0 mg kg-1(n=4) 23.4 (1.86) 4.6 (0.78)b <0.0001
In 3-desacetyl-vecuronium-induced NMB, mean time to recovery of the TOF ratio to 90% 
was 3.2 minutes after administration of sugammadex 0.5 mg kg-1, compared to 2.6 minutes 
after sugammadex 1.0 mg kg-1. The higher dose of sugammadex provided a slightly faster 
reversal, however, not statistically significantly so (p=0.84).
In vecuronium-induced NMB, reversal by the administration of sugammadex 0.5 mg kg-1 
was considerably slower than by sugammadex 1.0 mg kg-1. Mean time to recovery of the 
TOF ratio to 90% was 17.1 minutes after sugammadex 0.5 mg kg-1, compared to 4.6 min­
utes after sugammadex 1.0 mg kg-1, which difference is statistically significant (p=0.0069). 
This is typically shown in Figures 3 and 4, presenting TOF ratio registrations for vecuronium 
and 3-desacetyl-vecuronium, respectively. Figure 3b clearly shows a faster recovery of 
vecuronium-induced NM B after administration of sugammadex 1.0 mg kg-1, compared to 
sugammadex 0.5 mg kg-1 (Fig. 3a). Figure 4a shows a slightly faster reversal of 3-desacetyl- 
vecuronium-induced NM B after sugammadex 1.0 mg kg-1, compared to sugammadex 0.5 
mg kg-1 (Figure 4b).
Comparison of the recovery times after reversal with sugammadex 0.5 mg kg-1 shows that 
the reversal of 3-desacetyl-vecuronium-induced NM B is significantly faster than reversal 
of vecuronium-induced NM B with the same dose of sugammadex (p=0.0059). However, 
reversal with sugammadex 1.0 mg kg-1 of 3-desacetyl-vecuronium-induced NM B is not 
significantly faster than reversal of vecuronium-induced NM B with the same dose of 
sugammadex (p=0.31).
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Monitoring for another hour did not reveal any signs of residual paralysis or recurrence of 
NMB. Heart rate and blood pressure did not change more than 20%  of baseline values. 
The body temperature of the animals stayed between 37° and 38°C during the experi­
ments. The recoveries from anaesthesia were uneventful in all rhesus monkeys.
Figure 2: TOF registration of vecuronium-induced neuromuscular block in a rhesus monkey (placebo 
experiment).
In this experiment, vecuronium 10 ^g kg-1 i.v. was administered, followed by continuous infusion 
of vecuronium to maintain T1 at approximately 10% of the baseline value. When the infusion of 
vecuronium was stopped, the neuromuscular block (NM B) recovered spontaneously. This experiment 
was repeated in the same animal, again without reversal. The small insert figure is an overlap 
registration of both TOF ratio registrations of the first and second NM BA  administration in the same 
animal. TOF, train-of-four.
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Figure 3: Overlap of two registrations of the train-of-four (TOF) ratio versus time curve in the same 
animal after vecuronium administration.
Rhesus Monkey, vecuronium 
sugammadex 0.5 mg/kg
Time (h)
Figure 3a: spontaneous recovery of vecuronium-induced neuromuscular block (NM B) compared with 
recovery after administration of sugammadex 0.5 mg kg-1 iv.
Rhesus Monkey, vecuronium 
sugammadex 1.0 mg/kg
Time (h)
Figure 3b: spontaneous recovery of vecuronium-induced NM B compared with recovery after 
administration of sugammadex 1.0 mg kg-1 intravenously.
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Figure 4: Overlap of two registrations of the train-of-four (TOF) ratio versus time curve in the same 
animal after 3-desacetyl-vecuronium administration.
Rhesus Monkey, 3-desacetyl-vecuronium 
sugammadex 0.5 mg/kg
Time (h)
Figure 4a: spontaneous recovery of 3-desacetyl-vecuronium-induced neuromuscular block (NMB) 
compared with recovery after administration of sugammadex 0.5 mg kg-1 intravenously.
Rhesus Monkey, 3-desacetyl-vecuronium 
sugammadex 1.0 mg/kg
Time (h)
Figure 4b: spontaneous recovery of 3-desacetyl-vecuronium-induced NM B compared with recovery 
after administration of sugammadex 1.0 mg kg-1 intravenously.
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Vecuronium undergoes hydrolysis to three pharmacologically active metabolites, 3-de- 
sacetyl-vecuronium, 17-desacetyl-vecuronium and 3,17-desacetyl-vecuronium.18 The 
most potent metabolite, 3-desacetyl-vecuronium, accounts in humans for approximately 
12% of the total clearance of vecuronium.14 It has significant neuromuscular blocking po­
tency, up to 50-70% in cats and 80%  in humans, of its parent compound vecuronium.1314 
Therefore, 3-desacetyl-vecuronium is a potent NM BA and is probably responsible for 
reported episodes of prolonged NM B after long-term administration of vecuronium in 
critically ill patients or patients with renal failure.111219
The present study shows that NM B induced by 3-desacetyl-vecuronium in rhesus mon­
keys, like that produced by vecuronium, can be effectively and rapidly reversed by sugam­
madex. The rhesus monkey model was chosen because it is not allowed to administer 
3-desacetyl-vecuronium in humans. Both sugammadex dosages administered (0.5 mg kg-1 
and 1.0 mg kg-1) were adequate in reversing the effect of 3-desacetyl-vecuronium within 
4 minutes. There was no significant difference in recovery times between the two different 
doses of sugammadex, indicating that sugammadex 0.5 mg kg-1 is close to the optimal 
dose for reversing a 90% 3-desacetyl-vecuronium-induced NMB.
It has already been shown in human experiments that reversal of vecuronium-induced 
NM B by sugammadex is efficient and safe.8-10 In the present study, reversal of vecuronium- 
induced NM B by sugammadex 1.0 mg kg-1 was also significantly faster than spontaneous 
recovery. However, after administration of sugammadex 0.5 mg kg-1, mean time to reversal 
to a TOF ratio of 90%  was still 17.1 minutes, which is a significantly slower recovery than 
recovery of vecuronium-induced NM B with sugammadex 1.0 mg kg-1 (p=0.0069), indicat­
ing that sugammadex 0.5 mg kg-1 is not yet the optimal dose. The vecuronium experiments 
in this study were performed to assess a possible difference in efficacy of sugammadex 
for reversing 3-desacetyl-vecuronium-induced NM B and vecuronium-induced NMB. Both 
doses of sugammadex provided an adequate recovery of 3-desacetyl-vecuronium-induced 
NMB, whereas the low dose of sugammadex did not for vecuronium-induced NMB. It also 
has to be taken into account that the infusion rates for 3-desacetyl-vecuronium in these 
experiments were higher, and therefore probably also the amount of NM BA molecules 
present in the rhesus monkey. These data suggest a difference in affinity of sugammadex 
for the NM BA molecules.
The equilibrium affinity constant (KA) of vecuronium for sugammadex is 10.000.000 M -1 
(compared to the KA of rocuronium for sugammadex: 25.000.000 M -1).20 The exact KA 
of 3-desacetyl-vecuronium is not known, as an isothermal microcalorimetry was not 
performed.
However, the efficacy of reversal of NM B depends not only on the affinity of sugammadex 
for the N M BA  molecule, but also on the distribution kinetics and potency of the NM BA
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and the number of NM BA molecules that need to be encapsulated to reverse NMB, that 
is, the plasma concentration of the NM BA at the time of reversal. Furthermore the efficacy 
depends on the number of sugammadex molecules present, that is, at a higher concentra­
tion the probability is greater for the two molecules to meet and form a complex. In this 
experiment, plasma concentrations of the NMBAs and sugammadex were not measured. 
In the rhesus monkeys that received vecuronium, part of the NM BA probably could have 
been metabolised into 3-desacetyl-vecuronium, at the time of reversal by sugammadex. 
Also other factors could play a role, such as differences in speed of diffusion of the NMBAs 
from the neuromuscular junction to the extravascular volume.
Conclusions regarding the difference in reversing power of sugammadex for the two 
NMBAs based on the results of this study must be made with caution and should be 
substantiated with further experiments.
No complete data are available on the potency and duration of effect of 3-desacetyl- 
vecuronium in rhesus monkeys, compared to the parent compound vecuronium. In the 
present study, the ED90 of both compounds proved to be about the same. The spontane­
ous recovery experiments of the present study show that recovery from 90% constant 
NM B induced by vecuronium is longer than that for the same NM B depth induced by 
3-desacetyl-vecuronium. Mean time (SEM) to spontaneous recovery to a TOF 90% is 24.2 
(1.24; n=12) minutes after vecuronium, compared to 19.2 (1.32; n=12) minutes after 
3-desacetyl-vecuronium.
Prolonged NM B due to its metabolite 3-desacetyl-vecuronium has been reported after 
repeated or continuous administration of vecuronium for days in the ICU .12,19 Risk factors 
for this prolonged paralysis are high concentrations of 3-desacetyl-vecuronium and renal 
failure.12-19-21 For 3-desacetyl-vecuronium, the liver is the main organ of elimination and 
renal clearance accounts for 20%  of the total drug clearance.1214 This means that hepatic 
failure could also lead to an accumulation of 3-desacetyl-vecuronium and prolonged 
NMB, which has been shown in animal studies.22 The results of the present study show 
that reversal of such a state of prolonged NM B should be possible with sugammadex, as 
sugammadex also efficiently, and even more so, reverses 3-desacetyl-vecuronium-induced 
NMB. It should be realised that the present study, performed in the rhesus monkey, is dif­
ferent from the situation of critically ill humans in the ICU, who could possibly also suffer 
from muscle weakness due to critical illness polyneuromyopathy (CIP) or sepsis-induced 
myopathy.2324 The use of NMBAs itself has been described as a risk factor for developing 
CIP.23 However, vecuronium is still used in many ICUs throughout the world for facilita­
tion of mechanical ventilation in patients resisting such ventilation.
Human studies have shown that sugammadex is effective in reversing vecuronium-induced 
N M B.8-10 However, if sugammadex was not capable of encapsulating and inactivating the 
metabolite 3-desacetyl-vecuronium, there would be a risk that after successful reversal 
of long duration vecuronium-induced NM B by sugammadex, the patient would develop
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residual paralysis due to the active metabolite 3-desacetyl-vecuronium. The present results 
show that there is little chance that such residual paralysis will occur after administration 
of sugammadex.
Sugammadex is a water-soluble molecule, which is excreted mainly by the kidneys. In pre- 
clinical and clinical studies, renal excretion of the unchanged product was observed.6725 
After sugammadex administration in renal failure patients, clearance of sugammadex was 
much reduced and the terminal elimination half-time and mean residence time of sugam­
madex was 15-20 times higher in the renal failure group compared to the control group.26 
Sugammadex is biologically inactive, and has been shown to be well tolerated. However, 
at present no data are available on long-term safety aspects of sugammadex in patients 
with renal failure or critically ill patients in the ICU.
It should be realised that this investigation was performed in the rhesus monkey and that 
extrapolation of these results to humans, especially patients in ICU with organ failure, is 
not straightforward. However, although volume of distribution and potency of the NM BA 
may differ in the rhesus monkey compared to humans, the affinity of the N M BA  for sugam­
madex is not species-dependent.
In conclusion, sugammadex rapidly and effectively reverses NM B induced by 3-desacetyl- 
vecuronium in the rhesus monkey. It provides a rapid reversal of NM B at a lower dose of 
sugammadex than the dose needed to reverse NM B induced by vecuronium. As prolonged 
NM B after administration of vecuronium in critically ill patients and patients with renal 
failure has been attributed to high plasma concentrations of 3-desacetyl-vecuronium, the 
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REVERSAL OF NEUROMUSCULAR BLOCK BY SUGAMMADEX
Rocuronium and vecuronium are aminosteroidal neuromuscular blocking agents (NMBAs) 
widely used in anaesthesia and intensive care medicine.1 They are used for facilitation of 
endotracheal intubation and to allow surgical access to body cavities, in particular the 
abdomen and thorax, without hindrance from voluntary or reflex muscle movement. Also 
NMBAs are sometimes needed for patients in the intensive care unit (ICU) to facilitate 
compliance with mechanical ventilation, when sedation alone has proved inadequate. 1 
Recovery from rocuronium- or vecuronium-induced neuromuscular block (NM B) occurs 
spontaneously, as the NM BA diffuses away from the effect site, the neuromuscular junction 
(NMJ), and is metabolized in the liver and/or eliminated in the bile or the urine.1 However, 
there is a large inter-individual variability in duration of action of the NMBAs. As with all 
other non-depolarizing NMBAs, this includes the risk of residual paralysis at the end of 
surgery. Postoperative residual curarization (PORC) is defined as an acceleromyographic 
Train of Four ratio (TOF ratio) < 0.9.2-5 PORC is a risk factor for postoperative pulmonary 
complications, such as aspiration and hypoxia, which contribute to anaesthesia related 
morbidity and mortality.6-8 Conventionally, acetylcholinesterase inhibitors (in combination 
with muscarinic agonists) were used for the prevention and treatment of PORC, but these 
drugs have many side-effects and are also ineffective in reversing a profound NM B.9;10 
Sugammadex is a new selective relaxant binding agent, designed to encapsulate and in­
activate the aminosteroidal NMBAs, especially rocuronium.11 It provides a rapid recovery 
from NMB, even when a profound NM B is present, and it has minimal side effects.12-14 This 
thesis describes the use of sugammadex as a reversal agent in renal failure.
THE EFFICACY OF SUGAMMADEX IN RENAL FAILURE
Prolonged NM B has been reported after administration of rocuronium in patients with 
renal failure, compared with patients with normal renal function, although not consis­
tently.15-17 Inter-individual variability is also increased in renal failure patients, resulting in 
a less predictable duration of action.18 As patients with renal failure are more vulnerable 
for developing a prolonged NMB, sugammadex may be very useful in this patient group, 
as PORC and postoperative respiratory complications are more likely (chapter 2).
The animal study performed in the cat (chapter 3) investigated the efficacy of sugammadex 
in reversing rocuronium-induced NM B in an animal model of acute renal failure. After 
complete interruption of renal perfusion, sugammadex rapidly and effectively reversed the 
neuromuscular blocking effect of rocuronium.
This finding was later confirmed in the clinical study on efficacy of sugammadex in pa­
tients with renal failure (creatinine clearance (CLcr) < 30 ml min-1) compared with patients
120 Chapter 8
with normal renal function (chapter 4). The rocuronium-induced NM B was rapidly and 
effectively reversed by administration of sugammadex 2.0 mg kg-1. Mean time to recovery 
of the TOF ratio to 0.9 was 2.0 minutes for the renal failure patients, compared to 1.65 
minutes for the controls, which was not a statistically significant difference. Clinical signs 
of recurrence of NM B were not observed in any of the patients.
The findings in both investigations confirm that reversal of rocuronium-induced NM B by 
sugammadex depends on the rapid binding of rocuronium and not on its renal elimination. 
The free rocuronium molecules in the plasma are rapidly encapsulated by sugammadex, 
forming a complex with a high affinity. As a result the concentration of free rocuronium 
molecules in the plasma will rapidly decrease. Due to the concentration gradient more 
rocuronium molecules will diffuse from the NMJ (the effect site) to the plasma, and NMB 
is reversed.19 In conclusion, it is rather the redistribution of the rocuronium molecules 
than elimination of the drug by renal excretion, which is responsible for the rapid recovery 
from NMB. Further investigation is necessary to test the ability and dose requirement of 
sugammadex in reversing a profound NM B in renal failure patients.
The duration of action of vecuronium is not prolonged in renal failure patients. How­
ever, residual paralysis has been described after cumulative doses and after long-term 
administration in critically ill patients on the ICU, who suffered from renal failure.20-22 
High plasma concentrations of 3-desacetyl-vecuronium, the principal metabolite of 
vecuronium were found in these patients.20;21 3-Desacetyl-vecuronium has a significant 
neuromuscular blocking potency, and accumulation of this metabolite was held respon­
sible for the residual paralysis described. An animal study performed in the rhesus monkey 
(chapter 7) showed that sugammadex rapidly and effectively reversed NM B induced by 
3-desacetyl-vecuronium. These results indicate that the described state of prolonged NMB 
can be reversed with sugammadex.
PHARMACOKINETICS OF SUGAMMADEX IN RENAL FAILURE
Administration of sugammadex leads to an altered distribution and elimination of ro­
curonium. The major routes of elimination of rocuronium are biliairy and urinary excre­
tion.23 Rocuronium is mainly taken up by the liver and metabolized and/or excreted in 
the bile and faeces in high concentrations. In the absence of sugammadex, only a limited 
amount of rocuronium is excreted via the renal route.23
Sugammadex is a water soluble molecule, and is rapidly and dose-dependently excreted in 
the urine.24 When sugammadex was administered after administration of rocuronium, su­
gammadex was found to increase the urinary excretion of rocuronium in a dose dependent 
manner. This indicates that sugammadex enhances the renal clearance of rocuronium.19;25
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After administration of sugammadex, the plasma clearance of rocuronium assimilates into 
the plasma clearance of sugammadex, with increasing doses of sugammadex.
It is suggested that the extrarenal route of elimination is unavailable to rocuronium en­
capsulated by sugammadex.12 The plasma concentration of total rocuronium (free plus 
encapsulated) decreases less rapidly after administration of sugammadex. This implies 
that the elimination of rocuronium is even slowed by the administration of sugammadex. 
Encapsulation by sugammadex diverts the elimination of rocuronium from its normal 
pathway of hepatic clearance to the less effective renal clearance.25 This makes the use of 
sugammadex in renal failure patients questionable. Nevertheless the reversal is effective 
since the complex of rocuronium and sugammadex has a high affinity constant.
The clinical study performed on the pharmacokinetics of rocuronium and sugammadex in 
renal failure patients compared to patients with normal renal function showed large differ­
ences in the pharmacokinetics of both drugs between the two patient groups (chapter 5). 
For the first 60 min after administration, median plasma concentrations of sugammadex 
were similar in the control and renally impaired groups. At later time points, plasma 
concentrations of sugammadex showed a slower decline in the renally impaired group 
compared with the control group. A similar effect was seen for rocuronium.
Total plasma clearance of sugammadex was 17 times lower in the renal failure group. 
The mean terminal elimination half-life (t ,A p) of sugammadex was 2.3 hours in the control 
group, whereas it was 35.7 hours in the renal failure group. This effect was less for the 
pharmacokinetic variables of rocuronium. After the administration of sugammadex, the 
total plasma clearance of rocuronium was four times lower in the renal failure group 
than in the control group. Regression analyses showed that both for sugammadex and 
rocuronium the correlation between clearance of the drug and creatinine clearance is 
highly significant. Also urinary excretion of both sugammadex and rocuronium was much 
reduced in the renal failure group compared to the control group.
It is clear that patients with renal insufficiency retain the rocuronium-sugammadex com­
plex for a longer period of time than patients with normal renal function. However, the 
effect of renal impairment on the pharmacokinetic variables was smaller for rocuronium 
than for sugammadex. This suggests that in patients with renal failure, extrarenal clearance 
of rocuronium does take place, in spite of encapsulation by sugammadex. Even after 
encapsulation of rocuronium by sugammadex, there may still be a low concentration of 
free rocuronium available for hepatic clearance.
One of the problems of this pharmacokinetic study was, that the assay method used could 
not distinguish between free rocuronium and rocuronium encapsulated by sugammadex, 
as the sugammadex-rocuronium complex dissociates on the liquid chromatography col­
umn.24 Therefore, all measured concentrations in urine and plasma, are total concentrations 
and do not indicate the degree of encapsulation. This makes it impossible to determine
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whether there are still some free rocuronium molecules left, which are available for the 
hepatic elimination route.
More research is needed to determine the long-term disposition of the sugammadex-ro- 
curonium complex in patients with renal failure. Also, investigations should be performed 
to determine whether rocuronium is still eliminated by the liver, after administration of 
sugammadex.
SAFETY OF SUGAMMADEX IN RENAL FAILURE
Available evidence suggests that the rocuronium-sugammadex complex will remain stable 
over time. The complex exists in equilibrium with a very high association constant (KA 
=25x106 M -1).11;26 However, there may be concerns for patients with severe renal failure, 
who will retain the complex for a longer period of time than patients with normal renal 
function. These patients may suffer more from possible side effects of sugammadex. More 
importantly, should the sugammadex-rocuronium complex dissociate, there would be a 
risk of recurrence of NMB.
In the clinical study (chapter 4), the patients with renal failure were monitored for at least 
24 hours using oxygen saturation and respiratory rate monitoring. They were also moni­
tored for 48 hours for clinical signs of PORC. Recurrence of NM B was not observed in any 
of the patients during the neuromuscular monitoring or postoperative clinical monitoring 
period.
In the study on the efficacy of sugammadex in cats with ligated renal pedicles (chapter 
3), there was a tendency towards a decrease in heart rate after the administration of su­
gammadex (not statistically significant). This could be interpreted as a restoration of the 
increase in heart rate caused by the preceding injection of rocuronium. In the clinical 
study in humans (chapter 4) and the study on the reversal of 3-desacetyl-vecuronium by 
sugammadex in rhesus monkeys (chapter 7), such a heart rate decreasing effect was not 
observed.
The adverse events possibly related to sugammadex in the clinical study (chapter 4) were 
diarrhoea (n=2), nausea (n=1), headache (n=1), and coughing and movement under 
anaesthesia (n=3). Coughing and movement after sugammadex has been reported in 
other studies as well.13;25;27 This may be due to the rapid onset of effect of sugammadex 
in reversing NM B at a time of relatively light anaesthesia. In such a situation stimulation 
of the trachea by the endotracheal tube is more likely to be the cause of coughing and 
subsequent movement.
Urinary N-acetyl-glucosaminidase (NAG) is a measure of proximal renal tubule damage. 
In several clinical studies on sugammadex, abnormal values of NAG were documented in 
a few patients who received sugammadex.13;25;28 One study also documented microalbu­
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minuria and abnormal urine ß2-microglobulin values.25 It is uncertain what the clinical 
relevance is of these findings and how this should be interpreted. In the clinical study 
described in this thesis (chapter 4), urinary NAG, microalbuminuria and ß2-microglobulin 
values above the safety ranges were seen predominantly in the renally impaired group and 
were already present at the pre-operative screening assessment.
No data on prolonged follow-up are available on the safety of sugammadex in patients 
with renal failure, where elimination of the sugammadex-rocuronium complex is compro­
mised. No data on its long-term disposition are available yet. Sugammadex is a modified 
y-cyclodextrin, an oligosaccharide forming a cylindrical capsule with a lipophilic internal 
cavity and a hydrophilic exterior.11 Cyclodextrins are water-soluble molecules, which are 
used as solubilising agents for many drugs and foods. They do not possess any intrinsic 
biological activity and it is therefore unlikely that side effects will occur. Sugammadex has 
been shown to be well tolerated in many clinical trials in humans.12-14;25;27 Also, high doses 
of sugammadex, up to 96 mg kg-1, were tolerated well in healthy volunteers. The most 
common adverse event was dysgeusia (a bitter or metallic taste).29
Toxicity studies on y-cyclodextrins after oral or parenteral administration show that the 
drugs are well tolerated and safe to use in the dose ranges recommended for sugam­
madex.30 The clinical safety profile is comparable to other cyclodextrins used as carrier 
agents, for example for voriconazole and itraconazole.31 In rats, it was observed that 
sugammadex can bind to mineralized tissues (hydroxy-apatite) such as bones and teeth, 
although a single dose of sugammadex is unlikely to create any long-lasting effect.31;32 
It is important to know the final disposition of sugammadex in renal patients who can­
not excrete the molecule. Adverse reactions have occurred with drugs and intravenous 
fluids depositing in tissue, for example the deposition of hydroxyethyl starch (HES) in 
dermal and endoneural tissues, causing pruritus sometimes weeks or months after HES 
exposure.33 Further investigations of the long-term safety aspects of sugammadex in renal 
failure patients are needed.
SUGAMMADEX AND HAEMODIALYSIS
Haemodialysis membranes are classified into high and low flux membranes, depending 
on their permeability. High flux membranes are more porous non-cellulosic membranes 
with increased permeability, particularly to larger molecules.34
In the clinical study in humans (chapter 5), nine out of the 15 patients with renal failure 
underwent haemodialysis at the time of the investigation. In patients undergoing low-flux 
haemodialysis (n=7) no significant reductions in sugammadex plasma concentrations 
were observed after dialysis. The median reduction ratio (RR) of sugammadex was 0.93. 
In patients undergoing high-flux haemodialysis (n=2), the median RR of sugammadex was
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0.58.35 The low flux membranes seemed almost ineffective in removing sugammadex from 
the circulation, whereas high-flux membranes reduced the sugammadex plasma concen­
tration by more than 40%. Due to the small number of subjects included, these results 
must be viewed as preliminary. However, they were in agreement with the results of an in 
vitro study on the dialysability of sugammadex, which concluded that sugammadex could 
be efficiently removed from the plasma by dialysis using a high flux membrane but not a 
low flux membrane.36
Further investigation is necessary to obtain more detailed information regarding the dial­
ysability of sugammadex.
SUGAMMADEX AND NEUROMUSCULAR MONITORING
In all published studies investigating sugammadex, the primary efficacy parameter was 
time to recovery of an acceleromyographic TOF ratio to 0.9. Time to recovery of the first 
twitch of the TOF (T1) was not described.
Fade, a gradual diminution of evoked response during repetitive nerve stimulation, is 
expressed by the TOF ratio and it represents presynaptic acetylcholine receptor (nAChR) 
blockade. Postsynaptic acetylcholine receptor blockade is expressed by the depression 
of the single twitch response or T1.37 During spontaneous recovery from NM B induced 
by a non-depolarizing NMBA, the fade effect persists longer than the depression of T1. 
Fade disappears and the TOF ratio recovers to > 0.9 only after normalization of the twitch 
height.38 When a NM B is reversed by anticholinesterases, the time course of reversal from 
NM B is the same: first full recovery of T1, and then recovery of the TOF ratio to 0.9.1 
As described in chapter 6, after reversal of a rocuronium-induced NM B by an optimal 
dose of sugammadex, the recovery of the TOF ratio to > 0.9 precedes the return of T1 
to 90%. The TOF ratio may be fully recovered, when T1 is still depressed. It can be con­
cluded that the TOF ratio as the only measurement for adequate reversal from NM B is no 
longer reliable in all cases after reversal with sugammadex. Twitch height has to be taken 
into account as well. This phenomenon may be explained by a difference in affinity of 
rocuronium for the different nAChRs in the NMJ: the neuronal presynaptic nAChR (which 
is responsible for the fade phenomenon) and the postsynaptic muscle nAChR (which is 
responsible for the single twitch height).39
The clinical implications of this finding, however, are not clear. In the investigation de­
scribed in chapter 6, full recovery of T1 followed recovery of the TOF ratio within a few 
minutes. In the patients with renal impairment, recovery of T1 was significantly slower 
compared to patients with normal renal function. Also the differences in recovery times 
between TOF ratio and T1 were larger in this patient group. Renal patients may therefore 
be more vulnerable for the development of residual paralysis, even when a TOF ratio of
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0.9 has been reached. Further studies need to be conducted to investigate the clinical 
implications of this finding.
FUTURE OF SUGAMMADEX
Sugammadex is capable of antagonizing an aminosteroidal-induced NM B from any level 
of NM B at any time. This gives the anaesthetist the possibility to apply anaesthesia meth­
ods best suitable for the individual patient. It diminishes the importance of inter-individual 
variability in the duration of action of the NMBAs; it may not be relevant anymore if a NMB 
lasts longer than the operation. In an individual patient we can reverse the aminosteroidal- 
induced NM B at any time needed. The introduction of sugammadex may change the use 
of NMBAs in the context of balanced anaesthesia.40;41
However, there are still some questions to be answered regarding sugammadex. The Euro­
pean registration authorities (EMEA) registered sugammadex for clinical use in July 2008, 
but the FDA (Food and Drug Administration, USA) has asked more data on hypersensitivity 
testing, as there have been reports on possible allergic reactions to sugammadex, one of 
which has been substantiated by a positive skin test.29;31 There were reports of two cases 
of serious adverse events related to bronchospasm after administration of sugammadex.27 
Even though both cases had a history of asthma, these complications might also suggest 
the risk of allergic or hypersensitivity reactions following sugammadex.
The FDA also expressed concerns regarding the potential of sugammadex to bind to bone 
and teeth of developing rats and implied that safety was not well established in paediatric 
populations.32 More paediatric registration studies are needed to get valid paediatric 
documentation of the use of sugammadex in different clinical scenarios.40 
Currently succinylcholine is the NM BA of choice when performing a rapid sequence 
induction (RSI) of anaesthesia, for example when the patient has a full stomach. A dose of 
succinylcholine 1.0 mg kg-1 provides superior intubating conditions within 1 minute after 
administration.42 Rocuronium, when administered in a high dose (1.2 mg kg-1) provides 
similar intubating conditions in a similar speed.42 However, when rocuronium is admin­
istered in such a high dose, the duration of action is much prolonged, and can take more 
than 1 to 1.5 hours. Therefore, until recently, a RSI with rocuronium was only performed 
in case of contra-indications for succinylcholine. Succinylcholine has many side effects 
and is contra-indicated in several diseases, such as burn trauma, muscle crush injuries, 
muscle denervations, myotonic dystrophy and malignant hyperthermia.43;44 
To compare the time of sugammadex reversal of profound rocuronium-induced NM B with 
time to spontaneous recovery from succinylcholine, a randomized study was performed. 
Patients received either rocuronium 1.2 mg kg-1 or succinylcholine 1.0 mg kg-1. Sugam­
madex 16 mg kg-1 was administered 3 minutes after rocuronium administration. This study
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showed that with sugammadex the mean time to recovery of the first twitch (T1) of the 
TOF from profound rocuronium-induced NM B was 6.2 minutes, which was significantly 
shorter than the time to spontaneous recovery from succinylcholine-induced NM B (10.9 
minutes).45
In conclusion, with the availability of sugammadex, rocuronium has become a good 
alternative for succinylcholine when the anaesthetist has to perform a RSI, even for short 
procedures. Future trials are needed to establish the efficacy and safety of sugammadex in 
situations such as cannot intubate cannot ventilate and failed intubation during RSI using 
high-dose rocuronium.
In the trials investigating sugammadex, patients with known or suspected neuromuscular 
diseases were excluded. The use of NMBAs in patients with these disorders is of great 
concern. Depolarizing NMBAs are contra-indicated, because of the risk of hyperkalemia, 
rhabdomyolysis or even cardiac arrest.46 Non-depolarizing NMBAs may have a prolonged 
duration of action in these patients, which may result in PORC.44;47 Patients with neuro­
muscular disorders would benefit from a reversal agent such as sugammadex which does 
not interfere with acetylcholinesterase in the NMJ. Some case reports have already been 
published on the successful use of sugammadex as a reversal agent for NM B in patients 
with Duchenne muscular dystrophy, myotonic dystrophy and myasthenia gravis.48-50 
Many clinicians are aware of the relatively high costs of sugammadex, especially com­
pared to the classical reversal combination of neostigmine and atropine. W ill the routine 
reversal of profound NM B by sugammadex be cost-effective in terms of time savings 
in operating theatre programs?51;52 However, the most important question on the use of 
sugammadex is whether the routine reversal of NM B by sugammadex will decrease post­
operative pulmonary complications, such as atelectasis and pneumonia. Further research 
is required to determine the effects of sugammadex on predictability of recovery from 
NM B and efficient use of resources; but most importantly on patient safety and outcome.
CONCLUSION: CLINICAL IMPLICATIONS FOR RENAL FAILURE PATIENTS
Sugammadex rapidly and effectively reverses NM B induced by rocuronium, even when 
renal function is severely impaired. It is the redistribution of rocuronium molecules which 
is responsible for the rapid recovery from NMB, and not the elimination of the drugs by 
renal excretion. However, there are large differences in pharmacokinetics of rocuronium 
and sugammadex between patients with normal renal function and patients with severe 
renal impairment. Total plasma clearance of sugammadex is 17 times lower in renal 
failure patients compared to controls, and t1/2ß of sugammadex is more than 15 times 
prolonged. Urinary excretion of sugammadex and rocuronium is much reduced in renal 
failure patients.
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Although sugammadex was tolerated well by patients with severe renal failure, long-term 
follow up on the safety of sugammadex in renal patients is needed, as the sugammadex- 
rocuronium complex is retained longer in the body and the disposition of the drug is not 
known.
Because renal patients are more at risk of developing PORC after the use of aminosteroidal 
NMBAs, they would benefit from the use of sugammadex, as this would decrease the 
risk of PORC and subsequently the incidence of postoperative pulmonary complications. 
Benzylisoquinolines are not dependent on renal function, and often recommended as 
NMBAs in renal failure patients. However, they may evoke histamine release. Also the 
duration of action of the benzylisoquinolines shows inter-individual variations, and the 
risk of developing PORC remains. Succinylcholine has many unwanted side effects in 
renal failure patients, most importantly hyperkalemia. Other NMBAs with a short duration 
of action are not available.
Although the use of sugammadex in patients with renal failure is questionable, the advan­
tages of sugammadex for patients with renal insufficiency probably outweigh the risks of 
possible long-term effects of sugammadex.
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This thesis describes the influence of renal failure on the efficacy and safety of reversal of 
neuromuscular block (NMB) induced by aminosteroidal neuromuscular blocking agents 
(NMBAs) by the reversal agent sugammadex. It also describes the pharmacokinetics of 
rocuronium and sugammadex in patients with severe to end-stage renal failure compared 
to healthy controls.
Chapter 1 provides a general introduction to the research presented in this thesis. Ro­
curonium and vecuronium are aminosteroidal NMBAs used in anaesthesia and intensive 
care medicine. The effect of all NMBAs is variable in intensity and duration. This frequently 
results in the occurrence of postoperative residual paralysis, which is a major risk factor 
in the development of postoperative pulmonary complications, such as atelectasis and 
pneumonia. Reversal of NM B can be achieved by administration of acetylcholinesterase 
inhibitors, but these have many side effects.
Sugammadex, a modified y-cyclodextrin, is a selective relaxant binding agent, designed 
to reverse the neuromuscular blocking effects of the aminosteroidal NMBAs, especially 
rocuronium. Sugammadex encapsulates the NM BA molecules in the plasma, forming a 
complex with a high affinity, which leads to a rapid decrease of the concentration of free 
NM BA  molecules in the plasma. As a result of the concentration gradient of free molecules 
between plasma and the effect site, the neuromuscular junction (NMJ), steroidal NM BA 
molecules rapidly diffuse away from the NMJ into the plasma. This leads to a rapid recov­
ery of NMB.
Sugammadex is a water-soluble molecule, cleared by the kidneys. Also, the sugammadex- 
rocuronium complex is cleared by the kidneys. To investigate the implications for the 
efficacy and safety of sugammadex in patients with renal failure, the studies presented in 
this thesis were conducted.
Chapter 2 is an introductory chapter, with an historic overview on the use of NMBAs 
and reversal agents. A number of important issues associated with the administration of 
NMBAs and reversal agents in patients with renal failure are discussed.
Inter-individual variability in the effect of the aminosteroidal NMBAs is increased in renal 
failure patients, resulting in a less predictable duration of action. Prolonged NM B after 
administration rocuronium has been reported in patients with renal failure. Residual pa­
ralysis has also been described after long-term administration of vecuronium in critically ill 
patients with renal failure. 3-Desacetyl-vecuronium, an active metabolite of vecuronium, 
which has 80%  of the potency of the parent compound vecuronium, was held responsible 
for this prolonged NMB. Therefore, patients with renal insufficiency have an increased risk 
of residual paralysis and postoperative respiratory complications.
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In this chapter, the development and the mechanism of action of sugammadex is also 
described. Sugammadex does not appear to undergo metabolism and is primarily excreted 
in the urine as the unchanged drug. Also the sugammadex-rocuronium complex is mainly 
excreted by the kidneys. When sugammadex is administered after a dose of rocuronium, 
urinary excretion of rocuronium increases with increasing doses of sugammadex. The 
normal route of elimination for rocuronium, hepatic elimination, is expected to be un­
available for encapsulated rocuronium.
This raises concerns regarding the safety of sugammadex in patients with renal failure: 
when the elimination pathway of rocuronium is diverted from hepatic clearance to renal 
clearance after administration of sugammadex, what will happen to the complex when 
renal clearance is decreased? W ill the reversal of rocuronium-induced NM B by sugam­
madex be effective? Is there a possible risk, when rocuronium is not cleared from the 
body, that paralysis will recur? The investigations presented in this thesis were conducted 
to answer these questions.
The study described in chapter 3 investigated the influence of renal failure on the efficacy 
of reversal of rocuronium-induced NM B by sugammadex. An animal model in the cat was 
used: both renal pedicles of anaesthetized cats were ligated to create a model of acute 
renal failure. Neuromuscular monitoring was performed by single twitch monitoring. 
Rocuronium was administered to induce NMB, and after this first administration NMB 
recovered spontaneously. Then the renal pedicles of the cats were ligated. Directly after 
induction of NM B by a second dose of rocuronium, in Group 1 placebo and in Group 
2 sugammadex was administered. Sugammadex reversed rocuronium-induced NMB 
significantly faster than spontaneous recovery (p<0.0001). The reversal of NM B by sugam­
madex was rapid and effective, even after interruption of the renal perfusion in these 
anaesthetized cats. This demonstrates that reversal of NM B is not dependent on the renal 
elimination of the sugammadex-rocuronium complex.
After the study in animals, a clinical study in humans was performed, which is presented 
in chapters 4 and 5. Thirty adult patients, undergoing elective surgery under general 
anaesthesia, were included in this trial: 15 ASA class II-III patients with severe renal 
failure (creatinine clearance (CLcr) <30 ml min-1) and 15 ASA class I-II control patients. 
Neuromuscular function was monitored continuously by acceleromyography and the 
Train-of-Four (TOF). A single i.v. dose of rocuronium 0.6 mg kg-1 was administered. At 
reappearance of the second twitch response (T2), a single i.v. dose of sugammadex 2.0 mg 
kg -1 was given. Primary efficacy variable was the time to recovery of the TOF ratio to 0.9. 
Plasma and urine sampling were conducted to determine the plasma concentration of 
sugammadex and rocuronium and the percentage of the administered dose of sugam­
madex and rocuronium excreted in the urine.
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Chapter 4 describes the efficacy and safety results of this clinical trial. Administration 
of sugammadex at reappearance of T2 after a bolus dose of rocuronium resulted in a 
mean time to recovery of the TOF ratio to 0.9 of 2.0 min for renal patients, and 1.65 min 
for controls. This was not a significant difference. Recurrence of NM B was not observed 
in any of the patients during a 48 hour postoperative monitoring period. These findings 
confirm that reversal of rocuronium-induced NM B by sugammadex can be attributed to 
rapid binding of rocuronium and is not dependent on its elimination by renal excretion. 
Five patients, two in the renally impaired group and three in the control group, experi­
enced a total of eight adverse events (AEs) possibly related to sugammadex. These were 
diarrhoea (n=2), nausea (n=1), anaesthetic complications (coughing and movement dur­
ing anaesthesia shortly after administration of sugammadex) (n=3), headache (n=1) and 
decreased oxygen saturation (n=1). This decreased oxygen saturation was not considered a 
clinical sign of recurrence of NMB, but was attributed to the i.v. administration of opioids 
in the recovery ward and was successfully treated with oxygen. Coughing or movement 
after sugammadex has been reported in other studies. This may be due to the rapid onset 
of the effect of sugammadex in reversing NM B at a time of relatively light anaesthesia. No 
sugammadex-related serious adverse events (SAEs) were reported.
In chapter 5 the pharmacokinetics (PKs) of rocuronium and sugammadex in patients with 
renal failure and healthy controls are described. PK parameters were calculated using 
conventional non-compartmental analysis methods. O f the 30 patients enrolled in the 
study, PK data could be obtained in 26 patients.
This study showed large differences in the PKs of sugammadex and rocuronium between 
patients with renal failure and healthy controls. For the first 60 min after administration, 
median plasma concentrations of sugammadex were similar in the control and renally 
impaired groups. At later time points, plasma concentrations of sugammadex showed a 
slower decline in the renally impaired group compared with the control group. A similar 
effect was seen for rocuronium.
Statistically significant differences were observed between the control and the renal fail­
ure groups for sugammadex in total plasma clearance (CL), and the related parameters, 
elimination half-life (t1/2 p) and mean residence time (MRT). MRT was 20 times higher, t1/2 p 
was 15.5 times higher and CL was 17 times lower in the renal failure group compared 
with the control group.
Statistically significant differences were also observed in these variables for rocuronium. 
The MRT was 4.6 times higher, t1/2 was 2.5 times higher and CL was four times lower in 
the renally impaired group compared with the control group. Regression analyses showed 
that both for sugammadex and for rocuronium, the correlation between CL and CLcr was 
highly significant (P<0.0001).
Urinary excretions of sugammadex and rocuronium were much lower in the renal failure 
group than in the control group. In renal failure patients, the median total amount of
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sugammadex excreted in urine (in 72 h) was 29%  of the administered dose, compared to 
73% (in 24 h) in the control group. For rocuronium, a much smaller fraction of the dose 
was excreted in the urine than for sugammadex, both for the renally impaired group and 
the control group. Median total amount of rocuronium excreted in urine was 4 .4%  of the 
administered dose in 72 h in the renal failure group and 42%  in 24 h in the control group. 
As urinary excretion is the main route of elimination of the sugammadex-rocuronium 
complex, the extrarenal route of elimination is expected to be unavailable for encapsu­
lated rocuronium. Encapsulation by sugammadex diverts the elimination of rocuronium 
from its normal primary pathway of hepatic clearance to renal clearance. As the effect of 
renal impairment on the PK variables was smaller for rocuronium than for sugammadex, 
it is suggested that in patients with renal failure, extrarenal clearance of rocuronium does 
take place, in spite of complexation.
Chapter 6 describes the temporal relationship of recovery of the first twitch of the TOF 
(T1) and the TOF ratio, after reversal of rocuronium-induced NM B with sugammadex. The 
TOF ratio reflects the effects of the NM BA at the presynaptic membrane of the NMJ and 
the T1 response reflects the events at the postjunctional membrane. During spontaneous 
recovery from non-depolarizing NMBAs the T1 response of the TOF normally recovers 
to baseline, while at this point the TOF ratio may still be no more than 0.7, which is 
considered insufficient recovery from NMB. The same pattern occurs after reversal of non­
depolarizing NMBAs with acetylcholinesterase inhibitors.
The data in chapter 6 are derived from two prospective studies investigating the efficacy 
of sugammadex in reversing rocuronium-induced NMB. Retrospectively, the times to 
recovery of T1 to 90%  were retrieved from the original recorded neuromuscular database 
of the patients included in these investigations.
After reversal of rocuronium-induced NM B with an optimal dose of sugammadex (16 
mg kg-1 for profound NM B or 2 mg kg-1 after reappearance of T2), the TOF ratio recovered 
to 0.9 significantly faster than T1 recovered to 90%. This means that after reversal of 
rocuronium-induced NM B by sugammadex the return of a normal TOF ratio can, dose- 
dependently, precede the return of a normal T1 twitch height and the traditional relation­
ship between TOF ratio and T1 recovery is no longer valid. Therefore, the TOF ratio as the 
only measurement for adequate reversal of NMB, is no longer reliable in all cases after 
reversal with sugammadex, and twitch height has to be taken into account as well. Further 
investigation for the clinical implications of this finding is needed.
Chapter 7 describes a study in anaesthetized rhesus monkeys, investigating the ability 
of sugammadex to reverse a NM B induced by 3-desacetyl-vecuronium. 3-Desacetyl- 
vecuronium is the principal metabolite of the aminosteroidal NM BA vecuronium, and 
has significant neuromuscular blocking potency. The use of vecuronium is associated
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with residual paralysis, with an increased risk after cumulative doses and long-term ad­
ministration in critically ill patients with renal failure. Accumulation of this metabolite 
3-desacetyl-vecuronium is considered the main cause of residual paralysis in these 
patients. It is important to know if such a residual paralysis can be terminated with sugam­
madex. Also, theoretically, after reversal of a vecuronium-induced NM B by sugammadex, 
3-desacetyl-vecuronium might cause residual paralysis, should sugammadex not be 
capable of inactivating this active metabolite.
Experiments were performed in anaesthetized female rhesus monkeys. A NM B was 
induced by either vecuronium or 3-desacetyl-vecuronium. After the first administration 
of the N M BA  the NM B was allowed to recover spontaneously. Then the procedure was 
repeated. After the second administration of N M BA  a bolus dose of sugammadex 0.5 or 
1.0 mg kg-1 was given. For each NM BA placebo experiments were performed in which 
the second recovery from NM B was also spontaneous. For all experiments, the time to 
recovery of the TOF ratio to 90% was retrieved. Sugammadex rapidly and effectively 
reversed NM B induced by 3-desacetyl-vecuronium in the rhesus monkey: recovery was 
significantly faster than spontaneous recovery. Sugammadex also provided a rapid reversal 
of NM B at a lower dose of sugammadex than the dose needed to reverse NM B induced 
by vecuronium. The results of this investigation indicate that sugammadex should be able 
to reverse NM B due to high plasma concentrations of 3-desacetyl-vecuronium after long­
term administration of vecuronium.
Chapter 8 presents the general discussion and conclusions of the thesis. In this chapter 
also the future of sugammadex and implications for further research are discussed. 
Sugammadex rapidly and effectively reverses a rocuronium-induced NMB, even when 
renal function is severely impaired. Therefore, reversal of NM B by sugammadex depends 
on the rapid binding of the NM BA and not on its renal elimination. It is rather the redis­
tribution of the rocuronium molecules than elimination of the drug by renal excretion, 
which is responsible for the rapid recovery from NMB.
From the pharmacokinetic study on sugammadex and rocuronium, it can be concluded 
that patients with renal insufficiency retain the rocuronium-sugammadex complex for a 
longer period of time than patients with normal renal function. Sugammadex was well- 
tolerated by all patients, both renal patients and controls, and recurrence of NM B was 
not observed in any of the patients. However, no data on prolonged follow-up are avail­
able on the safety of sugammadex in patients with renal failure, where elimination of the 
sugammadex-rocuronium complex is compromised. No data on its long-term disposition 
are available yet. The Food and Drug Administration has asked more data on hypersen­
sitivity testing and expressed concerns regarding the potential of sugammadex to bind to 
bone and teeth tissue. Further investigation is needed.
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As patients with renal failure are more at risk of developing residual paralysis after the use 
of aminosteroidal NMBAs, they would benefit from a reversal agent such as sugammadex. 
Although the use of sugammadex in patients with renal failure is still matter of discussion, 
the advantages for patients with renal insufficiency probably outweigh the risks of possible 
long-term effects of sugammadex.
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Dit proefschrift beschrijft de invloed van nierinsufficiëntie op de effectiviteit en veiligheid 
van de antagonist sugammadex in het opheffen van spierrelaxatie, ofwel een neuro­
musculaire blokkade (NMB), geïnduceerd door een spierrelaxans van de groep van de 
aminosteroiden. Het proefschrift beschrijft ook de pharmacokinetiek van rocuronium en 
sugammadex bij patiënten met ernstig tot terminaal nierfalen in vergelijking met gezonde 
controles.
Hoofdstuk 1 geeft een algemene introductie op het onderzoek dat wordt gepresenteerd 
in dit proefschrift. Rocuronium en vecuronium zijn spierrelaxantia van de groep van de 
aminosteroiden, die regelmatig worden gebruikt in de anesthesiologie en de intensive care 
geneeskunde. De werkingsduur en de intensiteit van effect van alle spierrelaxantia is zeer 
variabel. Dit heeft regelmatig het optreden van postoperatieve restverslapping tot gevolg, 
een belangrijke risicofactor op het ontwikkelen van postoperatieve longcomplicaties, 
zoals atelectase en pneumonie. Het opheffen van NM B is mogelijk door het toedienen 
van acetylcholinesterase remmers, maar deze hebben veel bijwerkingen.
Sugammadex, een gemodificeerd y-cyclodextrine, is een selectieve antagonist van spier­
relaxantia en is ontwikkeld om het spierverslappende effect van de aminosteroidale 
spierrelaxantia, in het bijzonder van rocuronium, op te heffen. Sugammadex kapselt de 
spierrelaxans moleculen in die aanwezig zijn in het plasma (encapsulatie), waarbij een 
complex wordt gevormd met een hoge affiniteit. Dit leidt tot een snelle daling van de 
concentratie van vrije spierrelaxans moleculen in het plasma. Als gevolg van de concen- 
tratiegradiënt van de vrije moleculen die ontstaat tussen plasma en de plaats van effect, de 
neuromusculaire junctie (NMJ), diffunderen de spierrelaxans molecules weg van de NMJ 
naar het plasma. Dit leidt tot het snel opheffen van de neuromusculaire blokkade.
Het sugammadex molecuul is wateroplosbaar en wordt geklaard door de nieren. Ook het 
sugammadex-rocuronium complex wordt uitgescheiden door de nieren. De studies die 
worden gepresenteerd in dit proefschrift zijn uitgevoerd om de implicaties voor de effec­
tiviteit en veiligheid van sugammadex in patiënten met nierinsufficiëntie te onderzoeken.
Hoofdstuk 2 is een inleidend hoofdstuk, met daarin een historisch overzicht van het ge­
bruik van spierverslappers en antagonisten. Een aantal belangrijke zaken aangaande het 
gebruik van spierrelaxantia en antagonisten bij patiënten met nierinsufficiëntie worden 
besproken.
Bij patiënten met nierfalen is de inter-individuele variabiliteit in het effect van aminoste­
roidale spierrelaxantia verhoogd, met als gevolg een minder voorspelbare werkingsduur. 
Verlengde NM B is beschreven na de toediening van rocuronium aan nierpatiënten. Ook na 
langdurige toediening van vecuronium aan kritisch zieke patiënten met nierinsufficiëntie
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is restverslapping beschreven. Voor deze verlengde NM B wordt 3-desacetyl-vecuronium 
verantwoordelijk gehouden, een actieve metaboliet van vecuronium, met 80% van de 
potentie van vecuronium zelf. Concluderend, patiënten met nierinsufficiëntie hebben een 
verhoogd risico op restverslapping en daarmee postoperatieve longcomplicaties.
In dit hoofdstuk wordt tevens de ontwikkeling en het werkingsmechanisme van sugam­
madex beschreven. Sugammadex lijkt niet gemetaboliseerd te worden en wordt primair 
als onveranderd molecuul uitgescheiden in de urine. Ook het sugammadex-rocuronium 
complex wordt voornamelijk door de nieren uitgescheiden. Wanneer sugammadex wordt 
toegediend na een dosis rocuronium, neemt de uitscheiding van rocuronium in de urine 
toe, met stijgende doses sugammadex. Men neemt aan dat de gebruikelijke uitscheidings- 
route voor rocuronium, via de lever, niet mogelijk is voor rocuronium dat een complex 
heeft gevormd met sugammadex.
Dit roept vragen op over de veiligheid van sugammadex bij patiënten met nierinsuffici- 
entie: als de uitscheidingsroute van rocuronium zich heeft verplaatst van de lever naar 
de nieren nadat sugammadex is toegediend, wat gebeurt er dan met het complex als de 
nierfunctie is verminderd? Zal het opheffen van NM B geïnduceerd door rocuronium nog 
effectief zijn met sugammadex? Is er een mogelijk risico op het heroptreden van spierver- 
slapping, als rocuronium niet uitgescheiden kan worden uit het lichaam? Om deze vragen 
te beantwoorden werden de onderzoeken uitgevoerd, die worden gepresenteerd in dit 
proefschrift.
De studie die wordt beschreven in hoofdstuk 3 onderzocht de invloed van nierinsuffici- 
entie op de effectiviteit van sugammadex in het opheffen van een NM B geïnduceerd door 
rocuronium. Er werd gebruik gemaakt van een diermodel in de kat: om een model van 
acuut nierfalen te creëren werden beide nierpedikels geligeerd van katten onder algehele 
anesthesie. Neuromusculaire monitoring werd uitgevoerd door middel van single twitch 
zenuwstimulatie. Om NM B te induceren werd rocuronium toegediend, en na deze eerste 
toediening herstelde de NM B zich spontaan. Daarna werden de nierpedikels van de kat­
ten afgebonden. Direct na inductie van de NM B door een tweede dosis rocuronium, werd 
in Groep 1 een placebo en in Groep 2 sugammadex toegediend. Sugammadex maakte de 
NM B ten gevolge van rocuronium significant sneller ongedaan dan de spontane hersteltijd 
(p<0.0001). Het opheffen van de spierverslapping door sugammadex was snel en effectief, 
zelfs na onderbreking van de nierperfusie. Dit toont aan dat het opheffen van NM B niet af­
hankelijk is van de uitscheiding van het sugammadex-rocuronium complex via de nieren.
Na deze dierstudie werd een klinische studie bij mensen uitgevoerd, welke wordt gepre­
senteerd in hoofdstukken 4 en 5. Dertig volwassen patiënten, die electieve chirurgie onder 
algehele anesthesie ondergingen, werden in deze trial geincludeerd: 15 ASA klasse II-III 
patiënten met ernstige nierinsufficiëntie (creatinine klaring (CLcr) <30 ml min-1) en 15 ASA
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klasse I-II controle patiënten. Neuromusculaire functie werd continu bewaakt middels 
acceleromyografie en de Train-of-Four (TOF). Een eenmalige dosis rocuronium 0.6 mg 
kg-1 werd i.v. toegediend. Na het verschijnen van de tweede twitch (T2) van de TOF werd 
een eenmalige dosis sugammadex 2.0 mg kg -1 i.v. toegediend. Primaire variabele voor de 
effectiviteit was de tijd tot het herstel van de TOF ratio tot 0.9. Er werden bloedafnames 
gedaan om plasma concentraties te bepalen van sugammadex en rocuronium en er werd 
urine verzameld om het percentage van de toegediende dosis sugammadex en rocuro­
nium te bepalen dat werd uitgescheiden in de urine.
Hoofdstuk 4 beschrijft de resultaten van deze klinische trial wat betreft effectiviteit en 
veiligheid. De toediening van sugammadex na het optreden van T2 na een eenmalige 
dosis rocuronium, resulteerde in een gemiddelde tijd tot het herstel van de TOF ratio tot 
0.9 van 2.0 minuten bij nierpatiënten en 1.65 minuten bij controle patiënten. Dit verschil 
was niet significant. Bij geen enkele patiënt werd het heroptreden van spierverslapping 
gezien tijdens de bewakingsperiode tot 48 uur postoperatief. Deze resultaten bevestigen 
dat het opheffen van NM B geïnduceerd door rocuronium met sugammadex toegeschre­
ven kan worden aan de snelle binding van rocuronium en dat dit onafhankelijk is van de 
uitscheiding van het complex door de nieren.
Vijf patiënten, twee in de groep nierpatiënten en drie in de controlegroep, hadden in 
totaal acht adverse events die mogelijk gerelateerd waren aan sugammadex. Het ging om 
diarree (n=2), misselijkheid (n=1), anesthesie complicaties (hoesten en bewegen onder 
anesthesie kort na de toediening van sugammadex) (n=3), hoofdpijn (n=1) en gedaalde 
zuurstofsaturatie (n=1). Deze gedaalde zuurstofsaturatie werd niet gezien als een klinisch 
teken van het heroptreden van NMB, maar werd toegeschreven aan de i.v. toediening van 
opioiden op de verkoeverkamer en werd succesvol behandeld met zuurstof. Hoesten en 
bewegen na de toediening van sugammadex is gerapporteerd in andere studies. Dit is 
mogelijk ten gevolge van de snelle inwerking van sugammadex en het opheffen van de 
spierverslapping op een moment van relatief lichte anesthesie. Er werden geen serious 
adverse events gerapporteerd die gerelateerd waren aan sugammadex.
In hoofdstuk 5 wordt de pharmacokinetiek (PK) van rocuronium en sugammadex in nier­
patiënten en gezonde controles beschreven. PK parameters werden berekend door middel 
van conventionele non-compartiment analyse methoden. Van de 30 patiënten die werden 
geincludeerd in de studie, konden er van 26 patiënten PK data worden verkregen.
Deze studie toonde grote verschillen aan in de PK van sugammadex en rocuronium tussen 
nierpatiënten en gezonde controles. In de eerste 60 minuten na de toediening waren de 
mediane plasmaconcentraties van sugammadex gelijk in controles en nierpatiënten. Op 
latere tijdstippen lieten de plasmaconcentraties van sugammadex een langzamere daling 
zien in de groep nierpatiënten ten opzichte van de controlegroep. Een soortgelijk effect 
werd gezien voor rocuronium.
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Tussen de controles en de groep nierpatiënten werden er voor sugammadex statistisch 
significante verschillen gezien voor totale plasma klaring (CL), en voor gerelateerde para­
meters eliminatie halfwaardetijd (t1/2p) and mean residence time (MRT). MRT was 20 keer 
verhoogd, t1/2p was 15.5 keer verhoogd en de CL was 17 keer verlaagd in de groep nier­
patiënten vergeleken met de controle groep. Ook voor rocuronium werden er statistisch 
significante verschillen gezien voor deze variabelen. De MRT was 4.6 maal verhoogd, t1/2 
was 2.5 maal verhoogd en de CL was vier maal lager in de groep nierpatiënten vergeleken 
met de controle groep. Regressie analyses toonden aan dat de correlatie tussen CL en CLcr 
zeer significant was zowel voor sugammadex als voor rocuronium (P<0.0001).
De uitscheiding van sugammadex en rocuronium in de urine was veel lager in de groep 
nierpatiënten dan in de controle groep. In de patiënten met nierinsufficiëntie was de 
mediane totale hoeveelheid sugammadex dat werd uitgescheiden in de urine 29 %  van 
de toegediende dosis (in 72 uur), vergeleken met 73% (in 24 uur) in de controlegroep. Van 
rocuronium werd een veel kleinere fractie van de dosis in de urine uitgescheiden dan van 
sugammadex, zowel in de groep nierpatiënten als in de controlegroep. Mediane totale 
hoeveelheid rocuronium die werd uitgescheiden in de urine van de groep nierpatiënten 
was 4 .4%  van de toegediende dosis in 72 uur, en 4 2 %  in 24 uur in de groep controles. 
Aangezien urinaire excretie de belangrijkste route is voor de uitscheiding van het sugam- 
madex-rocuronium complex, wordt aangenomen dat de extrarenale route onmogelijk is 
geworden voor rocuronium dat een complex heeft gevormd met sugammadex. Encapsu­
late door sugammadex verplaatst de eliminatie van rocuronium van de normale route van 
uitscheiding via de lever naar uitscheiding via de nieren. Het effect van nierinsufficiëntie 
op de PK variabelen is kleiner voor rocuronium dan voor sugammadex, wat suggereert 
dat bij patiënten met nierfalen er toch uitscheiding van rocuronium plaatsvindt buiten de 
klaring via de nieren, ondanks de vorming van het sugammadex-rocuronium complex.
Hoofdstuk 6 beschrijft de tijdsrelatie tussen het herstel van de eerste twitch van de TOF 
(T1) en de TOF ratio, na het opheffen door sugammadex van een NM B geïnduceerd door 
rocuronium. De TOF ratio weerspiegelt het effect van het spierrelaxans op de presynap- 
tische membraan van de NMJ en T1 weerspiegelt het effect op de postjunctionele mem­
braan. Tijdens het spontane herstel van een niet-depolarizerend spierrelaxans, herstelt 
eerst T1 van de TOF naar het oorspronkelijke niveau, terwijl op dat moment de TOF ratio 
nog niet altijd hersteld is tot 0.7, wat aangeeft dat de spierkracht dan nog onvoldoende is 
hersteld. Hetzelfde patroon treedt op na opheffen van een niet-depolarizerende NM B met 
acetylcholinesterase remmers.
De data in hoofdstuk 6 werden afgeleid uit twee prospectieve studies, die de effectiviteit 
van sugammadex onderzochten in het opheffen van een NM B geïnduceerd door rocu­
ronium. De tijden tot het herstel van T1 tot 90%  werden retrospectief verkregen uit de
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originele neuromusculaire database van de patiënten die geïncludeerd waren in deze 
studies.
Na het opheffen van de NM B geïnduceerd door rocuronium met een optimale dosis 
sugammadex (16 mg kg-1 in geval van een diepe NM B of 2 mg kg-1 na het verschijnen van 
T2), herstelde de TOF ratio significant sneller naar 0.9 dan dat T1 herstelde naar 90%. Dit 
betekent dat, na het opheffen van een rocuronium-geïnduceerde NM B door sugammadex, 
het herstel van een normale TOF ratio vooraf kan gaan aan het herstel van de T1 twitch 
tot een normale hoogte, afhankelijk van de dosering sugammadex. De traditionele relatie 
tussen herstel van TOF ratio en T1 is dan niet langer geldig. Om deze reden is de meting 
van de TOF ratio als enige meting van het adequaat herstel van NM B niet langer in alle 
gevallen betrouwbaar na het opheffen van NM B door sugammadex. Er zal ook rekening 
gehouden moeten worden met de twitch hoogte. De klinische consequenties van deze 
bevinding dienen verder onderzocht te worden.
Hoofdstuk 7 beschrijft een studie waarin het vermogen werd onderzocht van sugamma­
dex om een NM B geïnduceerd door 3-desacetyl-vecuronium op te heffen, in rhesusapen 
onder algehele anesthesie. 3-Desacetyl-vecuronium is de belangrijkste metaboliet van 
het aminosteroidale spierrelaxans vecuronium, en heeft een significante spierverslap­
pende werking. Het gebruik van vecuronium is geassocieerd met restverslapping, met 
een verhoogd risico na cumulatieve doses en na langdurige toediening aan kritisch zieke 
patiënten met nierfalen. Restverslapping in deze patiënten wordt meest waarschijnlijk 
veroorzaakt door stapeling van deze metaboliet 3-desacetyl-vecuronium. Het is belangrijk 
om te weten of zulke restverslapping kan worden opgeheven met sugammadex. Ook zou 
het theoretisch mogelijk zijn dat 3-desacetyl-vecuronium restverslapping zou kunnen ver­
oorzaken na het opheffen van een vecuronium-geïnduceerde NMB, mocht sugammadex 
niet in staat zijn om deze actieve metaboliet te inactiveren.
Er werden experimenten uitgevoerd in vrouwelijke rhesusapen onder algehele anesthesie. 
Een NM B werd geïnduceerd door ofwel vecuronium ofwel 3-desacetyl-vecuronium. Na de 
eerste toediening van het spierrelaxans herstelde de NM B zich spontaan. Deze procedure 
werd herhaald. Na deze tweede toediening van het spierrelaxans werd nu een eenmalige 
dosis sugammadex 0.5 of 1.0 mg kg-1 toegediend. Voor elk spierrelaxans werden tevens 
placebo experimenten uitgevoerd, waarbij het tweede herstel van NM B spontaan verliep. 
Bij alle experimenten werd de tijd tot herstel van de TOF ratio tot 0.9 bijgehouden. Sugam­
madex beëindigde een NM B geïnduceerd door 3-desacetyl-vecuronium snel en effectief 
in de rhesusapen: het herstel was significant sneller dan spontaan herstel. Sugammadex 
zorgde ook voor een snel herstel van NM B met een lagere dosis sugammadex dan de dosis 
die nodig was om een NM B geïnduceerd door vecuronium op te heffen. De resultaten 
van dit onderzoek wijzen erop dat het mogelijk is om een NM B ten gevolge van hoge
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plasmaspiegels 3-desacetyl-vecuronium, na langdurige toediening van vecuronium, op te 
heffen met sugammadex.
Hoofdstuk 8 geeft de algemene discussie en de conclusies van dit proefschrift weer. In 
dit hoofdstuk worden tevens de toekomst van sugammadex en de implicaties voor verder 
onderzoek besproken.
Sugammadex heft snel en effectief een door rocuronium geïnduceerde NM B op, zelfs 
wanneer de nierfunctie ernstig is beschadigd. Hieruit blijkt dat het opheffen van de NMB 
door sugammadex afhankelijk is van de snelle binding van het spierrelaxans en niet van 
de uitscheiding van het spierrelaxans via de nieren. Het is eerder de redistributie van de 
rocuronium moleculen die verantwoordelijk is voor het snelle herstel van de NMB, dan 
de uitscheiding van rocuronium via de nieren.
Uit de pharmacokinetische studie naar sugammadex en rocuronium kan worden gecon­
cludeerd dat patiënten met nierinsufficiëntie het sugammadex-rocuronium complex lan­
gere tijd vasthouden dan patiënten met een normale nierfunctie. Sugammadex werd goed 
verdragen door alle patiënten, zowel door nierpatiënten als controles, en bij geen enkele 
patiënt werd heroptreden van de NM B geobserveerd. Van de andere kant zijn er nog geen 
data beschikbaar over lange termijn follow-up wat betreft de veiligheid van sugammadex in 
patiënten met nierinsufficiëntie, bij w ie de uitscheiding van het sugammadex-rocuronium 
complex is vertraagd. Er zijn ook nog geen data over of en waar sugammadex op de lange 
termijn in het lichaam wordt opgeslagen. De Food and Drug Administration heeft meer 
data gevraagd over hypersensitiviteit en heeft haar zorgen geuit over de mogelijkheid dat 
sugammadex zou binden aan bot- en tandweefsel. Meer onderzoek is noodzakelijk. 
Aangezien patiënten met nierinsufficiëntie meer risico lopen op het ontwikkelen van 
restverslapping na het gebruik van aminosteroidale spierrelaxantia, zouden juist zij pro­
fiteren van een antagonist zoals sugammadex. Hoewel het gebruik van sugammadex bij 
nierpatiënten nog discutabel is, wegen de voordelen voor patiënten met nierinsufficiëntie 









Een proefschrift schrijven doe je nooit alleen. "M ijn " boekje is nu klaar, maar dit zou 
zeker niet mogelijk zijn geweest zonder de hulp van vele anderen. In dit meest gelezen 
deel van het proefschrift wil ik dan ook de patiënten, collega's, vrienden en familieleden 
bedanken die er in de afgelopen 6 jaar voor gezorgd hebben dat ik dit promotietraject tot 
een goed einde kon brengen. Een aantal personen wil ik in het bijzonder noemen:
Prof. dr. Leo Booij, mijn promotor. In 2001 werd ik door u aangenomen voor de opleiding 
tot anesthesioloog, en daarmee was ik een van de laatste assistenten anesthesiologie van 
"uw " lichting. Uw  encyclopedische kennis over spierverslappers en antagonisten was 
natuurlijk al legendarisch en werkte op mij zeer inspirerend. Bedankt dat u het op u heeft 
genomen om mijn promotor te zijn.
Dr. Jacques Driessen, mijn copromotor. Beste Jacques, vanaf het eerste moment dat ik 
werd betrokken bij de sugammadex studies was jij mijn vaste begeleider. Ik kon altijd 
bij je terecht voor vragen en hulp, de deur stond altijd open. Jouw enthousiasme voor 
onderzoek werkte aanstekelijk en ik zal dan ook zeker niet de laatste promovendus zijn 
die door jou wordt begeleid. Naast de gezamenlijke sugammadex-missie heb je me ook 
enthousiast gemaakt voor de kinderanesthesiologie. Dank voor alle leerzame momenten.
Dr. Jan van Egmond, mijn copromotor. Beste Jan, jij was al vanaf de eerste dierexperimen­
tele onderzoeken betrokken bij de ontwikkeling van sugammadex. Je was altijd bereid 
jouw (enorme) kennis over "jouw kindje" te delen. Daarnaast was je steeds beschikbaar 
als statistische vraagbaak. Je bent nu met pensioen, maar ik kan me niet voorstellen dat je 
onderzoeksdrang nu ten einde is.
Dr. Marc Snoeck, mijn copromotor. Beste Marc, dank voor al je hulp bij de klinische 
nierstudie en de uitwerking daarvan in de verschillende artikelen. Je hebt me laten zien 
dat onderzoek doen in de periferie zeker niet onderdoet voor onderzoek in de academie! 
Bovendien was het erg gezellig samenwerken.
Prof. dr. Frans Russel wil ik bedanken dat hij voorzitter wilde zijn van de manuscriptcom­
missie.
Prof. dr. Hans van der Hoeven. Beste Hans, bedankt dat je zitting wilde nemen in de 
manuscriptcommissie. Daarnaast zijn we tijdens het uitvoeren van de klinische studie 
geweldig ondersteund door de Research Unit van de Intensive Care.
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Prof. dr. Jennifer Hunter. Dear Jennie, many thanks for your help during the clinical trial 
and for your support and constructive criticism when writing the articles. I would also like 
to thank you for sharing your extensive knowledge on muscle relaxants and organ failure.
I greatly appreciate that you are a member of the manuscript committee.
Prof. dr. Gert Jan Scheffer, voor het grootste deel van mijn assistententijd mijn opleider. 
Uiteindelijk is het allemaal begonnen met jouw vraag of ik geïnteresseerd was in het doen 
van onderzoek. Bedankt voor de kansen die je mij hebt gegeven, vooral in het combineren 
van mijn opleiding met het doen van onderzoek.
Dr. Hans de Boer. Beste Hans, op jouw uitstekende onderzoekswerk naar sugammadex, 
was het voor mij gemakkelijk voortborduren. Je adviezen en mental coaching zijn voor 
mij zeer waardevol geweest.
Francien van de Pol. Beste Francien, ik vraag me af hoe hoofdstuk 3 en 7 er uit zouden 
hebben gezien zonder jouw uitstekende werk op het dierenlab. Ik ben je uitermate dank­
baar voor je inzet en jouw geweldige geheugen!
De mensen bij Organon, later Schering-Plough, en weer later MSD: dr. Anton Bom, de 
"uitvinder" van sugammadex, Marten Heeringa, Michiel van den Heuvel, Martine Prins, 
Gerard Kuiper en vele anderen. Dank voor jullie hulp tijdens het uitvoeren van de studies 
en bij het schrijven van de artikelen. Zelfs in de laatste weken voordat sommigen van jul­
lie (noodgedwongen) Organon moesten verlaten, bleven jullie behulpzaam. Ik bewonder 
jullie inzet en wens jullie allen veel succes in de toekomst.
Frank Hope, from Organon Newhouse in Scotland. Thanks for your help in performing the 
cats study in Nijmegen.
De afdeling nefrologie van het UM C St. Radboud, vooral prof. dr. Jack Wetzels, dr. Henk 
van Hamersvelt en dr. Ruud de Sévaux. Jullie nefrologische blik tijdens het uitvoeren van 
de klinische nierstudie en het schrijven van de artikelen was voor mij als anesthesioloog 
soms hard nodig.
De research verpleegkundigen Peter van Uden, Irma Prudon en Tijn Bouw, Leen van der 
Sant en O lof Moesker. Jullie hulp en ondersteuning bij het uitvoeren van de klinische 
studie in het Radboud en het C W Z  was essentieel. Peter, jij bent al een hele tijd werkzaam 
bij de hematologie. Halverwege de studie moest je helaas de anesthesie verlaten; wat een 
gemis voor onze afdeling. Tijn, Leen en Olof, jullie moesten de taken van Peter overnemen 
middenin de trial. Dat hebben jullie op een geweldige manier gedaan! Irma, jij bent
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inmiddels een carrière begonnen als physician assistant in de Radboud. Ze zullen jouw 
gedrevenheid in het C W Z  vast heel erg missen!
Dr. Elizabeth Flockton. Dear Liz, thank you very much for your dedicated work performing 
the renal trial in Liverpool. And thanks a lot for your great sense of humour, when we were 
both nervously waiting to give our presentation at the ESA congress in Munich.
Alle anesthesiologen, arts-assistenten, anesthesiemedewerkers, doktersassistenten, 
operatie-assistenten, verkoeververpleegkundigen, chirurgen en poli-medewerkers van het 
UM C St. Radboud wil ik hartelijk bedanken voor hun medewerking tijdens de klinische 
studie. Iedereen hield altijd zijn ogen open voor mogelijke "kandidaten". Bovendien 
waren jullie allemaal zeer geduldig en coöperatief als ik weer eens aan kwam zetten 
met mijn meetarm of als er bij een onderzoekspatiënt op de PACU een heel schema aan 
bloedafnames verricht moest worden.
AIOS anesthesiologie Dominique Bonthuis en Rutger Verhage. Beste Dominique, dankzij 
jouw inzet en hulp bij het uitvoeren van de klinische experimenten ging het circus gewoon 
door als ik er eens niet was. Beste Rutger, grote plannen hadden we voor vervolgstudies 
met sugammadex. Helaas is het er (nog!) niet van gekomen. Ik wens jullie beiden veel 
succes met jullie verdere loopbaan als anesthesioloog-intensivist.
En waar zou een onderzoeker zijn zonder goede secretariële ondersteuning? Dames van 
het secretariaat, in het bijzonder Bianca en Mariska, bedankt!
Al mijn collega's van de afdeling anesthesiologie van het UMC St. Radboud wil ik bedan­
ken voor de fijne opleidingstijd die ik als assistent en fellow op deze afdeling heb gehad. 
Ik denk nog vaak terug aan die gezellige assistentenkamer en die enorme koelkast! Ik ben 
er trots op dat ik in Nijmegen ben opgeleid tot anesthesioloog.
Mijn "studieclubje" met wie ik de opleiding heb doorlopen: Michiel Vaneker, Hettie Cus­
ters, Remco Berendsen, Polina Nassikovker, Roy van den Berg, Martin Seesink en Steven 
Renes. Dank voor jullie humor, relativeringsvermogen en vriendschap. Noodzakelijke 
ingrediënten voor een draaglijke assistententijd!
Prof. dr. Robert Jan Stolker, diensthoofd anesthesiologie van het Erasmus MC, Rotterdam. 
Beste Robert Jan, ik kwam bij jou in dienst met een half voltooid proefschrift. Je vertrouwen 
en steun tijdens de afronding van dit promotietraject heb ik zeer gewaardeerd. Nu deze 
klus bijna is geklaard, heb ik hopelijk meer tijd om mij op andere projecten te storten.
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Mijn lieve collega's van het Sophia Kinderziekenhuis in Rotterdam wil ik bedanken voor 
hun steun, interesse en collegialiteit. In al die dagen dat ik aan mijn proefschrift werkte, 
hielden jullie de kliniek draaiende. In het bijzonder wil ik Antonia Gonzalez Candel 
bedanken voor haar ongelooflijke planningstalent, grenzend aan tovenarij, waardoor ze 
het altijd weer klaarspeelde om mij vrij te plannen voor de wetenschap. Gail Scoones 
heeft mij zeer geholpen met adviezen op het gebied van de Engelse taal. W at een luxe om 
een native speaker één deur verder te hebben zitten!
Michiel Vaneker, mijn paranimf. Niet alleen volgden we samen de opleiding tot anes­
thesioloog, ook stapten we allebei in een promotietraject. Dankzij jouw inzet kregen we 
zelfs een eigen onderzoekskamer, met bovendien eerste rang uitzicht op de landingsplaats 
van de traumahelikopter (niet geheel toevallig). Ik bewonder jouw enorme energie en 
enthousiasme.
Jochem van den Berg, mijn paranimf. Ik zie ons nog zitten in jouw Opel Manta, ieder 
weekend op en neer tussen Eindhoven en Leuven. Ik denk ook nog vaak terug aan al onze 
gesprekken over de toekomst, opleidingsplaatsen, specialismen, in België blijven of toch 
terug naar Nederland. Ik vind het mooi dat we nu allebei hebben bereikt waar we toen 
nog van droomden.
Mijn ouders, mijn zus Mijke en zwager Remco, en mijn schoonouders; kortom, mijn 
veilige thuishaven in het verre Brabant. Jullie staan altijd voor me klaar, en daarvoor ben 
ik jullie ontzettend dankbaar. Pap en mam, bedankt ook voor de steun die jullie altijd 
geweest zijn. Ondanks dat ik niet het onderwijs in ben gegaan, zoals 99% van de familie, 
stonden jullie altijd achter mijn keuzes.
En dan tot slot, Bart, Tom en Sofie. Ik noem jullie nu als laatste, maar jullie komen voor 
mij natuurlijk altijd op de eerste plaats! Lieve kindjes, jullie zijn het allermooiste wat er 
bestaat! Lieve Bart, ik ben blij dat het lot ons allebei "ongunstig" gezind was die zomer in 
1994, zodat we allebei op hetzelfde kot in Leuven terechtkwamen. Het zijn drukke tijden 
geweest: allebei specialiseren, allebei promoveren en dan nog 2 mooie kindjes erbij. 
Dank voor al je geduld, steun en liefde.
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